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ABSTRACT
Twenty-five percent of the genetic susceptibility to breast cancer is explained by the
susceptibility genes known so far. The aims of this study were to investigate the genetic
background of familial breast/ovarian cancer and sporadic breast cancer in Eastern Finnish
population.
 The frequency and type of germ-line mutations in known high-risk breast/ovarian cancer
susceptibility genes, BRCA1 and BRCA2, were evaluated in 36 Eastern Finnish breast/ovarian
cancer families. In addition, the autosomes were screened for linkage disequilibrium-based
association using 435 microsatellite markers to identify new chromosomal regions and genes on
them as genetic risk factors for sporadic breast cancer in a case-control set from the Eastern
Finnish population.
 Germ-line mutations in BRCA1 and BRCA2 genes were observed in 19.4 % of the studied
Eastern Finnish breast/ovarian cancer families. The observed Eastern Finnish mutation spectrum
differs from those observed in the Northern and Southern parts of the country as only two of the
eight most common Finnish founder mutations were detected in the Eastern Finnish families. In
addition, a novel BRCA2 4088insA mutation was found in one family. It has not been found
elsewhere in Finland and it appears to be associated with a favourable clinical outcome of breast
and ovarian cancer patients but is also highly penetrant.
 In the two-staged autosome-wide scan altogether 27 microsatellite markers in 16
chromosomes showed association with breast cancer. In the haplotype analysis three
chromosomal regions, 3p26, 11q23 and 22q12-q13 were further suggested as candidate
locations for breast cancer associated genes. Breast cancer associated risk factors potentially
locate also in the vicinity of single associated markers.
 The associated region on chromosome 22q12-q13 was further studied using 10 SNP markers.
Significant association was detected with one SNP located in the intronic sequence of TMPRSS6
gene encoding matriptase-2. The heterozygous genotype and the minor allele were associated
with increased risk of breast cancer. Matriptase-2 is a serine protease with functions in
processes occurring in both normal and pathological conditions, including cancer progression.
Thus, TMPRSS6 is a potential novel candidate for breast cancer risk affecting gene.
 In the AI analysis of 22q12-q13 abundant AI was detected more centromeric than previously
reported, further supporting the existence of a tumour suppressor gene or genes in this region.
 This study revealed that the proportion of mutations in high-penetrance genes predisposing
to familial breast/ovarian cancer in Eastern Finland is similar to other parts of the country, but
the mutation spectrum is different. This study also shows that several low-penetrance risk
factors for sporadic breast cancer, some of which may be population specific, exist in the
Eastern Finnish population.
National Library of Medicine Classification: QU 477, QZ 50, WP 322, WP 870
Medical Subject Headings: Breast Neoplasms/epidemiology; Breast Neoplasms/genetics; Chromosomes,
Human, Pair 11/genetics; Chromosomes, Human, Pair 22/genetics; Chromosomes, Human, Pair
3/genetics; Female; Finland/epidemiology; Genes, BRCA1; Genes, BRCA2; Genetic Markers; Gene
Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Microsatellite Repeats/genetics;
Ovarian Neoplasms/epidemiology; Ovarian Neoplasms/genetics; Genetics, Population; Risk Factors
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1. INTRODUCTION
Breast cancer is the most common cancer among women in industrialised countries.
Approximately one in ten women in Finland will develop breast cancer during her
lifetime. Currently more than 4000 new breast cancer cases are diagnosed yearly and the
number is increasing (Finnish Cancer Registry). At year 2005 ovarian cancer was the
ninth most common cancer in the Finnish female population accounting 424 new
ovarian carcinomas (Finnish Cancer Registry).
 Many risk factors (hormonal, environmental) for breast cancer are known but most of
the genetic background and molecular mechanisms still remain to be elucidated.
Although mutations in BRCA1 (Hall et al. 1990, Miki et al. 1994) and BRCA2 (Wooster
et al. 1994, Wooster et al. 1995) genes are known to confer a high lifetime risk of breast
cancer, together with the other susceptibility genes so far identified, ATM (Swift et al.
1987, Easton 1994, Athma et al. 1996), CHEK2 (Bell et al. 1999, CHEK2-Breast
Cancer Consortium 2002), TP53 (Easton 1999), PALB2 (Rahman et al. 2007), and
BRIP1 (Seal et al. 2006), these genes explain only ? 25 % of the familial aggregation of
breast cancer (Antoniou and Easton 2006).
 Several linkage studies in large family material have been conducted but other
BRCA1/2-like, high-risk, high-penetrance breast cancer susceptibility genes have not
been found. Therefore, the yet unidentified genes presumably are numerous and confer
a moderate risk (Thompson and Easton 2004). In a study investigating the genetic
models of the non-BRCA1/2 familial clustering of breast cancer the findings suggest
that several common, low-penetrance genes may account for the residual familial
aggregation of breast cancer (Antoniou et al. 2002). It is most likely that low-penetrance
genes for breast cancer susceptibility are present in the general population (Pharoah et
al. 1997).
 In Finland, 26 different BRCA1 and BRCA2 mutations have been found among
female and male breast cancer and ovarian cancer patients (Vehmanen et al. 1997a,
Vehmanen et al. 1997b, Roth et al. 1998, Huusko et al.1998, Sarantaus et al. 2000,
Syrjäkoski et al. 2000, Sarantaus et al. 2001a, Sarantaus et al. 2001b, Pääkkönen et al.
2001, Eerola et al. 2001, Vahteristo et al. 2001a, Syrjäkoski et al. 2004a). Fourteen of
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these, seven in each gene, are considered as founder mutations as they are recurrent and
account for the majority of all detected BRCA1 and BRCA2 mutations in Finland. Some
of these mutations are unique to the Finns. Due to the population history the Finns are
genetically isolated homogeneous population and founder effects can be seen in several
autosomal recessive diseases and cancer predisposition syndromes (Norio et al. 1973,
Nyström-Lahti et al. 1994, Moisio et al. 1996). This effect has been observed among
BRCA1 and BRCA2 mutations also and it has an impact on diagnostics as well
(Sarantaus et al. 2000). The proportion of BRCA1 and BRCA2 mutations among
Southern, Western and Northern Finnish breast/ovarian cancer families has been studied
but in Eastern Finnish population it has not been reported yet.
 Linkage disequilibrium (LD) -based genetic association studies are suitable tools for
detecting low-penetrance susceptibility genes that likely interact with environmental
and lifestyle factors as well as with other genetic factors to cause disease. Young,
isolated populations (e.g. the Eastern Finns) may provide more help by reducing the
genetic heterogeneity. LD, or allelic association, is based on the assumption that the
affected share a genetic variant/mutation, which is so close to the marker that the
probability of a recombination event to occur between them is minimal. In young (15-
25 generations) isolated populations the number of meioses is relatively low and LD is
thought to extend further than in older populations (Ophoff et al. 2002). LD analysis has
been used to discover genes for several diseases of the Finnish disease heritage e.g.
neuronal ceroid lipofuscinosis and diastrophic dysplasia (Järvelä 1991, Hästbacka et al.
1992), as well as in other isolated populations and complex diseases like severe bipolar
disorder and congenital muscular dystrophy (Ophoff et al. 2002, Toda et al. 1996). In
detection of susceptibility genes for complex disease also SNP haplotypes have been
successfully used in the Finnish population (Laitinen et al. 2004).
 In the present study the proportion of BRCA1 and BRCA2 germ-line mutations was
evaluated in breast/ovarian cancer families of Eastern Finnish origin. Also, to find new
genetic medium or low-penetrance risk factors for sporadic breast cancer, the autosomes
were screened utilizing linkage disequilibrium-based association and 435 microsatellites
in a breast cancer case-control set from Eastern Finland. One of the associated regions
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(22q12-q13) was further investigated by SNP association analysis to identify the
putative breast cancer related gene.
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2. REVIEW OF THE LITERATURE
2.1 Breast cancer
2.1.1 Incidence of breast cancer
Breast cancer is the most common cancer among women in industrialised countries.
Each year over one million new cases are diagnosed in the world and it is the leading
cause of cancer death (Globocan 2002). The incidence is highest in Northern America,
Western and Northern Europe, and Australia/New Zealand (Globocan 2002). In Finland
the proportion of breast cancer is approximately one third (31.8 % in 2005) of all female
cancers (Finnish Cancer Registry). One in ten women in our country will be affected
with breast cancer at some point in her life. Every year more than 3 500 new cases are
diagnosed and the number is increasing, the number of new cases in 2005 already being
4 027 (Finnish Cancer Registry). The age-adjusted incidence of breast cancer was 86.7
per 100 000 person years in the year 2005 in Finland (Finnish Cancer Registry). In 2005
the number of breast cancer deaths was 804, i.e. the age-adjusted mortality rate was 14.7
per 100 000 person years. The age-adjusted mortality rate has remained rather
unchanged since the 1950's (14 - 16 / 100 000 person years). Thus, a relative decline in
breast cancer mortality has been observed following the initiation of the population
based mammography screening programme in 1987 (Finnish Cancer Registry 2002 and
2004, Botha et al 2003). Male breast cancer in Finland is rare, accounting for less than 1
% of all breast cancers annually (Finnish Cancer Registry 2002).
2.1.2 Epidemiology and risk factors for breast cancer
Oestrogens have an important role in the development and progression of breast cancer.
The life-time exposure to oestrogen is related to the risk of developing the disease (Pike
et al 1979). Thus, the risk of breast cancer rises throughout a woman's lifetime (Finnish
Cancer Registry 2002). Breast cancer before the age of 25 years is rare, except in certain
familial cases (Finnish Cancer Registry 2002). Risk factors for breast cancer are early
age at menarche (MacMahon et al 1982), nulliparity or delayed first childbirth (Layde et
al. 1989, Ewertz et al. 1990, Kelsey et al. 1993), short duration of breast-feeding (Layde
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et al. 1989, Kelsey et al. 1993), low number of children (Layde et al. 1989, Ewertz et al.
1990), late menopause (Trichopoulos  et al. 1972, Collaborative Group on Hormonal
Factors in Breast Cancer 1997), postmenopausal obesity (Folsom et al. 1990, Hunter
and Willett 1993), extended use of oral contraceptives (Collaborative Group on
Hormonal Factors in Breast Cancer 1996) and long-term oestrogen replacement therapy
(Collaborative Group on Hormonal Factors in Breast Cancer 1997), which all are
surrogates for oestrogen exposure. Higher education and socio-economic status has
been found to associate with increased breast cancer risk, which is largely explained by
nulliparity, later age at first childbirth and greater use of synthetic hormones (Heck and
Pamuk 1997, Pukkala and Weiderpass 1999).
 Increased risk of breast cancer is associated with carcinoma of the contralateral
breast, a history of benign breast disease e.g. atypical hyperplasia and sclerosing
adenosis (Dupont and Page 1985, Carter et al. 1988, Wang et al. 2004, Bernstein et al.
1992), and ionising radiation (Howe and Mclaughlin 1996, Preston et al. 2002, Pukkala
et al. 2006). Also cigarette smoke has been associated with an increase in risk for breast
cancer (Gram et al. 2005, Johnson 2005) and accumulation of environmental
oestrogens, xeno-oestrogens, may have a role in breast cancer aetiology (Davis et al.
1993). Physical inactivity and several dietary factors such as fat or energy intake and
high consumption of cooked red meat (Bernstein et al. 1994, Bartsch et al. 1999, Nair et
al. 1999, Zheng et al. 1998) as well as high alcohol consumption enhance breast cancer
risk (Garfinkel et al. 1988, Smith-Warner et al. 1998). Many epidemiological studies
have observed a positive association between adult height and risk of breast cancer,
although the explanation for this is not clear (Tretli 1989, Vatten and Kvinnsland 1990,
Hunter and Willett 1993). Also race and ethnicity, national origin and geographical
location have an influence on breast cancer risk (Ziegler et al. 1993).
 Family history of breast/ovarian cancer is a known risk factor. It is recognized that a
woman with a first-degree relative with breast cancer has twice the risk of developing
the disease herself (Pharoah et al. 1997). Genetic susceptibility accounts for 5-10 % of
all cases of breast cancer (Claus et al. 1996). Mutations in BRCA1 and BRCA2 genes
account for approximately 15 % of the excess familial relative risk of breast cancer
(Peto et al. 1999, Anglian Breast Cancer Study Group 2000) and in total the so far
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known breast cancer susceptibility genes account for no more than 25 % of the familial
aggregation of breast cancer (Easton 1999). In addition, numerous low-penetrance
genetic variants exist and these contribute together with environmental and lifestyle
factors and with other genes to cause breast cancer (Antoniou et al. 2002).
2.1.3 Prognostic factors in breast cancer
Breast cancer is predominantly a postmenopausal disease and appearance at young age,
<35 years, is related to aggressive disease and reduced survival (Shannon and Smith
2003). Tumour stage is the most important prognostic factor in breast cancer and it is
the basis for selecting patients for different treatment strategies. Breast cancer stage is
assessed according to the TNM classification of the UICC and it involves tumour size,
lymph node status and distant metastases (International Union Against Cancer 2002).
Histological grade, based on tubule formation, nuclear pleiomorphism, and the number
of mitoses, has independent prognostic value in breast cancer (WHO 2003). Expression
of oestrogen and progesterone receptors in the tumour tissue predicts a good response to
hormonal therapy of breast cancer (Clarke et al. 2004), whereas ERBB2 (HER2/neu)
gene amplification and/or protein overexpression in the tumour tissue is associated with
poor prognosis (Ross et al. 2003). Gene expression profiling of breast tumours has
enabled classification of tumours by their gene expression patterns, and provided
insights into development of new potential diagnostic and prognostic markers (Perou et
al. 2000, van't Veer et al. 2002, Sorlie et al. 2003, Chang et al. 2005).
2.2 Ovarian cancer
2.2.1 Incidence of ovarian cancer
Ovarian cancer is among the most common cancers in women worldwide with over
200,000 new cases annually. The incidence rates are highest in Europe, North America
and Australia/New Zealand (Globocan 2002). In Finland, ovarian cancer was the ninth
most common of female cancers accounting for 424 new cases in year 2005 (Finnish
Cancer Registry). In 2005 the ovarian cancer incidence was 8.4 and mortality rate 5.0
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per 100 000 person years. In addition to ovarian carcinomas, approximately 110
borderline tumours are diagnosed annually. The estimation of the number of new cases
of ovarian cancer in 2006 is 507. (Finnish Cancer Registry).
2.2.2 Epidemiology and risk factors for ovarian cancer
The risk factors for ovarian cancer include genetic and environmental (hormonal and
lifestyle) factors, many of them shared with breast cancer risk. Ageing and family
history of ovarian or breast cancer increase the risk. Also hormone replacement therapy
has been associated with increased risk. The number of full-term pregnancies and use of
oral contraceptives are inversely correlated with risk, and late age at menarche, early
age at menopause and breastfeeding modestly reduce the risk. Also tubal sterilisation
has been associated with reduction in risk. The effects of obesity, physical activity and
fertility treatment are unclear. (Bertone-Johnson 2005).
 It is established that at least 10 % of all epithelial ovarian cancers are hereditary, with
the BRCA genes contributing to at least 90 % of these cases and small percentages
attributable to hereditary nonpolyposis colorectal cancer (HNPCC) syndrome (MSH2
and MLH1 genes) and perhaps some yet to be discovered susceptibility gene (Boyd
2003). It is presumed that genetic and environmental factors affect the penetrance of
BRCA gene mutations for ovarian cancer but very few factors have been identified to
date. One such factor is the HRAS1 variable number of tandem repeat (VNTR). The rare
alleles have been suggested to increase the ovarian (but not breast) cancer risk in
BRCA1 mutation heterozygotes (Phelan et al. 1996). HRAS1 VNTR rare alleles have
been shown to increase the relative risk of ovarian cancer in general population also
(Weitzel et al. 2000).
2.2.3 Prognostic factors in ovarian cancer
The most important prognostic factor in ovarian cancer is the FIGO (International
Federation of Gynaecology and Obstetrics) stage. Stage I tumours are limited to ovaries,
stage II to ovaries with pelvic extension, stage III to ovaries with peritoneal implants
and stage IV to ovaries with distant metastasis. (Cancer Committee of the FIGO, 1986).
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Histological grade describing the tumour differentiation is also associated with
prognosis (WHO 2003). The best-known and well-described serum marker for ovarian
cancer is the CA125 antigen (Whitehouse and Solomon 2003).
2.3 Familial breast cancer and high risk genes
Breast cancer attributable to family history of the disease has been reported to account
for 5-10 % of all cases of breast cancer (Claus et al. 1996). A number of genes exist
with a proven high penetrance to familial breast cancer when mutated. High-risk breast
and ovarian cancer susceptibility genes, BRCA1 (Hall et al. 1990, Miki et al. 1994) and
BRCA2 (Wooster et al. 1994, Wooster et al. 1995), are estimated to explain ~15-20 % of
the excess familial relative risk of breast cancer (Table 1) (Peto et al. 1999, Anglian
Breast Cancer Study Group 2000). Other loci for breast cancer susceptibility have also
been identified, including PTEN, TP53, ATM, CHEK2, BRIP1 and PALB2, but these are
of lower frequency in the general population (Table 1) (Easton 1999, CHEK2-Breast
Cancer Consortium 2002, Seal et al. 2006, Rahman et al. 2007). Moderate family
history of breast cancer has been shown to independently predict breast cancer risk
without associated BRCA1 or BRCA2 mutations (Pharoah et al. 1997). Overall, breast
Table 1. Breast cancer risks conferred by inactivating mutations in known susceptibility genes.
Contribution to
Gene
Overall relative
risk of breast
cancer
Breast
cancer (%)
Familial
risk (%) References
BRCA1 >30 at <40 years
14 at >60 years
1-2 *  Thompson and Easton 2004,
Antoniou et al. 2003
BRCA2 11 1-2 *  Thompson and Easton 2004,
Antoniou et al. 2003
ATM 2.37 0.86 †  Renwick et al. 2006
CHEK2 2.34 0.7 0.5†  CHEK2 Breast Cancer Case-
Control Consortium, 2004
PALB2 2.3 0.23 0.24†  Rahman et al. 2007
BRIP1 2.0 (3.5 at <50) 0.2 †  Seal et al. 2006
*Collectively these account for ~15-20 % of the overall familial risk of breast cancer (Peto et al. 1999,
Anglian Breast Cancer Study Group 2000).
†Collectively these account for ~2.3 % of the overall familial relative risk (Rahman et al. 2007).
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cancer is approximately twice as common in women with an affected first-degree
relative; this risk increases with the number of affected relatives and is greater for
women with relatives affected at a young age (Collaborative Group on Hormonal
Factors in Breast Cancer 2001). However, in families with both breast and ovarian
cancers, the aggregation of these two cancers appears to be explained by
BRCA1/BRCA2 mutation-carrier probability (Claus et al. 1998).
2.3.1 BRCA1 and BRCA2 genes
In 1990 linkage to marker D17S74 on chromosome 17q21 was detected in a study using
23 families with 146 breast cancer cases (Hall et al. 1990). In most of the families the
typical features for hereditary breast cancer were seen; early age of onset, bilateral cases
and male breast cancer. Later the BRCA1 (Breast Cancer 1 gene) gene was identified
and cloned on 17q21 (Miki et al. 1994). In another linkage study using 22 families with
at least one male breast cancer case strong negative LOD score values were obtained
suggesting that male breast cancer is not linked to the BRCA1 locus on 17q (Stratton et
al. 1994). An analysis using 15 families with no linkage to BRCA1 locus revealed
linkage to 13q12-q13, which was presumed to be the locus for BRCA2 (Breast Cancer 2
gene) (Wooster et al. 1994). BRCA2 gene was cloned on chromosome 13q12 in 1996.
Both genes encode charged and exceptionally large proteins. (Tavtigian et al. 1996).
(Figure 1).
BRCA1 ~80 kb
BRCA2 ~70 kb
Figure 1. Genomic structure of the BRCA1 and BRCA2 genes. BRCA1 gene spans over 80 kb of
genomic sequence consisting of 24 exons and BRCA2 approximately 70 kb with 27 exons (Miki
et al. 1994, Tavtigian et al. 1996). Modified from Håkansson et al. 1997.
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2.3.2 The BRCA1/2 proteins and their functions
2.3.2.1 Protein structure and functional motifs
Twenty-two of the 24 exons of BRCA1 gene encode an 1863 amino-acid-protein (Miki
et al. 1994). The protein is expressed in several tissues e.g. in ovary, testis and
mammary gland epithelial cells (Miki et al. 1994). The 3418 amino-acid BRCA2
protein is encoded by 25 of the 27 exons of BRCA2 gene (Tavtigian et al. 1996). The
BRCA2 protein does not share sequence homology with any other protein (Wooster et
al. 1995, Tavtigian et al. 1996). Like BRCA1, the BRCA2 protein is expressed in
several tissues, including mammary gland, spleen, ovary, lung, testis and thymus
(Tavtigian et al. 1996). Although BRCA1 and BRCA2 proteins have only little
resemblance to each other or other proteins of known function, they contain structural
motifs that give clues of their biochemical functions. (Figure 2).
 In its amino-terminal region BRCA1 contains a zinc binding RING-finger motif that
is found in regulatory proteins and appears to be involved in protein-protein interactions
(Miki et al. 1994, Saurin et al. 1996). This motif has a role in e.g. the interaction of
BARD1 (BRCA1-associated RING domain protein) and BAP1 (BRCA1-interacting
protein 1) with BRCA1, as well as in BRCA1 homodimer formation (Wu et al 1996,
Jensen et al. 1998, Brzovic et al. 1998). Two nuclear localization signals (NLS) locate
in BRCA1 exon 11 but presumably only one (NLS1) of them is needed for the nuclear
localization of BRCA1 (Chen et al. 1996, Thakur et al. 1997). The carboxy terminal-
region of BRCA1 contains a conserved BRCT (BRCA1 C-terminal) domain that acts as
a protein-binding site and interacts with multiple transcription factors (Koonin et al.
1996), and a region that has been shown to have transcriptional activation potential
(Chapman & Verma 1996). (Figure 2).
 In the C-terminal region of BRCA2 protein locates three oligonucleotide/oligo-
saccharide binding folds (OB1, OB2, OB3) that bind DSS1 and single-stranded DNA
(Yang et al. 2002a). This provided a structural and biochemical basis for understanding
the loss of recombination-mediated double-strand break repair in BRCA2-associated
cancers (Yang et al. 2002a). Also an the amino-terminal region within exon 3 of
BRCA2 has been shown to have transcriptional activation potential (Milner et al. 1997).
In its' central part, in exon 11, BRCA2 contains eight conserved sequence motifs, the
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BRC repeats that interact directly with RAD51 protein (Bork et al. 1996, Bignell et al.
1997, Wong et al. 1997). Within the final 156 residues in the carboxy-terminal of
BRCA2 resides two nuclear localization signals (NLS) that are required for the nuclear
localization and proper function of the BRCA2 protein (Spain et al. 1999). (Figure 2). In
addition, both BRCA1 and BRCA2 have been suggested to have properties of granins as
they include a motif similar to the granin consensus at the C-terminus of the protein
(Jensen et al. 1996).
Figure 2. Structural domains and functional motifs of BRCA1 and BRCA2 proteins. The
borders of exon 11 are shown with black lines. NLS=nuclear localization signal; OB1, OB2,
OB3=oligonucleotide/oligo-saccharide binding folds; OCCR=ovarian cancer cluster region.
Some of the most important interacting proteins are shown below the proteins. See text for
details. Modified from Borg 2001.
2.3.2.2 Proposed functions
BRCA1 and BRCA2 proteins interact with a number of regulatory proteins and they
seem to have multiple fundamental functions. BRCA1 interacts directly and indirectly
with numerous molecules, including tumour suppressors, oncogenes, DNA damage
OCCR
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repair proteins, cell cycle regulators, transcriptional activators and repressors, e.g.
BRCA2, BARD1, ATM, ATR, CHEK2, BLM, MSH2, MSH6, MLH1 and RFC1-
RFC2-RFC4 complex (Wang et al. 2000, Borg 2001, Welcsh and King 2001). BRCA2
interacts with Rad51, BRCA1, DSS1, EMSY, P/CAF, BRAF35, Plk1, USP11,
FANCD2 and G, androgen receptor (AR), BCCIP??? and PALB2 (Xia et al. 2006).
Both BRCA1 and BRCA2 proteins localize to the nucleus of dividing cells and work in
pathways that are required for the maintenance of chromosome structure (Chen et al.
1996, Thakur et al. 1997, McAllister et al. 1997, Scully et al. 1997a, Chen et al. 1998a,
Welsch et al. 2000). BRCA1 and BRCA2 have major roles in maintaining genomic
integrity e.g. through tumour suppression, transcription regulation, cell proliferation and
differentiation, cell cycle control and participating in DNA repair. Recently it has been
reported that BRCA2 is the Fanconi anaemia D1 protein and, as such, plays a key role
in complex series of nuclear events that promote DNA crosslink repair (Howlett et al.
2002, Taniguchi and D'Andrea 2006). Also BRCA1 has been proposed to be involved in
the Fanconi anaemia-BRCA pathway (Garcia-Higueira et al. 2001, D'Andrea and
Grompe 2003). In their role as tumour suppressors BRCA1 and BRCA2 behave as
caretakers, suppressing genome instability as they are essential for preserving the
chromosome structure (Xu et al. 1999, Tirkkonen et al. 1997, Patel et al. 1998,
Gretarsdottir et al. 1998).
BRCA1 and BRCA2 are considered as gatekeeper tumour suppressor genes that are
involved in multiple tumour types, and as caretaker genes (Schutte et al. 1995,
Thompson et al 1995, Holt et al. 1996, Wang et al. 2002, Kinzler and Vogelstein 1997).
Gatekeepers directly regulate the growth of tumours by inhibiting growth or promoting
death (Kinzler and Vogelstein 1997). BRCA genes have been shown to suppress breast
cancer cell growth (Thompson et al. 1995, Holt et al. 1996, Wang et al. 2002).
According to Knudson's double hit hypothesis the inactivation of a tumour suppressor
(or gatekeeper) gene needs two mutations, usually one germ-line and one somatic, and
leads to tumour development (Knudson 1971). Mutations in caretaker genes do not
directly result in tumour formation but instead they cause genetic instability which leads
to increased mutations in the genome and eventually to tumour formation (Kinzler and
Vogelstein 1997). Tumours arising in women carrying a single germ-line mutant
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BRCA1 or BRCA2 allele exhibit LOH at this locus, losing the wild-type allele and
retaining the mutant copy of the gene, implying that BRCA1 and BRCA2 proteins
function as tumour suppressors (Smith et al. 1992, Collins et al. 1995, Cornelis et al.
1995). How these proteins exert the tumour suppressor functions is incompletely
understood.
BRCA1 and BRCA2 participate in the biological response to DNA damage,
which involves the activation of cell cycle checkpoints and the recruitment of the
machinery for DNA repair. Failure to activate these checkpoints or DNA repair
following DNA damage manifests as increased sensitivity to genotoxic agents (Patel et
al. 1998, Sharan et al. 1997, Xu et al. 2001, Scully et al. 1997b). In addition to the role
in DNA repair after damage caused by exposure to exogenous agents, BRCA1 and
BRCA2 proteins function in DNA damage response after endogenous damage that arise
during processes such as DNA replication or transcription (Yarden and Brody 1999,
Milner et al. 1997, Chapman et al. 1996, Scully et al. 1997c, Fuks et al. 1998, Bochar et
al. 2000, Venkitaraman 2002, Welcsh et al. 2000, Scully and Livingston 2000).
Although both are essential for error-free homologous recombination (HR) BRCA1 and
BRCA2 have distinct roles in DSB repair. Disruption of BRCA2 prevents efficient
homologous recombination (HR) but single-stranded annealing (SSA) and non-
homologous end-joining (NHEJ), which are more error-prone, are used (Xia et al. 2001,
Moynahan et al. 2001, Tutt et al. 2001), whereas in  BRCA1 deficient cells SSA and
HR appear to be decreased and NHEJ predominates as the mechanism for DSB repair
(Moynahan et al. 1999). The major role of BRCA2 is through control of the RAD51
recombinase (Chen et al. 1998b, Wong et al. 1997, Davies et al. 2001, Pellegrini et al.
2002, Yang et al. 2002a, Venkitaraman 2002, Pellegrini and Venkitaraman 2004), while
BRCA1 performs a distinct and more general function as a link between the
sensing/signaling and effector components of the mammalian response to DNA damage,
helping to ensure that the ensuing response is appropriate to the initiating lesion (Wang
et al. 2000, Zhong et al. 1999, Cortez et al. 1999, Lee et al. 2000, Venkitaraman 2002).
Chromosomal instability provoked by BRCA deficiency is the result of incorrect routing
of DSB processing down inappropriate pathways, rather than the failure of repair per se
(Venkitaraman 2002).
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2.3.3 Cancer risks conferred by mutations in the BRCA genes
In a recent analysis of pooled pedigree data unselected for family history with breast or
ovarian cancer from 22 studies, the average cumulative risks in BRCA1 mutation
carriers by age 70 years were 65 % for breast cancer and 39 % for ovarian cancer. The
corresponding estimates for BRCA2 were 45 % and 11 % (Antoniou et al. 2003). In high
risk families the risks are somewhat higher, especially for breast cancer in BRCA2
mutation carriers; ~85 % by age 70 and the risk for ovarian cancer ~27 % (Easton et al.
1995, Ford et al. 1998). The risk in BRCA1-mutation carriers by age 70 is ~70 % for
breast cancer and ~40 % for ovarian cancer (Easton et al. 1995, Ford et al. 1998). The
risk for subsequent breast or ovarian cancer is also high in breast cancer patients
carrying BRCA1 and BRCA2 mutations (Easton et al. 1995, Breast Cancer Linkage
Consortium 1999). The cumulative risk for male breast cancer in BRCA2 mutation
carriers has been estimated to be 3-6 % by age 70 years (Easton et al. 1997, Thompson
and Easton 2001). Although the majority of families with male breast cancer are
connected with germ-line BRCA2 mutations, also BRCA1 is suggested to contribute a
larger fraction to male breast cancer than previously thought (Couch et al. 1996, Frank
et al. 2002).
 In addition to the high risks of breast and ovarian cancers, BRCA2 mutations may be
associated with increased risks of several other cancers. Statistically significant
increases in risks were observed for prostate cancer, pancreatic cancer, stomach cancer,
gallbladder and bile duct cancer and malignant melanoma (Breast Cancer Linkage
Consortium 1999). The overall increases in risks for other than breast and ovarian
cancer are quite small, except for prostate cancer in BRCA2 mutation carriers where the
cumulative risk has been estimated to be 10-34 % by age 80 years (Breast Cancer
Linkage Consortium 1999, Thompson and Easton 2001). In BRCA1 mutation carriers
the overall increased risk of cancer at sites other than breast and ovary is small and is
observed in women but generally not in men. BRCA1 mutations may confer increased
risks of other abdominal cancers in women and increased risks of pancreatic cancer in
men and women (Thompson et al. 2002a).
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2.3.3.1 Variation in cancer risks conferred by BRCA mutations
Depending on the BRCA mutation different risks of breast, ovarian, and other cancers,
and possibly different probabilities for particular tumour types or tumour progression
are conferred (Gayther et al. 1995, Gayther et al. 1997a, Scott et al. 2003). Different
hypotheses have been introduced as the biological explanation for the variation in
cancer risk by mutation location but none of them has been confirmed (Thompson and
Easton 2001, Thompson et al. 2002b, Ware et al. 2006). The risk of cancer among the
carriers may also differ considerably, due to e.g. chance, genetic, hormonal, dietary, and
environmental modifying factors (Antoniou et al. 2000, Antoniou et al. 2002,
Thompson and Easton 2004).
 A lower risk of ovarian cancer in relation to breast cancer risk has been reported to
be associated with mutations in the 3' end of the BRCA1 gene, whereas the mutations in
the central part of the gene confer a lower breast cancer risk than other mutations (Risch
et al. 2001, Gayther et al. 1995, Thompson et al. 2002b). For BRCA2, mutations in the
central part of the gene, in a region known as the ovarian cancer cluster region, OCCR
(Figure 2), at nucleotides 3035-6629, appear to be associated with a lower breast cancer
risk and higher ovarian cancer risk than other BRCA2 mutations (Gayther et al. 1997a,
Thompson and Easton 2001). Later, the OCCR was slightly modified on statistical
grounds to comprise nucleotides 3059-4075 and 6503-6629 (Thompson and Easton
2001). Also splice-site mutations in both BRCA1 and BRCA2, as well as substitutios in
the BRCA2 gene have been suggested to confer higher risks than substitutions in the
BRCA1 gene (Scott et al. 2003).
 Possible genetic factors that modify the effect of BRCA gene mutations, besides
BRCA genes themselves, include rare HRAS1 alleles and a polymorphism in the RAD51
gene (Phelan et al. 1996, Levy-Lahad et al. 2001, Wang et al. 2001a).
2.3.4 Clinical features of BRCA gene mutation-associated cancers
Several histopathological and clinical features differ among BRCA1, BRCA2 and
sporadic breast cancers. The pathological characteristics of BRCA2-associated breast
tumours are less clear than for BRCA1, and overall their behaviour seems to be more
similar to those in sporadic cases. (Table 2).
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Table 2. Clinical features of BRCA1 and BRCA2 mutation-associated breast and ovarian
cancers.
BRCA1-associated  BRCA2-associated References
Breast carcinomas diagnosed at
younger age
Bilateral cancer more common
Breast carcinomas diagnosed at
younger age
Bilateral cancer more common
Ovarian carcinomas diagnosed at
younger age
Hall et al. 1990, Easton et al.
1993, Miki et al. 1994, Wooster
et al. 1994, Ford et al. 1994,
Easton et al. 1995, Boyd et al.
2000, Risch et al. 2001
Often ER- and PR-  Predominantly ER+ and PR+ Johannsson et al. 1997, Loman
et al. 1998, Lakhani et al. 2000
 Evidence of higher average grade
(effect weaker than for BRCA1)
High histological grade
High mitotic count
More often highly proliferating and
aneuploid
Marcus et al. 1996, Breast
Cancer Linkage Consortium
1997, Johannsson et al. 1997,
Lakhani et al. 1998
Overrepresentation of medullary or
atypical medullary tumours
Breast Cancer Linkage
Consortium 1997
Distinguished gene expression
patterns in tumours
 Distinguished gene expression
patterns in tumours
Hedenfalk et al. 2001
A trend towards worse survival in
breast cancer found in some studies
 Less data but not likely to be very
different from sporadic
Worse survival also reported
Foulkes et al 1997, Verhoog et
al. 1998, 2000, Loman et al.
2000, Stoppa-Lyonnet et al.
2000, Goode et al. 2002a,
Robson et al. 2003, Brekelmans
et al. 2006
Ovarian carcinomas typically of serous histology, moderate to high grade and
advanced stage
Mucinous subtype underrepresented
Rubin et al. 1996, Boyd et al.
2000, Moslehi et al. 2000,
Risch et al. 2001, Lakhani et al.
2004
A trend towards better survival in
ovarian cancer (due to enhanced
susceptibility to chemotherapy)
Little data available, better survival
when combined analysis with
BRCA1
Rubin et al. 1996, Pharoah et
al. 1999, Boyd et al. 2000, Ben
David et al. 2002, Narod and
Boyd 2002, Cass et al. 2003
 Significantly different groups of genes are expressed by breast cancers with BRCA1
mutations and breast cancers with BRCA2 mutations, and sporadic breast tumours, and
thus, these three groups can be distinguished from each other. This supports further the
molecular difference between cancers with underlying germ-line mutations in BRCA1
and BRCA2 genes as well as cancers without such mutations. (Hedenfalk et al. 2001).
Also ovarian tumours segregate into "BRCA1-like" and "BRCA2-like" subgroups
according to the gene expression profiles. Mutations in BRCA1 and BRCA2 may lead to
carcinogenesis through distinct molecular pathways that also appear to be involved in
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sporadic cancers. (Jazaeri et al. 2002).
2.3.5 Mutation spectrum and founder mutations in the BRCA genes
More than 1 500 different mutations or polymorphisms have been identified in the
BRCA1 gene and almost 1 900 in the BRCA2 gene (BIC, February 2006). The majority
of mutations are frameshift mutations caused by small insertions or deletions, or
alterations affecting the splice-site (BIC). Most of these mutations hamper the ability of
the plausible tumour-suppressor or caretaker gene to block the development of cancer.
 A mutational hotspot in the BRCA1 or BRCA2 gene has not been described but
frequent founder mutations have been discovered in some populations, of which the
Icelandic and Ashkenazi Jewish populations are the most studied. In Iceland the
preponderance of a single BRCA2 999del5 mutation has been observed (Gudmundsson
et al. 1996, Thorlacius et al. 1996). (Table 3). It is estimated to account for up to 76 %
of families with multiple cases of female breast cancer and/or male breast cancer
(Thorlacius et al. 1996). In addition to the 999del5 mutation in the BRCA2 gene, only
one rare mutation in the BRCA1 gene has been identified in the Icelandic population
(Bergthorsson et al. 1998).
Table 3. Predominant founder mutations in BRCA1 and BRCA2 genes.
Population Founder mutation
Freq. in
population
Breast cancer risk
in female carriers Reference
Icelandic BRCA2 999del5   0.6 %
 (1/170)
37 % at age 70 Johannesdottir et al. 1996,
Thorlacius et al. 1997,
Thorlacius et al. 1998
Ashkenazim BRCA1 185delAG ~1 % 36 % (life-time) Fodor et al. 1998
BRCA1 5382insC   0.25 % Fodor et al. 1998
BRCA2 6174delT ~1 % 36 % (life-time) Fodor et al. 1998
 The Ashkenazi Jews have three ancestral founder mutations, 185delAG and
5382insC in BRCA1 (Simard et al. 1994) and 6174delT in BRCA2 (Tavtigian et al.
1996) (Table 3). These mutations account for almost all the BRCA1/2 mutations found
in this population. The life-time risk for breast cancer among Ashkenazi Jewish carriers
(regardless of age of onset or family history of cancer) of the BRCA1 185delAG or
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BRCA2 6174delT mutations is approximately 3 times the overall risk for the general
population (Fodor et al. 1998). Different estimations of higher risks of breast and
ovarian cancer among the carriers of the Ashkenazi Jewish founder mutations in any
population have been also published (Struewing et al. 1997, King et al. 2003, Antoniou
et al. 2005).
 In addition to the Ashkenazi Jews, the 5382insC mutation and another BRCA1
mutation, 4153delA, are frequent among breast/ovarian cancer families of Eastern
European, e.g. Russian, Hungarian, Latvian and Polish origin (Neuhausen et al. 1996,
Gayther et al. 1997b, Ramus et al. 1997a, Csokay et al. 1999, Gorski et al. 2000).
Patients being heterozygous carriers of two Ashkenazi Jewish founder mutations,
185delAG/6174delT and 5382insC/6174delT, have been detected (Ramus et al. 1997b,
Friedman et al. 1998). The observations suggest that the phenotypic affects of double
heterozygosity for BRCA1 and BRCA2 germ-line mutations are not cumulative
(Friedman et al. 1998). A patient of a non-Jewish ancestry carrying both BRCA1 and
BRCA2 mutations, G2508T/3295insA, as well as a patient homozygous for BRCA1
2800delAA mutation have also been observed (Liede et al. 1998, Boyd et al. 1995).
 In the Dutch population large Alu-mediated deletions in the BRCA1 gene are
recurrent and are among the founder mutations (Petrij-Bosch et al. 1997, Puget et al.
1997, Swensen et al. 1997). Alu-mediated duplications of the BRCA1 gene have been
found (Puget et al. 1999), and a genomic deletion in the BRCA2 gene in a Swedish
breast/ovarian cancer family has also been published (Nordling et al. 1998).
 Recurrent founder mutations are being identified in a growing number of populations
as the data on BRCA1 and BRCA2 mutations accumulates. Founder effect is also evident
in Finland (Vehmanen et al. 1997a, Huusko et al. 1998, Sarantaus et al. 2000).
2.3.6 BRCA mutations in Finland
In Finland 15 different BRCA1 and 11 different BRCA2 mutations have been found
among female and male breast cancer and ovarian cancer patients so far (Vehmanen
et al. 1997a, Vehmanen et al. 1997b, Roth et al. 1998, Huusko et al.1998, Sarantaus
et al. 2000, Syrjäkoski et al. 2000, Sarantaus et al. 2001a, Sarantaus et al. 2001b,
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Pääkkönen et al. 2001, Eerola et al. 2001, Vahteristo et al. 2001a, Syrjäkoski et al.
2004a). Fourteen of these, seven in each gene, are recurrent and are considered as
founder mutations in Finland as they account for the majority of all detected
mutations. Some of these mutations are unique to the Finns. The most recurrent
mutation in BRCA2 is the Icelandic founder mutation 999del5 (Table 4).
Interestingly, the Icelandic and Finnish BRCA2 999del5 mutations could have an
ancient common origin and in addition to Iceland and Finland the 999del5 mutation
has not been reported in other Nordic countries (Barkardottir et al. 2001). Large
genomic alterations have not been found in BRCA1 or BRCA2 gene in the Finnish
population (Lahti-Domenici et al. 2001, Laurila et al. 2005, Karhu et al. 2006).
Table 4. The four most recurrent founder mutations in the BRCA1 and BRCA2 gene in
Finland.
Gene Mutation
BRCA1 4216-2nt A?G
3604delA
3744delT/3745delT
4446C?T
BRCA2 999del5
7708C?T
8555T?G
9346-2ntA?T
 In the previous studies conducted in 88 Northern and 100 Southern Finnish
families BRCA1/2 mutations were found in 12.5 % and 21 % of the families, in 8-43
% depending on the strength of family history and being the highest in true high-risk
families with both breast and ovarian cancers. BRCA1 mutations were observed in 7
% and 10 % of studied breast/ovarian cancer families. The corresponding figures for
BRCA2 were 6 % and 11 %. (Huusko et al. 1998, Vehmanen et al. 1997a). The
proportion of BRCA2 mutations was slightly higher than BRCA1 mutations. The
highest (80 %) frequencies of BRCA mutations in Finland have been observed in
families with both breast and ovarian cancer and early-onset breast cancer, while in
families with later-onset breast cancer only, the mutation frequency has been the
lowest, 1.5 % (Vahteristo et al. 2001a). Among 1035 unselected Finnish breast
cancer cases BRCA2 mutations were considerably more frequent with the frequency
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of 1.4 %, than BRCA1 mutations with the frequency of 0.4 % (Syrjäkoski et al.
2000). In Finnish ovarian carcinoma families BRCA1/2 founder mutations were
found in 26 % (Sarantaus et al. 2001a) and BRCA2 mutations were slightly more
frequent than BRCA1 mutations. However, among unselected ovarian carcinoma
patients BRCA1/2 founder mutations account for an approximate 5 % of ovarian
carcinomas (Sarantaus et al. 2001b) and BRCA1 mutations are more frequent than
BRCA2 mutations.
2.3.7 Common polymorphisms and BRCA genes in sporadic breast/ovarian cancer
The most common polymorphisms which cause amino acid substitutions in the BRCA1
gene, Gln356Arg, Pro871Leu, Glu1038Gly and Ser1613Gly, do not make a significant
contribution to breast and ovarian cancer risk (Dunning et al. 1997, Wenham et al.
2003, Auranen et al. 2005). However, the homozygous 356Arg genotype was suspected
to be protective against breast cancer (Dunning et al. 1997). Cox and co-workers
(2005a) reported a haplotype in the BRCA1 gene that was associated with a small (18
%) increase in risk of sporadic breast cancer. However, the functional variants
responsible for the association were unclear. They also reported no association with
Gln356Arg and breast cancer. In another recent multiethnic study with breast cancer
case-control material no evidence for significant associations between risk of sporadic
breast cancer and common variation in BRCA1 was found (Freedman et al. 2005).
 The only common nonsynonymous SNP in the BRCA2 gene is Arg372His (N372H).
In a joint analysis of British, German and Finnish population the rare homozygotes
(HH) were first associated with a 30 % increase in risk of breast cancer, with the
strongest association observed in women <45 years of age (Healey et al. 2000a). This
was also observed in an Australian study (Spurdle et al. 2002) but not in studies
conducted in the US (Freedman et al. 2004, Cox et al. 2005b, Garcia-Closas et al.
2006). The rare homozygous genotype HH has also been shown to associate with
increased risk of ovarian cancer in Australian and British population (Auranen et al.
2003), whereas in a US study no association was detected (Wenham et al. 2003). In the
largest collaborative study conducted so far, no significant association was found
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between increased risk of breast cancer and the HH homozygotes, and only a marginally
statistically significant interaction of N372H with age (Breast Cancer Association
Consortium 2006).
 Somatic inactivating mutations in BRCA1 and BRCA2 gene are very rare and thus do
not play a major role in the tumorigenesis of sporadic breast or ovarian cancer (Futreal
et al. 1994, Meravjer et al. 1995, Miki et al. 1996, Lancaster et al. 1996, Teng et al.
1996, Weber et al. 1996). However, allelic deletions have been observed in sporadic
breast and ovarian cancers in both genes, which imply that BRCA genes may play roles
as tumour suppressor genes in sporadic breast and ovarian cancers also (Futreal et al.
1994, Takahashi et al. 1995, Beckmann et al. 1996, Gras et al. 2001, Yang-Feng et al.
1993). Also inactivation and reduction in expression levels of BRCA1 in sporadic breast
and ovarian cancers have been detected (Thompson et al. 1995, Taylor et al. 1998,
Wilson et al. 1999, Esteller et al. 2000, Russell et al. 2000). The silencing of the BRCA1
gene in primary breast and ovarian carcinomas occurs epigenetically by promoter
hypermethylation, especially in the presence of LOH (Dobrovic and Simpfendorfer
1997, Baldwin et al. 2000, Rice et al. 1998, Bianco et al. 2000, Esteller et al. 2000).
Hypermethylation of the BRCA2 promoter region has not been observed in breast cancer
(Collins et al. 1997) and only very rarely in ovarian cancers (Hilton et al. 2002). Instead,
it has been suggested that BRCA2 is silenced by overexpression of EMSY (Hughes-
Davies et al. 2003). EMSY binds to exon 3 of BRCA2 and thereby suppresses the
transcriptional activity of BRCA2 (Hughes-Davies et al. 2003).
 Other possible mechanisms leading to low BRCA1 expression are regulation of
protein stability, allele specific expression, p53 or ID4 mediated expression, activation
of the negative regulatory site in the first intron, loss of activation by transcription
factors or activation of NBR2 expression (reviewed in Mueller and Roskelley 2003).
BRCA1 protein has also been observed to be mislocalised to cytoplasm (Chen et al.
1995). However, the extent to which BRCA1 and BRCA2 contribute to the pathogenesis
of sporadic breast and ovarian cancer remains unclear as BRCA1 and BRCA2 may affect
through other more indirect mechanisms.
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2.3.8 Other genes involved in familial breast cancer
In addition to the hereditary breast and ovarian cancer syndrome caused by mutations in
the BRCA1 and BRCA2 genes, breast cancer occurs as a component of other inherited
cancer predisposition syndromes. Germ-line mutations in these predisposing genes are
however, very rarely seen in breast cancer patients without manifestations of other
features of the syndromes. Thus, the contribution of these genes (PTEN, TP53, ATM,
LKB1) to familial aggregation of site-specific breast cancer is marginal. Low-penetrance
genes accounting for the familial aggregation of breast cancer have been also identified.
These include CHEK2 and a recently identified PALB2.
2.3.8.1 PTEN and Cowden syndrome
Cowden syndrome (CS) is an autosomal dominant disorder, characterised by the
development of hamartomas and benign tumours in multiple organs, e.g. skin, intestine,
thyroid and breast, and an increased risk for breast, thyroid and endometrial carcinomas.
Mutations in the tumour suppressor PTEN gene (also known as MMAC1 or TEP1), on
chromosome 10q22-q23, are present in over 80 % of Cowden syndrome families (Nelen
et al. 1996, Liaw et al. 1997, Eng 2003). Truncating PTEN mutations in Cowden
syndrome families are associated with cancer and cause a 25-50 % lifetime risk of
breast cancer in women and the age at diagnosis of breast cancer in patients with CS is
approximately 10 years younger than in sporadic cases (Starink et al. 1986, Longy and
Lacombe 1996). The risk of male breast cancer might also be increased (Marsh et al.
1998, Fackenthal et al. 2001). No mutations in PTEN gene have been detected in breast
cancer families without CS features (Tsou et al. 1997, Carroll et al. 1999, Lauge et al.
1999). In sporadic breast cancer PTEN mutations or polymorphisms seem not to play a
significant role either (FitzGerald et al. 1998, de Jong et al. 2002, Haiman et al. 2006).
2.3.8.2 TP53 and Li-Fraumeni syndrome
The TP53 gene is located on chromosome 17p13 (McBride et al. 1986). The p53 protein
encoded by TP53 is a 53-kD phosphoprotein that has four distinct domains: an N-
terminal transactivation domain, a central DNA-binding domain, a tetrametization
domain and a C-terminal regulatory domain (Soussi and May 1996). p53 is a
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transcription factor and it is activated and stabilized in response to different forms of
cellular stress, e.g. ionizing radiation, chemotherapeutic drugs and UV light, via post-
translational modifications and protein-protein interactions, after which it transactivates
or transrepresses the genes involved in cell-cycle control, DNA repair, apoptosis, and
the formation of blood vessels (Vogelstein et al. 2000). p53 has been named as the
"guardian of the genome" due to the multiple roles of the wild-type p53 protein in
controlling the cell-cycle and proliferation (Lane 1992).
 Germ-line mutations in the TP53 gene cause Li-Fraumeni syndrome (Malkin et al.
1990). Li-Fraumeni syndome (LFS) is a rare autosomal dominant disorder,
characterised by an increased risk of soft tissue and osteosarcomas, leukaemias, brain
tumours, adrenocortical carcinomas, and breast cancer (Li and Fraumeni 1969, Li et al.
1988). The risk of developing breast cancer before the age of 45 is 18-fold higher
among LFS females compared to the general population (Garber et al. 1991). Germline
TP53 mutations have been found in approximately 70 % of LFS and 25 % of LFL (Li-
Fraumeni-like) families (Varley et al. 1997, Eng et al. 1997). Germ-line mutations in the
TP53 gene have been estimated to account for less than 1 % of breast cancer but recent
studies suggest a proportion higher than that, especially among cases with disease onset
at the age 30 years or younger (Börresen et al. 1992, Sidransky et al. 1992, Lalloo et al.
2003). Germ-line mutations in TP53 have also been found in Finnish breast cancer
families meeting the LFS/LFL criteria (Huusko et al. 1999, Rapakko et al. 2001).
 Germ-line mutations of TP53 in familial, non-LFS or non-LFL, early-onset, or
bilateral breast cancer cases are rare (Börresen et al. 1992, Lidereau and Soussi 1992,
Sidransky et al. 1992, Balz et al. 2002, Ohayon et al. 2005, Lalloo et al. 2006). An
Arg72Pro polymorphism is located in a proline-rich region of the TP53 gene that is
required for the growth suppression activity of p53 (Walker et al. 1996). After the initial
finding of increased risk of breast cancer in homozygous carriers of the proline allele
Arg72Pro has been examined in numerous studies for the possible role in breast cancer
risk (Sjalander et al. 1996). The largest case-control studies so far have found no
association between Arg72Pro and breast cancer risk (Wang-Gohrke et al. 2002,
Tommiska et al. 2005, Breast Cancer Association Consortium 2006).
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2.3.8.3 ATM
Ataxia-telangiectasia (A-T) is a rare autosomal recessive degenerative disorder caused
by biallelic mutations of the ATM gene on chromosome 11q22-q23 (Savitsky et al.
1995). A-T is characterized by progressive cerebellar ataxia, a weakened immune
system, hypersensitivity to ionizing radiation, highly increased susceptibility to
malignancies, primarily of lymphoid origin, and distinctive dilated blood vessels in the
eyes and skin. The ATM protein encoded by ATM is a large serine-threonine kinase that
is activated in response to DNA damage by ionizing radiation (Canman et al. 1998,
Kastan and Lim 2000). Upon activation ATM phosphorylates a wide array of
downstream targets that regulate cell cycle checkpoints, apoptosis, and DNA repair
(Kastan and Lim 2000, Bakkenist and Kastan 2003). ATM also regulates several
tumour suppressors, including p53, BRCA1 and CHEK2 (Canman et al. 1998, Banin et
al. 1998, Khanna et al. 1998, Cortez et al. 1999, Matsuoka et al. 1998).
 Studies based on relatives of A-T patients have shown that heterozygous carriers of
variant ATM are clinically unaffected but are shown to be at increased risk of cancer,
especially the female carriers who have a two- to seven-fold increased risk of breast
cancer (Swift et al. 1987, Pippard et al. 1988, Borresen et al. 1990, Swift et al. 1991,
Easton 1994, Athma et al. 1996, Olsen et al. 2001, Thompson et al. 2005). In contrast,
mutation screening of ATM in breast cancer case-controls sets outside A-T families have
produced mixed results and have suggested allelic heterogeneity of ATM and that only a
specific class of variants contribute to breast cancer risk in heterozygotes (FitzGerald et
al. 1997, Teraoka et al. 2001, Gatti et al. 1999, Chenevix-Trench et al. 2002). Recently
it has been shown in a UK study using familial breast cancer case-control population
that A-T-causing biallelic ATM mutations are breast cancer susceptibility alleles in
monoallelic carriers outside A-T families, and the combined ATM mutation prevalence
and contribution to breast cancer incidence is similar to CHEK2 1100delC; both confer
an estimated two-fold risk of breast cancer (Renwick et al. 2006). Association of some
of the missense variants (7271T>G, Ser49Cys) has been observed in other large case-
control studies also (Bernstein et al. 2006, Stredrick et al. 2006). In the Breast Cancer
Association Consortium study the Ser49Cys was not significantly associated with
overall breast cancer risk, but a modest association was not excluded either, and this
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SNP increased the risk of PR positive breast cancer (Cox et al. 2007). Results from
studies of association between common polymorphisms (SNPs) in ATM and risk of
breast cancer have been controversial so far (Angele et al. 2003, Tamimi et al. 2004a,
Lee et al. 2005a). In the Finnish population germ-line mutations in ATM have an
apparent but overall limited contribution to familial and sporadic breast cancer
predisposition outside A-T families (Pylkäs et al. 2007).
2.3.8.4 Checkpoint kinase 2, CHEK2 (CHK2)
2.3.8.4.1 CHEK2 gene and protein function
The cloning of the gene encoding the checkpoint kinase 2, CHEK2, was reported by
five laboratories in 1998/1999 (Matsuoka et al. 1998, Blasina et al. 1999, Chaturvedi et
al. 1999, Brown et al. 1999, Tominaga et al. 1999). The CHEK2 (also known as CHK2)
gene locates on chromosome 22q12.1 and spans 50 kb of genomic DNA. Fourteen
exons encode a 543-amino-acid protein with 83 % identity to mouse Chk2 and 34 %
identity to Drosophila Dmnk (Matsuoka et al. 1998). CHEK2 is a also the human
homolog of the Saccharomyces cerevisiae Rad53 and Schizosaccharomyces pombe
Cds1 protein kinases that have crucial roles in controlling cell-cycle checkpoints after
DNA damage and stalled replication (Matsuoka et al. 1998, Blasina et al. 1999,
Chaturvedi et al. 1999, Brown et al. 1999). At the protein level the structure is
dominated by several evolutionally conserved elements (Matsuoka et al. 1998, Bartek et
al. 2001).
 CHEK2 is a G2 checkpoint protein kinase that plays a critical role in maintaining
genomic stability (DNA repair) and coordinates cell cycle responses. In mammalian
cells CHEK2 is activated in response to replication blocks and DNA damage caused by
UV light or ionising radiation (Matsuoka et al. 1998). ATM phosphorylates CHEK2
which in turn phosphorylates other key cell cycle proteins, including BRCA1 and p53
(Matsuoka et al. 1998, Chehab et al. 2000, Lee et al. 2000, Shieh et al. 2000). In
addition to ATM-dependent activation CHEK2 is activated in an ATM-independent,
ATR-dependent manner (Matsuoka et al. 1998, Chaturvedi et al. 1999, Blasina et al.
1999, Hirao et al. 2002). CHEK2 has been also shown to regulate apoptosis through a
p53-independent pathway by phosphorylating the promyelocytic leukemia protein, PML
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(Yang et al. 2002b). Furthermore, CHEK2 has been reported to regulate also E2F1
transcription factor activity in response to the DNA-damaging agent etoposide (Stevens
et al. 2003). On the other hand, E2F1 expression results in increase in CHEK2 protein
levels and it may be essential for p53 activation and apoptosis induction (Rogoff et al.
2004). Ectopic expression of E2F1 induces the ATM-dependent phosphorylation of
CHEK2 and stimulates the kinase activity of CHEK2 (Powers et al. 2004). NBS1 is also
required for the induction of CHEK2 phosphorylation induced by E2F1 (Powers et al.
2004). Moreover, CHEK2 plays a critical role in the pro-apoptotic transcription factor
p73 protein induction following DNA damage and modulation of E2F1 makes an
important contribution (Urist et al. 2004). A recent study suggests that a mitotic
checkpoint kinase TTK participates in the regulation of DNA damage by functioning
upstream of CHEK2 and phosphorylating it (Wei JH et al. 2005). DNA-PK is also
suggested to be involved in activation of CHEK2 in response to DNA damage (Li and
Stern 2005).
 Checkpoint mechanisms and DNA-repair machinery are needed for temporary
halting of cell-cycle progression in proliferating cells, in order to provide time for repair
and prevent fixation and propagation of harmful mutations (Hartwell and Weinert 1989,
Elledge 1996, Weinert 1998, Walworth 2000, Bartek et al. 2001). When DNA damage
occurs, activated CHEK2 targets several cell cycle modulators. These events ultimately
lead to cell cycle arrest, DNA repair, or programmed cell death. Failures in the
checkpoint machinery can result in developmental malformations, embryonic lethality
or the accumulation of mutations that could potentially lead to genetic disease,
including cancer (Hartwell 1992, Hartwell and Kastan 1994, Weinert 1997, Dasika et al.
1999). CHEK2 mutations have been detected in tumours and it has been suggested that
constitutive activation of ATM-CHEK2 pathway occurs at pre-invasive stages of major
types of human tumours, including colon, breast and lung carcinomas (Bartkova et al.
2005).
2.3.8.4.2 CHEK2 germ-line mutations and risk of breast cancer
The first germ-line CHEK2 mutations were reported as early as in 1999 in both sporadic
and hereditary human cancers. Germ-line mutations in CHEK2, including 1100delC,
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were detected in Li-Fraumeni syndrome patients without TP53 mutations (Bell et al.
1999). The findings suggested that CHEK2 is a tumour suppressor gene conferring
predisposition to sarcoma, breast cancer and brain tumours, and provided a link between
the central role of p53 inactivation in human cancer and the well-defined G2 checkpoint
in yeast (Bell et al. 1999). The 1100delC mutation was also detected in Finnish families
suggestive of Li-Fraumeni syndrome (Vahteristo et al. 2001b). Recent studies have
confirmed that CHEK2 is mutated in a subset of familial breast cancers (CHEK2-Breast
Cancer Consortium 2002, Vahteristo et al. 2002, Meijers-Heijboer et al. 2003,
Oldenburg et al. 2003). Both truncated and missense mutants of CHEK2 have lost their
kinase activity i.e. the ability to interact with, and efficiently phosphorylate, substrates
such as Cdc25A and p53 (Falck et al. 2001a, Falck et al. 2001b, Wu et al. 2001). It has
been suggested that the range of cancers associated with mutations of the CHEK2 may
be much greater than previously thought and they may increase the risk of cancer in
many different organs (Cybulski et al. 2004). However, this was not confirmed in a
large multicenter study (Thompson et al. 2006). Significant association to ovarian
cancer has not been detected either (Baysal et al. 2004).
 The CHEK2 1100delC was shown to be a relatively common low-penetrance allele
conferring susceptibility to breast cancer (CHEK2-Breast Cancer Consortium 2002,
Vahteristo et al. 2002, CHEK2 Breast Cancer Case-Control Consortium 2004) (Table
5). The 1100delC variant allele has been estimated to result in an approximately 2-fold
increase of breast cancer risk in women and a 10-fold increase of risk in men. In BRCA1
or BRCA2 mutation carriers the 1100delC allele did not confer increase in cancer risk,
possibly because of functional redundancy (CHEK2-Breast Cancer Consortium 2002,
CHEK2 Breast Cancer Case-Control Consortium 2004). The estimated 10-fold risk for
male breast cancer or the high carrier frequency among males (CHEK2-Breast Cancer
Consortium 2002) has not been confirmed in other studies and is likely to be smaller
(Syrjäkoski et al. 2004b, Neuhausen et al. 2004, Sodha et al. 2004, Ohayon et al. 2004).
 Vahteristo and co-workers (2002) suggested that CHEK2 acts as a low-penetrance
tumour-suppressor gene in breast cancer and that it makes a significant contribution to
familial clustering of breast cancer - including families with only two affected relatives,
which are more common than families that include larger numbers of affected women.
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In the collaborative analysis the prevalence of 1100delC was somewhat greater in
women reporting a first-degree relative with breast cancer and also some evidence was
seen that the prevalence in cases decreased with increasing age at diagnosis (CHEK2
Breast Cancer Case-Control Consortium 2004). 1100delC has also been observed to
associate with bilateral breast cancer (Vahteristo et al. 2002). A strong association of the
CHEK2 1100delC with a putative hereditary breast and colorectal cancer phenotype
(HBCC) was detected, suggesting a subtype of familial breast cancer (Meijers-Heijboer
et al. 2003). It was also suggested that CHEK2 1100delC mutation acts in synergy with
another as-yet-unknown cancer-susceptibility gene or genes (Meijers-Heijboer et al.
2003, Oldenburg et al. 2003, Johnson et al. 2005).
 Variation in 1100delC carrier frequencies in different populations have been
observed (CHEK2 Breast Cancer Case-Control Consortium 2004), and it is either
absent or occurs in similar frequencies among breast cancer cases and controls in many
populations. Thus, it is evident that the contribution of CHEK2 mutations varies by
ethnic groups and from country to country. (Table 5). Other variants in CHEK2 have
not been detected to make a similar contribution to familial breast cancer susceptibility
as the 1100delC does (Allinen et al. 2001, Schutte et al. 2003, Dufault et al. 2004,
Friedrichsen et al. 2004). Though, significant associations have been found in some
study populations where the 1100delC is rare. (Table 6). Common polymorphisms in
CHEK2 are unlikely to confer an increased risk of breast cancer (Kuschel et al. 2003).
Table 6. Observed variants in CHEK2, other than 1100delC.
Variant Population Association with References
Ser428Phe Ashkenzi Jews familial breast cancer Shaag et al. 2005
Ile157Thr Byelorussian familial breast cancer Bogdanova et al. 2005
Ile157Thr Finnish, Polish, German,
Byelorussian
sporadic breast cancer Kilpivaara et al. 2004, Cybulski et al.
2004, 2006a, Bogdanova et al. 2005
deletion of
exons 9 and 10
Czech and Slovak, Polish 2-fold increase in risk
of breast cancer
Walsh et al. 2006, Cybulski et al. 2007
 The carriers of CHEK2 1100delC appear to develop ER and PR receptor positive
tumours more frequently than non-carriers (de Bock et al. 2004, Schmidt et al. 2007),
and an association with lobular histology and a CHEK2 variant has been suggested
(Huzarski et al. 2005, Cybulski et al. 2006). Tumours from 1100delC carriers also tend
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to be of higher grade than those of non-carriers (Kilpivaara et al. 2005). Tumours with
reduced CHEK2 expression had more often larger primary tumour size compared to
tumours with normal expression (Kilpivaara et al. 2005) and CHEK2 expression is often
reduced in tumours from patients with germ-line 1100delC (Vahteristo et al. 2002).
Otherwise a characteristic CHEK2 signature in breast tumours has not been discovered
yet (Cybulski et al. 2006, Schmidt et al. 2007). A worse disease-free survival has also
been suggested for the mutation carriers (de Bock et al. 2004, Schmidt et al. 2007).
2.3.8.5 LKB1 and Peutz-Jeghers syndrome
Peutz-Jeghers syndrome is a rare autosomal dominant disorder characterised by
mucocutaneous pigmentation and gastrointestinal polyposis. In addition to an elevated
risk of gastrointestinal cancers, an increased risk of cancers at other sites, such as breast,
ovary, uterus, cervix, lung, and testis, has been described. (Giardiello et al. 1987,
Tomlinson and Houlston 1997, Giardiello et al. 2000). The cumulative risk of breast
cancer by age 70 years has been reported to be as high as 45 % (95 % CI=27-68)
(Hearle et al. 2006). The Peutz-Jeghers syndrome is caused by germ-line mutations in
the serine-threonine kinase gene LKB1 (=STK11) located on chromosome 19p13
(Hemminki et al. 1998, Jenne et al. 1998). Germ-line mutations in the LKB1 gene have
not been reported in other than Peutz-Jeghers families, and this gene seems to play a
role in breast cancer susceptibility only in patients with Peutz-Jeghers syndrome (Chen
and Lindblom 2000, de Jong et al. 2002).
2.3.8.6 PALB2 and Fanconi anemia
Fanconi anemia (FA) is a rare autosomal recessive syndrome characterized by
congenital abnormalities, progressive bone-marrow failure, and cancer susceptibility.
(D'Andrea and Grompe 2003). FA is a genetically heterogeneous condition and thus far
the disease includes 13 subtypes (complementation groups), 12 of which have been
attributed to mutations in distinct genes, suggesting that their gene products function in
a common pathway (Taniguchi and D'Andrea 2006, Reid et al. 2007, Patel et al. 2007).
The most recently discovered of FA genes is PALB2 (Reid et al. 2007).
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PALB2 (partner and localizer of BRCA2) gene locates on chromosome 16p12 and
encodes a recently discovered protein that interacts with BRCA2 (Xia et al. 2006).
PALB2 colocalizes with BRCA2 in nuclear foci, promotes its localization and stability
in key nuclear structures (e.g. chromatin and nuclear matrix), and enables its
recombinational repair and checkpoint functions (Xia et al. 2006). Biallelic PALB2
germ-line mutations are responsible for a subset of Fanconi anemia (FA-N) cases
characterized by a phenotype similar to that caused by biallelic BRCA2 mutations (Reid
et al. 2007, Xia et al. 2007). Monoallelic PALB2 mutations were also found in
individuals with breast cancer from familial breast cancer pedigrees that were negative
for BRCA1 and BRCA2 mutations. PALB2 mutations showed an incomplete segregation
in affected relatives and were estimated to confer a 2.3-fold increase in breast cancer
risk and it was suggested that the risks of breast cancer associated with PALB2
mutations may be age dependent. The breast cancer population-attributable fraction of
PALB2 mutations in this UK population was estimated to be 0.23 % and the percentage
of familial relative risk due to PALB2 to be 0.24 %. (Rahman et al. 2007). A truncating
mutation, being a possible founder mutation, in PALB2 was also detected in familial and
sporadic breast cancer cases and in one prostate cancer family in the Finnish population
(Erkko et al. 2007). PALB2 is the first gene that encodes for a protein that interacts with
BRCA2 and confers an increased risk of breast cancer when mutated (Xia et al. 2006,
Rahman et al. 2007).
 The phenotypes associated with biallelic BRCA2 and PALB2 mutations are markedly
similar to each other and differ from the other ten known FA genes (Reid et al. 2007,
Xia et al. 2007). Biallelic mutations in BRIP1 cause one of the FA subtypes and
heterozygous mutations in BRIP1 confer an elevated risk of breast cancer (Levran et al.
2005, Seal et al. 2006). However, it is suggested that breast cancer susceptibility is
associated with only a subset of Fanconi anemia genes which is consistent with the
negative results of mutational screens of other FA genes (Seal et al. 2003). The
currently known FA genes that associate with breast cancer, BRCA2, PALB2 and
BRIP1, are not part of the FA core complex and are the only known FA genes that act
downstream of FANCD2 (Rahman et al. 2007).
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2.4 Sporadic breast cancer and low-penetrance susceptibility genes
Familial aggregation of breast cancer is thought to account for 5-10 % of all cases of
breast cancer (Claus et al. 1996). Currently known high-risk and high-penetrance
susceptibility genes confer approximately 20 % of this (Thompson and Easton 2004).
However, in twin studies heritable factors are observed even in one fourth of breast
cancer cases (Lichtenstein et al. 2000). It is assumed that several common, low to
moderate penetrance genes are present in the general population and account also for
the residual familial aggregation of breast cancer (Pharoah et al. 1997, Antoniou et al.
2002). The disease causing alleles of high-penetrance genes are relatively rare in the
general population, whereas the low-penetrance disease-associated alleles are common.
High-penetrance genes predispose to both earlier onset of the disease and multifocal
tumours. In contrast to these familial cases, sporadic breast cancers caused by low-
penetrance genes usually appear unilaterally and have relatively late age at diagnosis.
Low-penetrance genes are likely to interact with environmental and life-style factors as
well as with other genes to cause cancer. (Rebbeck 1999). As a result of this etiologic
complexity, malignant diseases that do not follow a simple Mendelian pattern of
inheritance in a substantial number of families have remained refractory to mapping by
linkage. (Le Marchand 2005). It has been observed that subtle effects of some genetic
variants may be magnified and only become detectable in the presence of certain
exposures (Low et al. 2006). The identification of such low or moderate-penetrance
susceptibility alleles is an extensive task. Utilising the candidate-gene approach,
polymorphisms in several genes have been tested in breast cancer case-control
association studies. In these studies the genes have been selected in pathways of known
or suspected breast cancer-associated factors, such as genes affecting the oestrogen
levels and metabolism, DNA repair or tumour growth. The genes studied for breast
cancer association in the Eastern Finnish population (KBCP) are listed in Table 7.
5 1
Ta
bl
e 
7.
 G
en
es
 st
ud
ie
d 
fo
r a
ss
oc
ia
tio
n 
w
ith
 b
re
as
t c
an
ce
r r
is
k 
in
 th
e 
Ea
st
er
n 
Fi
nn
is
h 
(K
BC
P)
 p
op
ul
at
io
n.
G
en
e
Po
ly
m
or
ph
is
m
A
ss
oc
ia
tio
n
Si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n 
w
he
n
st
ra
tif
ie
d
O
R
 (9
5%
 C
I)
R
ef
er
en
ce
O
es
tr
og
en
 b
io
sy
nt
he
sis
C
YP
17
5'U
TR
 T
19
31
C
 
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
92
 (0
.6
9-
1.
22
) f
or
 C
 a
lle
le
co
nt
ai
ni
ng
 g
en
ot
yp
es
M
itr
un
en
 e
t a
l. 
20
00
O
es
tr
og
en
 m
et
ab
ol
is
m
CY
P1
A1
Ile
46
2V
al
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
76
 (0
.5
0-
1.
14
) f
or
 Il
e/
V
al
 a
nd
V
al
/V
al
 c
om
bi
ne
d
Si
lla
np
ää
 e
t a
l. 
20
07
Th
r4
61
A
sn
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
67
 (0
.5
0-
5.
48
) f
or
 T
hr
/A
sn
Si
lla
np
ää
 e
t a
l. 
20
07
CY
P1
B1
Le
u4
32
V
al
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
In
cr
ea
se
d 
ris
k 
am
on
g 
sm
ok
er
s o
f 1
-9
ci
ga
re
tte
s/d
ay
2.
6 
(1
.0
7-
6.
46
) f
or
 L
eu
/V
al
5.
1 
(1
.3
0-
19
.8
9)
 fo
r V
al
/v
al
Si
lla
np
ää
 e
t a
l. 
20
07
CO
M
T
V
al
10
8/
15
8M
et
 
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
81
 (0
.5
8-
1.
13
) f
or
 V
al
/m
et
 a
nd
M
et
/M
et
 c
om
bi
ne
d
M
itr
un
en
 e
t a
l. 
20
01
c
SU
LT
1A
1
A
rg
21
3H
is
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
D
ec
re
as
ed
 ri
sk
 in
 p
re
m
en
op
au
sa
l
w
om
en
 w
ith
 a
t l
ea
st 
3 
pr
eg
na
nc
ie
s a
nd
on
e 
H
is
 a
lle
le
0.
23
 (C
I=
0.
09
-0
.6
3)
Si
lla
np
ää
 e
t a
l. 
20
05
b
G
ST
M
1
A
lle
le
 d
el
et
io
n
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
In
cr
ea
se
d 
ris
k 
am
on
g 
po
st
m
en
op
au
sa
l
G
ST
M
1 
nu
ll 
ge
no
ty
pe
s
1.
49
 (1
.0
3-
2.
15
)
M
itr
un
en
 e
t a
l. 
20
01
a
G
ST
M
3
3 
bp
 d
el
et
io
n 
in
in
tro
n 
6
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
00
 (0
.7
3-
1.
37
) f
or
 v
ar
ia
nt
 a
lle
le
co
nt
ai
ni
ng
 g
en
ot
yp
es
M
itr
un
en
 e
t a
l. 
20
01
a
G
ST
P1
Ile
10
5V
al
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
88
 (0
.6
6-
1.
18
) f
or
 Il
e/
V
al
0.
57
 (0
.3
1-
1.
04
) f
or
 V
al
/V
al
M
itr
un
en
 e
t a
l. 
20
01
a
G
ST
T1
A
lle
le
 d
el
et
io
n
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
18
 (0
.8
-1
.7
6)
 fo
r n
ul
l g
en
ot
yp
es
M
itr
un
en
 e
t a
l. 
20
01
a
M
nS
O
D
V
al
16
A
la
A
la
 a
lle
le
 c
ar
rie
rs
 a
t
in
cr
ea
se
d 
ris
k 
co
m
pa
re
d 
to
V
al
/V
al
1.
5 
(1
.1
-2
.0
)
M
itr
un
en
 e
t a
l. 
20
01
b
C
ar
ci
no
ge
n 
m
et
ab
ol
is
m
NA
T2
C
28
2T
T3
41
C
In
cr
ea
se
d 
ris
k 
as
so
ci
at
ed
 w
ith
 sl
ow
ac
et
yl
at
or
 g
en
ot
yp
es
 2
82
T/
28
2T
,
34
1C
/3
41
C,
 2
82
T/
34
1C
1.
32
 (1
.0
1-
1.
73
)
Ri
sk
 h
ig
he
r a
m
on
g 
w
om
en
 sm
ok
in
g
5<
 p
ac
k-
ye
ar
s
Si
lla
np
ää
 e
t a
l. 
20
05
a
AD
H
1B
3'
U
TR
 A
>G
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
79
 (0
.5
9-
1.
05
) f
or
 A
G
1.
38
 (0
.7
1-
2.
69
) f
or
 G
G
C
ox
 e
t a
l. 
20
07
Ta
bl
e 
7.
5 2
G
en
e
Po
ly
m
or
ph
is
m
A
ss
oc
ia
tio
n
Si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n 
w
he
n
st
ra
tif
ie
d
O
R
 (9
5%
 C
I)
R
ef
er
en
ce
D
N
A
 r
ep
ai
r
BR
CA
2
A
sn
37
2H
is
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
04
 (0
.8
3-
1.
30
) f
or
 A
sn
/H
is
1.
07
 (0
.6
1-
1.
87
) f
or
 H
is/
H
is
H
ea
le
y 
et
 a
l. 
20
00
a
XR
CC
1
A
rg
28
0H
is
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
15
 (0
.8
0-
1.
66
) f
or
 A
rg
/H
is
 a
nd
H
is
/H
is
 c
om
bi
ne
d
M
et
so
la
 e
t a
l. 
20
05
A
rg
39
9G
ln
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
In
cr
ea
se
d 
ris
k 
am
on
g 
ev
er
 s
m
ok
er
s a
nd
at
 le
as
t o
ne
 G
ln
 a
lle
le
2.
33
 (1
.3
0-
4.
19
)
Ri
sk
 h
ig
he
r a
m
on
g 
w
om
en
 sm
ok
in
g
5<
 p
ac
k-
ye
ar
s
M
et
so
la
 e
t a
l. 
20
05
XP
D
Ly
s7
51
G
ln
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
In
cr
ea
se
d 
ris
k 
am
on
g 
ev
er
 s
m
ok
er
s a
nd
G
ln
/G
ln
 g
en
ot
yp
e
2.
52
 (1
.2
7-
5.
03
)
Ri
sk
 h
ig
he
r a
m
on
g 
w
om
en
 sm
ok
in
g
5<
 p
ac
k-
ye
ar
s
M
et
so
la
 e
t a
l. 
20
05
AT
M
Se
r4
9C
ys
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
C
ox
 e
t a
l. 
20
07
H
or
m
on
e-
 a
nd
 g
ro
w
th
 fa
ct
or
-r
el
at
ed
 g
en
es
IG
FB
P3
-2
02
C
>A
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
20
 (0
.8
9-
1.
62
) f
or
 C
A
0.
91
 (0
.6
1-
1.
36
) f
or
 A
A
C
ox
 e
t a
l. 
20
07
VD
R
A
pa
I
a 
al
le
le
 c
ar
rie
rs
 a
t d
ec
re
as
ed
ris
k 
co
m
pa
re
d 
to
 A
A
0.
73
 (0
.5
4-
0.
98
)
Si
lla
np
ää
 e
t a
l. 
20
04
Ta
qI
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
68
 (0
.4
1-
1.
12
) f
or
 T
t a
nd
 tt
co
m
bi
ne
d
Si
lla
np
ää
 e
t a
l. 
20
04
TG
FB
1
Le
u1
0P
ro
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
91
 (0
.7
1-
1.
17
) f
or
 L
eu
/P
ro
1.
14
 (0
.6
8-
1.
91
) f
or
 P
ro
/P
ro
D
un
ni
ng
 e
t a
l. 
20
03
C
el
l c
yc
le
 c
on
tr
ol
ST
K
15
Ph
e3
Ile
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
02
 (0
.7
8-
1.
34
) f
or
 P
he
/Il
e
0.
61
 (0
.3
5-
1.
07
) f
or
 Il
e/
Ile
Br
ea
st 
Ca
nc
er
 A
ss
oc
ia
tio
n
C
on
so
rti
um
 2
00
6
CD
KN
1A
Se
r3
1A
rg
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
27
 (0
.8
1-
2.
00
) f
or
 S
er
/A
rg
3.
15
 (0
.3
3-
30
.4
3)
 fo
r A
rg
/A
rg
C
ox
 e
t a
l. 
20
07
O
th
er
 g
en
es
CA
SP
8
A
sp
30
2H
is
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
82
 (0
.5
7-
1.
16
) f
or
 A
sp
/H
is
6.
53
 (0
.3
4-
12
6.
92
) f
or
 H
is
/H
is
C
ox
 e
t a
l. 
20
07
IC
AM
5
V
al
30
1I
le
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
94
 (0
.6
0-
1.
48
) f
or
 V
al
/Il
e
1.
04
 (0
.6
6-
1.
63
) f
or
 Il
e/
Ile
C
ox
 e
t a
l. 
20
07
NU
M
A1
A
la
79
4G
ly
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
0.
69
 (0
.3
6-
1.
33
) f
or
 A
la
/G
ly
 a
nd
G
ly
/G
ly
 c
om
bi
ne
d
C
ox
 e
t a
l. 
20
07
Ta
bl
e 
7.
 (
co
nt
in
ue
d)
5 3
FG
FR
2
in
tro
n 
2 
G
>A
rs
29
81
58
2
G
A
 a
nd
 A
A
 a
t i
nc
re
as
ed
 ri
sk
co
m
pa
re
d 
to
 G
G
1.
36
 (1
.1
1-
1.
66
) p
er
 a
lle
le
Ea
st
on
 e
t a
l. 
20
07
LS
P1
in
tro
n 
10
 T
>C
rs
38
17
19
8
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
03
 (0
.8
2-
1.
30
) p
er
 a
lle
le
Ea
st
on
 e
t a
l. 
20
07
H
19
C>
T 
 rs
21
07
42
5 
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
03
 (0
.8
3-
1.
28
) p
er
 a
lle
le
Ea
st
on
 e
t a
l. 
20
07
TN
RC
9/
LO
C6
43
71
4
in
tro
n 
1 
C
>T
rs
80
51
54
2
C
T 
an
d 
TT
 a
t i
nc
re
as
ed
 ri
sk
co
m
pa
re
d 
to
 C
C
1.
37
 (1
.1
1-
1.
67
) p
er
 a
lle
le
Ea
st
on
 e
t a
l. 
20
07
in
tro
n 
1 
A
>G
rs
12
44
36
21
A
G
 a
nd
 G
G
 a
t i
nc
re
as
ed
 ri
sk
co
m
pa
re
d 
to
 A
A
1.
26
 (1
.0
3-
1.
55
) p
er
 a
lle
le
Ea
st
on
 e
t a
l. 
20
07
C>
T
rs
38
03
62
N
o 
ov
er
al
l a
ss
oc
ia
tio
n
1.
03
 (0
.8
3-
1.
27
) p
er
 a
lle
le
Ea
st
on
 e
t a
l. 
20
07
54
2.4.1 Steroid hormone biosynthesis, signalling and metabolism genes
Most of the known risk factors for breast cancer relate to the increased, prolonged or
life-time oestrogen exposure. Oestrogens also undergo extensive oxidative metabolism
via several enzymes, yielding catechol oestrogens (CE) and hydroxyestrone, some of
which are even carcinogenic. Therefore the genes encoding enzymes involved in
oestrogen and other steroid hormone biosynthesis, signalling and metabolism are strong
candidates for low-penetrance genetic risk factors for breast cancer, as allelic variants in
these enzymes may affect the hormone levels.
2.4.1.1 Steroid hormone biosynthesis genes
Oestrogen biosynthesis involves series of enzymatic steps from cholesterol to C-19
androgens and C-18 oestrogens (Figure 3, Table 8). Table 8 shows the genes involved
in steroid hormone biosynthesis and their observed association with breast cancer risk.
Figure 3. Oestrogen biosynthesis. CYP11A, CYP17 and CYP19 are particularly important. See
Table 8 for details.
2.4.1.2 Steroid hormone signalling genes
The sex hormones bind to specific receptors and form complexes that in turn bind to
sequences in the promoters of downstream, hormone-responsive genes and thus the sex
hormones control the activation of responsive genes. Therefore the steroid hormone
receptor genes ESR1 (oestrogen receptor alpha) (Walter et al. 1985, Menasce et al.
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1993), ESR2 (oestrogen receptor beta) (Enmark et al. 1997), PGR (progesterone
receptor) (Law et al. 1987, Misrahi et al. 1987) and AR (androgen receptor) (Chang et
al. 1988, Lubahn et al. 1988), as well as SHBG (sex hormone-binding globulin) are
candidates for breast cancer susceptibility genes. (Table 8). Women with higher
circulating levels of SHBG have been detected to have a lower risk of breast cancer
(Endogenous Hormones and Breast Cancer Collaborative Group 2002). Also
association between higher testosterone levels and increase in breast cancer risk in
postmenopausal women has been observed (Endogenous Hormones and Breast Cancer
Collaborative Group 2002).
2.4.1.3 Steroid hormone metabolism genes
Oestrogens are extensively metabolised by a number of oxidative and conjugative
reactions that can lead to their deactivation and subsequent elimination. Alternatively,
oxidation and conjugation reactions of oestrogens may generate metabolites that have
distinct biologic activities, including altered hormonal properties; genotoxicity; and/or
chemotherapeutic properties. In the metabolism of oestrogen are several enzymes/genes
involved (Figure 4). (Zhu and Conney 1998, Jefcoate et al. 2000, Thompson and
Ambrosone 2000). (Table 9).
 Oxidative metabolism of oestrogens is mediated by the same CYPs that metabolise
therapeutic agents and xenobiotics. Oestrogens are metabolised via two major
pathways, i.e. hydroxylation either at the A-ring or the D-ring, leading to formation of
catechol oestrogens (CE) and 16?-hydroxyestrone, respectively. (Martucci and Fishman
1993, Lippert et al. 2000). Oestrogen conjugation is a major route of oestrogen
metabolism. Hydroxylated oestrogens can be inactivated by O-methylation catalysed by
COMT (Zhu and Conney 1998, Cavalieri et al. 1997). Sulfate conjugation of oestrogens
and CEs is catalyzed by several members of a superfamily of cytosolic sulfotransferase
enzymes, SULTs (Glatt et al. 2001). Sulfation and methylation detoxifies CEs and
conjugated oestrogens are not appreciable ligands for the ERs, thus, they do not
promote ER-mediated activity (Zhu and Conney 1998). CEs are the major metabolites
of oestrogen, and they are intermediates for the generation of the reactive semiquinones
57
(CE-SQ) and guinones (CE-Q), which in turn have the ability to damage DNA and
protein through redox cycling and generation of reactive oxygen species (ROS), and
thus have been implicated as potential initiators of tumour formation (Cavalieri et al.
1997, Zhu and Conney 1998, Liehr 1997). Superoxide dismutases (SODs) comprise a
family of metalloenzymes that catalyse the conversion of superoxide anion into
hydrogen peroxide and molecular oxygen and thus protect cells from damage induced
by free radicals (Winterbourn 1993). CE-Q may be conjugated with glutathione (GSH)
catalysed by cytosolic glutathione S-transferases, GSTs, or reduced to CE by quinone
reductase NQO1 (Cavalieri et al. 1997). (Figure 4, Table 9).
Figure 4. Oestrogen metabolism.
 In addition to oestrogen metabolism, GSTs are a family of enzymes responsible for
the metabolism of a broad range of xenobiotics and carcinogens (Mannervik 1985).
GSTs catalyse the conjugation of glutathione (GSH) to a variety of endogenous and
exogenous electrophiles, increasing their water solubility and excretability (Ketterer
1988). Also NQO1 is involved in metabolising numerous endogenous and
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environmental quinones (Ernster and Navazio 1958, Grzeschik 1980, Povey et al. 1980,
Jaiswal et al. 1988, Chen et al. 1991). It is a 2-electron reductase that detoxifies
quinones derived from the oxidation of phenolic metabolites of benzene (Ernster 1967,
Lind et al. 1982). In the metabolism of xenobiotics NQO1 may act as either a
detoxification or activation enzyme, depending on the substrate.
2.4.2 Carcinogen and xenobiotics metabolism
Several enzymes are involved in the detoxification of xenobiotic compounds found in
e.g. tobacco smoke and cooked meat. Some of these enzymes are involved in the steroid
hormone metabolism also (introduced above, Table 9). The detoxifying enzymes
convert carcinogenic compounds in more soluble and more readily excreted form and
therefore reduce cancer risk. Some of the more soluble compounds, however, are even
more carcinogenic. Thus, genetic changes that increase or decrease the activity of the
detoxifying enzymes may increase the amount of reactive carcinogens and increase the
risk of cancer. Such enzymes are candidates for breast cancer susceptibility and objects
for genetic case-control association studies.
NAT1 and NAT2 genes are highly polymorphic and several different allelic variants
exist that determine the NAT1/NAT2-related biotransformation capacity resulting in
slow, intermediate or fast/rapid acetylator phenotype (Evans et al. 1960, Deguchi et al.
1990, Vatsis et al. 1991, Blum et al. 1991, Hickman et al. 1992, Lin et al. 1993,
Deguchi 1992, Butcher et al. 1998, Hughes et al. 1998). A difference in the acetylation
rate can alter the proportion of specific metabolites that are formed and genotoxicity by
substrates of NAT can be affected by the amount of acetylation. Relationship between
acetylator phenotype and DNA damage by chemicals that undergo N-acetylation has
been found and the acetylation polymorphism may be a factor in susceptibility to
toxicity and perhaps carcinogenicity of these chemicals (McQueen et al. 1982). The
association of NAT1 and NAT2 acetylator phenotypes and breast cancer has been
studied but the findings have been very inconsistent. (Table 10).
 MPO generates ROS endogenously and is linked to cancers through DNA damage
and the production of carcinogens (Klebanoff 1980, Van Rensburg et al. 1992, Petruska
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et al. 1992). MPO is present in breast secretions and is thought to be involved in the
chemical/metabolic induction of breast cancer (Josephy 1996, Williams et al. 2000).
Also, there are indications that steroid hormones regulate MPO expression (Bekesi et al.
2001). Thus, it is plausible to hypothesize that MPO could play a role in breast
carcinogenesis, and that factors that would increase lifetime exposures to estrogens,
such as age at menarche, could modify this relationship (Ahn et al. 2004). (Table 10).
 Alcohol consumption may increase the risk of breast cancer by increasing the
exposure to carcinogenic metabolites (Feron et al. 1991) or by influencing the levels of
reproductive steroid hormones that play a critical role in breast carcinogenesis
(Ginsburg et al. 1995). Alcohol dehydrogenases (ADHs) are enzymes involved in the
metabolism of ethanol to acetaldehyde. ADH plays a rate-limiting role in the metabolic
pathway for most human ethanol oxidation. (Bosron and Li 1986). Polymorphisms in
ADH genes have been studied for breast cancer association (Table 10).
2.4.3 Other hormone- and growth factor-related genes
Breast cancer risk is known to be strongly related to endogenous hormone exposure and
the genes responsive to such hormones are plausible candidates for being susceptibility
genes. Also genes encoding for many growth factors involved in cellular growth, cell
proliferation and differentiation, and angiogenesis are potent candidates for breast
cancer risk associated factors, as all these pathways are affected in tumour growth.
Several of these genes have been studied and some of them have shown association
with breast cancer risk.
2.4.3.1 Insulin-like growth factor family
Insulin-like growth factor family includes the insulin-like growth factors (IGFs) I and II
(IGF-I, IGF-II), six different IGF binding proteins (IGFBPs), and the receptors IGF-IR
and IGF-IIR. In addition, several IGFBP proteases hydrolyze IGFBPs, resulting in
release of the bound IGFs, and therefore indirectly regulate the action of IGFs. IGF
family members interact with several molecules that are involved in cancer
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development and progression, including the sex steroid hormones, tumour suppressors,
and other growth factors. (Yu and Rohan 2000).
 The IGF axis has been shown to play a role in mammary carcinogenesis (Hadsell and
Bonnette 2000). IGF-I and IGFBP3 concentrations vary greatly between individuals,
part of which is attributable to genetic effects (Juul et al. 1994, Juul et al. 1995, Harrela
et al. 1996), and  might affect the distribution of cancer risk in a population. High serum
levels of IGF-I have been shown to be associated with breast cancer risk among
premenopausal women (Hankinson et al. 1998, Renehan et al. 2004). The results on
IGFBP3 levels and association with breast cancer risk are uncertain, possibly due to
methodological reasons. A meta-analysis suggests an increase in risk with higher
IGFBP3 levels (Renehan et al. 2004). However, the biological role of IGFBP3 supports
the observation that higher circulating levels are protective (Al-Zahrani et al. 2006).
Polymorphisms in both genes associate with the circulating levels of their respective
proteins (Jernström et al. 2001, Schernhammer et al. 2003, Canzian et al. 2006, Al-
Zahrani et al. 2006). (Table 11).
 Growth hormone (GH) is the main stimulator of IGF-I and IGFBP3 production and
genetic variants affecting the release or biological action of GH might have an effect on
cancer risk. (Table 11).
2.4.3.2 Vitamin D receptor, VDR
Vitamin D receptor, VDR, is a ligand-activated transcription factor interacting with
many pathways, including p21, fibronectin and retinoic signaling, and its actions are
involved in e.g. calcium metabolism, cell proliferation and differentation, and immune
function (Uitterlinden et al. 2004). Several polymorphisms (TaqI, ApaI, BsmI and poly-
A which are all in LD with each other, and the only known protein polymorphism in the
VDR gene, FokI) have been studied in the vitamin D receptor VDR gene but conclusive
evidence on the association with increased risk of breast cancer has not been shown
(Arai et al. 1997, Dunning et al. 1999b, Colin et al. 2000, Whitfield et al. 2001, de Jong
et al. 2002, Uitterlinden et al. 2004, Chen et al. 2005). (Table 11).
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2.4.3.3 Vascular endothelial growth factor, VEGF
Formation of new blood vessels is needed for tumour growth, invasiveness and
metastasis, and vascular endothelial growth factor (VEGF) is the most important
regulator of angiogenesis (Ferrara et al. 1997, Ferrara et al. 2003). VEGF is an
endothelial cell-specific mitogen, an angiogenic inducer and a mediator of vascular
permeability (Ferrara et al. 1997). In breast cancer tissue the mRNA expression of
VEGF is increased compared to adjacent normal tissue (Yoshiji et al. 1996).
Polymorphisms in the VEGF have been suggested to be associated with an increased
and decreased risk of breast cancer. (Table 11).
2.4.3.4 Transforming growth factor beta, TGFB1
TGF? is a polypeptide cytokine that has a role in regulating cell growth, differentiation
and migration. It regulates e.g. normal mammary gland development and function by
activating the TGF? signalling pathway. There is a dual-role of action in which the
TGF? signalling suppresses tumour initiation but can also promote tumour progression
and metastasis when antiproliferative effect of the TGF? signaling pathway has been
overridden by other oncogenic mutations. (Bierie and Moses 2006, Derynck et al.
2001).
 A Leu10Pro polymorphism resides in the signal peptide sequence of TGF?1 and the
peptide with Pro at residue 10 causes a 2.8-fold increase in secretion compared with the
Leu form (Dunning et al. 2003). In a large collaborative study some evidence for
association with TGFB1 Leu10Pro and breast cancer risk was shown (Breast Cancer
Association Consortium 2006). This was further confirmed in an even larger sample
material (Cox et al. 2007). The analysis of Leu10Pro variant showed a significant dose-
dependent association of the Pro allele with increased risk of invasive breast cancer
(per-allele OR 1.08, CI=1.04-1.11, P(trend)=2.8 x 10-5), and it was estimated to account
for approximately 0.2 % of the excess familial risk of breast cancer in populations of
European ancestry (Cox et al. 2007). (Table 11).
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2.4.4 Genes involved in double-stranded DNA break repair
Double-strand breaks are frequently induced by e.g. certain chemicals, ionizing
radiation, and mechanical stress, and they are particularly difficult to repair compared
with other types of DNA damage. Inability to correctly repair DSBs can cause
chromosomal loss, translocations and deletions that may lead to activation of proto-
oncogenes, loss of function of tumour suppressor genes or global genomic instability
and thus, lead to tumorigenesis. (Khanna and Jackson 2001). The genes which normally
participate in the error-free repair of breaks in double-stranded DNA predispose to
breast and other cancers when inactivated and common variants of DSB-involved genes
have been implicated in epidemiological studies of breast cancer risk.
 Two general forms of DSB repair are found within eukaryotic cells: non-homologous
end-joining (NHEJ) and homologous recombination (HR). Several types of homologous
repair exist; gene conversion, break-induced replication (BIR) and single-strand
annealing (SSA). Similarly, there are several alternative end-joining mechanisms.
(Haber 2000). NHEJ repairs broken DNA ends by joining the broken strands together
and it does not need an undamaged partner and does not rely on extensive homologies
between the two recombining ends. Consequently, NHEJ is often prone to error, and
small deletions often occur at the site of fusion. HR uses homologous chromosomal or
sister chromatid DNA as template for synthesis of new error-free DNA. In HR, the
DNA ends are first resected in the 5' to 3' direction by nucleases. The resulting 3' single-
stranded tails then invade the DNA double helix of a homologous, undamaged partner
molecule, and are extended by the action of DNA polymerase, which copies information
from the partner. Following branch migration, the resulting DNA crossovers are
resolved to yield two intact DNA molecules. In contrast to NHEJ the HR is a high
fidelity process. (Khanna and Jackson 2001).
 In humans, several genes are involved in the NHEJ (KU70, XRCC5, DNA-PK,
XRCC4, LIG4) and HR (ATM, BRCA1, BRCA2, RAD51, RAD52, RAD54, RAD51B,
RAD51C, RAD51D, RPA, XRCC2, XRCC3, DMC1, ZNF350=ZBRK1, BRIP1=BACH1)
and proteins encoded by some of them (NBS1, MRE11, RAD50) have functions in both
pathways (van Gent et al. 2001). Polymorphisms have been studied in several of these
genes and some studies have reported associations, but others not (Table 12).
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Table 12. Genes involved in double-stranded DNA break repair that have been studied for
breast cancer association.
Gene, locus Contribution to breast cancer risk References
XRCC2, 7q36.1 suggested to modify risk, significant main
effect not confirmed
Kuschel et al. 2002, Rafii et al. 2002, Breast
Cancer Association Consortium 2006
LIG4, 13q22-q34 suggested to modify risk, significant main
effect not confirmed
Kuschel et al. 2002, Breast Cancer
Association Consortium 2006
XRCC3, 14q32.3 suggested association  with weak risk,
significant main effect not confirmed
Kuschel et al. 2002, Garcia-Closas et al.
2006, Breast Cancer Association
Consortium 2006XRCC4, Ku70,
5q13-q14
suggested association among Taiwanese Fu et al. 2003
RAD52,
12p13-p12.2
suggested association among Koreans Lee et al. 2005b
RAD51, 15q15.1 modifies risk among BRCA mutation carriers,
no role in sporadic breast cancer
Levy-Lahad et al. 2001, Wang et al. 2001a
RAD51D, 17q11 suggested association with increased risk Rodriguez-Lopez et al. 2004
ZNF350 suggested association in familial high-risk
subgroup
Garcia-Glosas et al. 2006
BRIP1 (BACH1),
17q22
truncating mutations are low-penetrance breast
cancer susceptibility alleles in familial breast
cancer, estimated breast cancer-attributed
fraction of 0.20 %, SNPs not associated
Sigurdson et al. 2004, Seal et al. 2006, Song
et al. 2007
FANCD2, 3p25.3 suggested association with increased risk Barroso et al. 2006
NBS1, 8q21 suggested association with increased risk,
mutations seem to contribute to risk
Kuschel et al. 2002, Lu et al. 2006, Steffen
et al. 2006
RAD50, 5q31 suggested low-penetrance risk allele among
Northern Finnish breast cancer cases
Heikkinen et al. 2006
BARD1, 2q34 see text for details
2.4.4.1 BARD1
The BRCA1-associated ring domain 1 (BARD1) protein was discovered as a binding
partner of BRCA1 (Wu et al. 1996). BARD1 and BRCA1 have several features in
common: similar protein structure, the embryonic lethality of their respective knockout
mice and induction of genetic instability when depleted from cells (Irminger-Finger and
Jefford 2006). BARD1 and BRCA1 form a functional heterodimer through the binding
of their RING-finger domains (Wu et al. 1996, Meza et al. 1998). The interaction is
required for several of the cellular and tumour suppressor functions of BRCA1.
BRCA1-BARD1 heterodimer has been described as the functional unit in DSB repair
(Jasin 2002). BARD1 and BRCA1 also associate with other repair proteins, such as the
MSH2-MSH6 complex, and this interaction indicates a role in DNA mismatch repair
(Wang et al. 2001b). Several reports have also demonstrated BRCA1-independent
functions of BARD1, primarily in apoptosis, and BRCA1-independent increased
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expression of BARD1 during mitosis, indicating that BARD1 on its own might have
crucial functions. Its cancer-associated activities seem to centre on two major pathways:
as an essential component of a ubiquitin ligase involved in DNA repair and cell-cycle
regulation, and p53-mediated apoptosis. (Irminger-Finger and Jefford 2006).
BARD1 gene locates on chromosome 2q34 (Wu et al. 1996, Thai et al. 1998).
Germline BARD1 mutations have been found in few cases of sporadic and familial, non-
BRCA1/2, breast and ovarian cancer patients and some tumours, but they account for
only a small fraction of cases of familial breast cancer overall (Thai et al. 1998,
Ghimenti et al. 2002, Ishitobi et al. 2003, Karppinen et al. 2004, Sauer and Andrulis
2005). One missense alteration, Cys557Ser has been suggested to associate with a
slightly increased risk of familial breast cancer (Ghimenti et al. 2002, Karppinen et al.
2006). Increase in risk was also observed in Icelandic case-control study, and the risk
among BRCA2 999del5 mutation carriers was further increased if they also carried the
BARD1 557Ser (Stacey et al. 2006). In the Chinese population other BARD1 variant
alleles have been suggested to be protective (Huo et al. 2006).
2.4.5 Genes involved in single-stranded DNA damage repair mechanisms
2.4.5.1 Base-excision repair
Base-excision repair (BER) is an important DNA repair pathway responsible for the
repair of single-stranded base damage resulting from X-rays, oxygen radicals,
methylation, deamination, and hydroxylation. BER acts on small lesions and involves
release of the damaged base and removal of up to a few neighboring nucleotides. BER
is particularly relevant for preventing mutagenesis. BER pathway includes several
proteins and the genes encoding them have numerous genetic variants. These genes
include XRCC1, ADPRT (PARP-1), PCNA, FEN1, OGG1, MUTYH, APEX1=APE1,
LIG3, LIG1, NTH1, and POLB (DNA polymerase ?). XRCC1 protein interacts with
DNA polymerase ?, DNA ligase III, PARP-1, and APE1 in the final ligation stage of
the BER DNA repair pathway, and of the BER genes XRCC1 is the most studied for
breast cancer association. (Hoeijimakers 2001, Goode et al. 2002b). (Table 13).
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Table 13. Polymorphisms studied for breast cancer association in genes involved in base-
excision repair (BER) and nucleotide-excision repair (NER).
Gene, locus Polymorphism Contribution to breast cancer References
BER
XRCC1,
19q13.2
Arg399Gln suggested association among African-
Americans and Asian populations,
suggested to modify risk among smokers
or with family history,
no overall association confirmed
Duell et al. 2001, Kim et al. 2002,
Figueiredo et al. 2004 ,Metsola et
al. 2005, Chacko et al. 2005,
Zhang et al. 2006, Breast Cancer
Association Consortium 2006
NER
XPD (ERCC2),
19q13.2
Asp312Asn association observed in some but not
confirmed in larger studies
Justenhoven et al. 2004, Försti et
al. 2004, Kuschel et al. 2005,
Breast Cancer Association
Consortium 2006
Lys751Gln suggested to associate with risk and
modify risk among smokers (Finns)
Justenhoven et al. 2004, Terry et
al. 2004, Metsola et al. 2005
Asp1140His marginal association among Finns Kumar et al. 2003
ERCC1,19q13.2 8092A>C suggested increased risk among Koreans Lee et al. 2005b
ERCC4 (XPF),
16p13.3
intronic variant suggested protective Milne et al. 2006
2.4.5.2 Nucleotide-excision repair
Nucleotide-excision repair (NER) deals with the wide class of bulky helix-distorting
lesions that interfere with base pairing and generally obstruct transcription and normal
replication. Most NER lesions arise from exogenous sources and affect only one of the
DNA strands (single-stranded). Two NER subpathways exist: global genome NER
(GG-NER) and transcription-coupled repair (TCR). (Hoeijimakers 2001). Numerous
proteins are involved in NER and genes encoding them include XPA-XPG, ERCC1,
RAD23A, RAD23B, CETN2, RPA1-3, GTF2H1-4, DDB1, DDB2, CSA, CSB, XAB2,
BRCA1, and BRCA2 (Friedberg 2001). Some of these genes are candidates and have
been studied for breast cancer risk association. XPD (=ERCC2) encodes a protein that is
an integral member of the basal transcription factor BTF2-TFIIH complex, and it is the
most studied of the NER genes for breast cancer association. (Table 13).
2.4.5.3 Mismatch repair
Mismatch repair (MMR) removes nucleotides mispaired by DNA polymerases and
insertion/deletion loops (ranging from one to ten or more bases) that result from
slippage during replication of repetitive sequences or during recombination. Defects in
this system dramatically increase mutation rates, fuelling the process of oncogenesis.
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Genes involved in MMR are hMLH1, hMSH2, hMSH3, hMSH6, hPMS1 and hPMS2.
(Hoeijimakers 2001). So far polymorphism only in hMLH1 has been associated with
increased risk of breast cancer in Korean population (Lee et al. 2005b).
2.4.6 Genes involved in cell cycle control
Cell cycle control is critical for normal growth and differentiation. Defects in
checkpoints contribute to genetic instability and cancer. Genes encoding proteins that
are involved in controlling cell cycle progression, include e.g. TP53, CHEK2, ATM,
RB1, CDKN1A, CDKN1B, CDKN2A, CCND1 and STK15.
The STK15 (AURORA2/AURKA/BTAK/ARK1) gene on chromosome 20q13 encodes
a serine/threonine kinase that acts as a key regulator of mitotic chromosome
segregation, and has a role in the etiology of cancer (Shindo et al. 1998, Hirota et al.
2003, Meraldi et al. 2004). A Phe31Ile polymorphism in STK15 has been reported to be
a low-penetrance susceptibility allele affecting multiple cancer types (Ewart-Toland et
al. 2005) and it has been studied for breast cancer association but the results are
inconsistent. (Table 14).
Table 14. Breast cancer association of genes involved in cell cycle control.
Gene, locus Variation Contribution to breast cancer References
STK15,
20q13
Phe31Ile differing results, suggested
increased risk in women < 40 years
of age
Sun et al. 2004, Ewart-Toland et al.
2005, Cox et al. 2006, Fletcher et al.
2006, Breast Cancer Association
Consortium 2006
CDKN2A,
9p21
inherited mutations predispose to breast cancer in the
context of a syndrome of melanoma,
pancreatic cancer, and breast cancer
in Swedish families
Borg et al. 2000
Ala148Thr suggested association in Polish
population
Debniak et al. 2005
CDKN2A gene on chromosome 9p21 is a tumour suppressor gene that is involved in
susceptibility of malignant melanoma and familial pancreatic carcinoma (Kamb et al.
1994, Monzon et al. 1998, Whelan et al. 1995, Sherr 2001). The p16 protein encoded by
CDKN2A is a cyclin dependent kinase inhibitor that suppresses cell proliferation
(Serrano et al. 1993). p16 is a cell-cycle regulator that inhibits the activities of cdk4 and
cdk6, two protein kinases that in turn phosphorylate the retinoblastoma protein which is
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necessary for progression through the G1 cell cycle checkpoint (Serrano et al. 1993,
Sherr 2001 ).  (Table 14).
2.4.7 Proto-oncogenes
Proto-oncogenes are involved in the regulation of normal cell growth and
differentiation. Mutations in proto-oncogenes lead to disturbances in the cell cycle and
can result in abnormal growth of proliferation. Germ-line mutations in proto-oncogenes
have not been found in syndromes conferring an increased susceptibility to breast
cancer. However, polymorphisms have been examined which would give a modest
elevation in risk. (Weber and Nathanson 2000).
 The proto-oncogene HRAS1 locates on chromosome 11p15 and encodes a protein
involved in mitogenic signalling, the process by which an extracellular growth factor
signal is transmitted to the nucleus (Junien et al. 1984, Barbacid 1987). A minisatellite
composed of 30-100 units of a 28-base pair repeat is tightly linked to HRAS1 (Capon et
al. 1983). The carriers of a certain class of rare alleles of the minisatellite locus are
proposed to be at increased risk of breast cancer, the relative risk being approximately
twofold (Krontiris et al. 1993). However, two most recent studies using a more accurate
method for allele sizing found no overall association and it seems that the earlier results
are false due to misclassification of alleles resulting from methodological reasons
(Firgaira et al. 1999, Tamimi et al. 2003). These findings suggested that the putative
associations of HRAS1 minisatellite alleles and breast cancer need to be re-evaluated
with the new method of sizing alleles.
 In one study an increased risk of breast cancer was observed to be associated with an
Asn11Ser polymorphism of the c-MYC gene (Wirtenberger et al. 2005). c-MYC encodes
for a transcription factor that is involved in cell proliferation and differentiation, cell
cycle progression, malignant transformation, genomic instability/DNA-damage
sensitization, and apoptosis (Patel et al. 2004).
HER2 (ERBB2, NEU) proto-oncogene gene locates on chromosome 17q21 and
encodes for a transmembrane glycoprotein p185 with a tyrosine kinase activity
(Schechter et al. 1984, Yang-Feng et al. 1985, Coussens et al. 1985, Akiyama et al.
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1986). p185 is a member of the epidermal growth factor receptor family that controls a
variety of cellular functions, including cell division, migration, adhesion,
differentiation, and apoptosis (Yarden and Sliwkowski 2001). HER2 amplification or
overexpression is seen in about 25 % of breast cancers and has been associated with
metastatic phenotype, endocrine therapy unresponsiveness, and poor prognosis (Menard
et al. 2004). A common variant in HER2, a SNP Ile655Val in the transmembrane region
could result in increased protein tyrosine kinase activity (Papewalis et al. 1991,
Fleishman et al. 2002). Several studies have evaluated the association of this HER2
polymorphism with breast cancer risk. Xie et al. (2000) first reported an increased risk
of breast cancer among Val allele carriers in Chinese population. Several larger studies
found no association (Millikan et al. 2003, Han et al. 2005, Benusiglio et al. 2005) but
others suggested even a protective effect (Nelson et al. 2005, Cox et al. 2005c), leaving
the question of HER2 and genetic breast cancer association still controversial.
2.4.8 Other genes studied for breast cancer association
Several other genes from different pathways have been studied for association with
breast cancer and many of them have not shown any significant associations. Genes
with significant association with breast cancer risk are introduced here.
 The CASP8 gene on chromosome 2q33 encodes caspase-8, one of the initiator
caspases that transduce apoptotic signals from the death receptors at the cell surface
(Kischkel et al. 1998, Hengartner 2000). Caspase-8 is activated by external death
signals and in response to DNA damage (Hengartner 2000). CASP8 Asp302His has
been estimated to account for approximately 0.3 % of the excess familial risk of breast
cancer in populations of European ancestry, and this site was not polymorphic in
Korean, Han Chinese or Japanese women. The functional consequences of the Asp to
His substitution are not yet known, and further experiments are needed to establish
whether Asp302His itself, or another variant in LD with it, is causative. (Cox et al.
2007). (Table 15).
AIB1 (NCOA3) gene locates on chromosome 20q11 and encodes the AIB1/SRC-3
(amplified in breast cancer 1/steroid receptor coactivator 3) protein (Anzick et al. 1997).
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AIB1 is amplified and overexpressed in breast and ovarian tumours and it enhances ER-
dependent transcription (Anzick et al. 1997). (Table 15).
Table 15. Other genes associating with breast cancer risk.
Gene, locus Polymorphism Contribution to breast cancer References
CASP8, 2q33 Asp302His reduced risk allele dose-dependent,
per allele OR 0.88, CI=0.84-0.92,
Ptrend=1.1x10-7
MacPherson et al. 2004, Frank et al.
2005, Breast Cancer Association
Consortium 2006, Cox et al. 2007
AIB1
(NCOA3),
20q11
3'UTR CAG/CAA
repeat length
polymorphism
proposed to modify risk among
BRCA mutation carriers but not
confirmed in all studies
Rebbeck et al. 2001, Kadouri et al.
2004, Haiman et al. 2000, Wilkening
et al. 2005, Hughes et al. 2005,
Spurdle et al. 2006
Gln586His
Thr960Thr
suggested protective effect among
BRCA mutation negative
Burwinkel et al. 2005
TNF?, 6p21.3 -417G>A increased risk suggested Gaudet et al. 2007
 -308 conflicting results de Jong et al. 2003
TNF?, 6p21.3 A252G suggested association in Korean
population
Lee et al. 2005c
FGFR2,
10q26
intron 2 C>T
(rs2981582)
increased risk allele dose-dependent Easton et al. 2007
 The HLA class III subregion has been suggested to have a role in susceptibility to
breast cancer (de Jong et al. 2003). Candidate genes in this region include TNF?
(tumour necrosis factor) and TNF?. Association with breast cancer risk and
polymorphisms in these genes have not been confirmed.  (Table 15).
 Recently, two large genome-wide searches identified the gene encoding fibroblast
growth factor receptor 2 (FGFR2) on chromosome 10q26 to associate with increased
risk of breast cancer (Easton et al. 2007, Hunter et al. 2007). FGFR2 is a receptor
tyrosine kinase that is amplified and overexpressed in 5-10 % of breast tumours (Moffa
et al. 2004, Adnane et al. 1991, Jang et al. 2001). Somatic missense mutations of
FGFR2 that are likely to be implicated in cancer development have also been
demonstrated in primary tumours and cell lines of multiple tumour types (Jang et al.
2001, Greenman et al. 2007). The minor allele of SNP rs2981582 in FGFR2 gene in
Europeans was associated with an increased risk in a dose-dependent manner, with a
higher risk in homozygous (10.5 %) than in heterozygous carriers (6.7 %) or common
homozygotes (5.5 %) (Easton et al. 2007). Haplotype analysis of 7 SNPs indicated that
multiple haplotypes carrying the minor allele of rs2981582 were associated with an
increased risk of breast cancer, implying that the association was being driven by
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rs2981582 itself or a variant strongly correlated with it. However, the variant causally
related to breast cancer risk could not be identified and functional studies will be
required to determine which variant it is. (Easton et al. 2007). (Table 15).
2.5 Strategies for finding new breast cancer susceptibility genes
2.5.1 Linkage disequilibrium
Linkage disequilibrium (LD) is the non-random association of alleles at adjacent loci.
The loci are in LD when a particular allele at one locus is found together on the same
chromosome with a specific allele at a second locus, more often than is mathematically
expected based on the allele frequencies. The extent and strength of LD in a population
depends on time and recombinational distance between markers. LD gradually decays
as the function of the number of generations, and the time required for disappearance of
LD depends on the distance between the loci (Figure 5). (Jorde 1995).
Figure 5. Linkage disequilibrium around an ancestral mutation (a black star). Recombination
causes the LD to gradually decay and limits the extent of the region of association over time but
markers that are physically close tend to remain associated with the ancestral mutation.
Chromosomal regions derived from the ancestral chromosome are shown in grey and new
regions introduced by recombination in white. G = generations during which recombination
occurs. M1-M8 = marker alleles.
G
Ancestral chromosome
M1 M2 M3 M4 Gene M5 M6 M7 M8
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 Power to detect LD tends to be greatest when a single disease-causing mutation that
accounts for a large proportion of the phenotypic variance of a trait has arisen recently
on a relatively uncommon haplotype background (Jorde 2000). Mutations responsible
for complex diseases will often persist for long periods of time because they are
typically less subject to the effects of natural selection than are mutations responsible
for Mendelian diseases. This can further diminish LD and the resultant power to detect
it (Jorde 2000). In addition to recombination and natural selection LD is also influenced
by other factors complicating the relationship between LD and physical distance, e.g.
mutation, chromosomal location (variable recombination rates), demographic history
(population structure, admixture or migration (gene flow), population growth, genetic
drift), and gene conversion (Laan and Pääbo 1997, Zavattari et al. 2000, Abecasis et al.
2001, Daly et al. 2001, Pritchard and Przeworski 2001, Ardlie et al. 2001). The strength
of LD and the distance over which it extends varies from one region of the genome to
another. LD also varies among populations, with European populations typically
showing lower nucleotide diversity and greater LD than African populations (Reich et
al. 2001). In young populations LD is thought to extend further than in older
populations (Mohlke et al. 2001, Ophoff et al. 2002, Varilo et al. 2003). Also
microsatellite markers have been observed to detect LD over longer distances than SNP
markers (Ophoff et al. 2002, Varilo et al. 2003). LD can be measured in a number of
ways but the most important pairwise measures of LD are r2 and |D'|. Both range from 0
(no disequilibrium) to 1 (complete disequilibrium), but their interpretation is different.
|D'| is a better measure for describing the patterns of LD and r2 is of more direct
relevance to the power of association studies. (Pharoah et al. 2004).
 The pattern of LD is structured in stretches of consistently high LD interspersed with
short intervals of rapid breakdown (Daly et al. 2001) (Figure 6). These LD blocks result
from the localization of recombination to irregularly spaced hot spots (Daly et al. 2001,
Jeffreys et al. 2001). In the regions of high recombination rate LD is lower and in
regions of low recombination LD is higher. The common haplotypes underlying blocks
of LD can be defined by testing a sufficiently large collection of SNPs. Focusing on
haplotype blocks greatly clarifies LD analyses. Once the haplotype blocks are identified
they can be treated as alleles and tested for LD, thereby reflecting the underlying
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population variation more accurately than any individual SNP (Daly et al. 2001,
Johnson et al. 2001). By determining the extended haplotypes at any given locus in a
population it is possible to identify exactly which SNPs will be redundant and which
will be essential to capture the haplotypes of a gene or a region of LD, i.e. the
haplotype-tagging SNPs, htSNPs (Johnson et al. 2001). Haplotype maps have been
constructed and information on htSNPs can be found in databases (Patil et al. 2001,
Dawson et al. 2002, Gabriel et al. 2002, Phillips et al. 2003, International HapMap
Consortium 2003, International HapMap Consortium 2005, Conrad et al. 2006).
 Linkage disequilibrium can be utilized in identification of disease loci e.g. in initial
locus positioning, restricting and fine mapping the critical chromosomal region and
searching for shared haplotypes, using different strategies (de la Chapelle and Wright
1998, Kruglyak 1999, Peltonen 2000).
Figure 6. The block-like structure of LD, with regions of low haplotype diversity separated by
recombinational hot spots. Lines below the blocks represent examples of the number of
common haplotypes that might be present for such blocks. The graphs plot LD as a function of
distance. The plots show that within a block LD decays gradually with distance, or not at all.
Within hot-spot areas LD falls away much more rapidly with distance. (Adapted from Goldstein
2001).
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2.5.2 Positional cloning of Mendelian genes
Positional cloning begins with linkage analysis. In pedigrees with a hereditary
(monogenic) disease the affected members share the disease phenotype and with an
increased probability they also share the genomic region that carries the disease gene.
Linkage analysis identifies the chromosomal region shared by the affected members in a
family. This region is estimated by genotyping genetic markers (e.g. STRs), typically
spaced by 5-10 cM, and then using the marker genotypes and the data on their
possibilities of transmission in the family in the linkage analysis. A calculated LOD
(logarithm of odds) score indicates the probability of the chromosomal region to be the
one with the disease gene. The LOD scores of studied families can be combined and so
strengthen the result and improve the finding of a true linkage. In addition to family or
pedigree-based linkage analysis, sib-pairs or trios can be used. After the initial locus
positioning LD-based fine-mapping is needed to identify the candidate-genes. In an
ideal case only a few genes in a region of 1 cM are restricted as candidates. Mutation
analysis of the candidate-genes finally indicates the disease gene, mutations in which
associate with the disease phenotype. (Peltonen et al. 2000, Botstein and Risch 2003).
Functional studies further confirm the gene-disease association.
 Family-based linkage studies have been the foundation for the many successes in
mapping of genes associated with Mendelian disorders, including many rare family
cancer syndromes such as multiple endocrine neoplasia type 2 and adenomatous
polyposis coli (APC). Linkage studies have also been successful in mapping BRCA1
and BRCA2, and genes for other common cancers, such as MSH2 and MLH1 in
colorectal cancer and CDKN2A in melanoma. Success of this approach is however,
limited to genes with rare, highly penetrant alleles. Linkage studies lack power to detect
the alleles conferring moderate risks that are likely to be the norm in complex disease.
Genetic heterogeneity limits the usefulness of combining data from multiple families, as
different genes may be responsible for disease clustering in different families. Within
families, phenocopies and incomplete penetrance are a problem, as the carrier status of a
putative disease allele cannot be definitively inferred from disease status. (Pharoah et al.
2004).
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2.5.3 Strategies for finding genes for complex diseases
2.5.3.1 Case-control association study
Although linkage studies have been highly successful in mapping the genes that
underlie monogenic disorders, these studies are of limited use for investigating
predisposition to polygenic disease, such as cancer (Pharoah et al. 2004). The main
alternative to linkage studies for disease gene mapping is the association study, in which
the frequency of a genetic variant in diseased individuals (cases) is compared to the
frequency of the variant in individuals without the disease (controls) (Risch 2000,
Cardon and Bell 2001). Allelic association is present when the distribution of genotypes
differs in cases and controls. Linkage disequilibrium is utilized in association studies as
it is based on the assumption that the affected share a genetic variant which is so close
to the marker locus that the probability of a recombination event to occur between them
is minimal. The observed marker-disease association in a region of high marker-marker
LD in a case-control set indicates that the locus related to disease susceptibility is
nearby. (Pharoah et al. 2004). Association studies for disease genes are generally based
on the "common variant, common disease" hypothesis (Chakravarti 1999). Genetic
variants arising a long time ago might have become common in the present population
at frequencies ranging from a few percent upwards. Some of these variants might
predispose to common diseases, and combinations of these variants are proposed to
underlie differences in disease susceptibility. One possibility to enhance the detection of
an association is haplotype analysis which combines the information of individual
markers (Baynes et al. 2007). Haplotypes mark recognizable chromosomal segments
that can be tracked through pedigrees and through populations when not broken up by
recombination and be treated for mapping purposes as alleles. (Strachan and Read
2003). Genetic association studies provide an efficient design for identifying common
variants that confer modest disease risks. (Pharoah et al. 2004). The power of
association studies can be increased by selecting cases with a family history of the
studied disease (Antoniou and Easton 2003).
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2.5.3.1.1 Genome-wide approach
The strategies of association studies are the genome-wide approach and a candidate-
gene (or pathway) approach. In the genome-wide approach the markers are genotyped
across the whole genome, instead of only a few candidate-genes. One starting point is to
use microsatellite (STR) markers for screening the genome to find associated
chromosomal regions. This application utilizes linkage disequilibrium and sets of STR
markers that are traditionally used for linkage studies and spaced by 5-10 cM. Marker
allele distributions are compared between cases and controls, and statistically significant
differences show markers that are in LD with the disease (breast cancer). LD regions are
then covered with additional markers spaced more closely, to refine the association.
Especially in younger populations the linkage disequilibrium is thought to extend
further and in general STR markers detect LD over longer distances than SNP markers.
 At present, mostly due to technical ease, the use of SNP markers is predominant and
there are two general strategies for genome-wide approach. The first uses quasi-random
or anonymous SNPs that are spaced accross the genome. The second strategy uses sets
of LD-based htSNPs that are specifically chosen. (Jorgenson and Witte 2006). Current
understanding is that 200,000-500,000 SNPs would be needed to adequately tag all
SNPs with a minor allele frequency of 5 % or more (Kruglyak 1999). It has been
suggested that concentrating on SNPs on genic regions in genome-wide association
studies can be more efficient for detecting causal variants than the existing indirect
approaches, which attempt to capture information on all variants (Jorgenson and Witte
2006).
2.5.3.1.2 Candidate-gene approach
The alternative to genome-wide association studies is the candidate-gene approach, in
which the studies are focused on candidate-genes that encode proteins thought to be
involved in the process of interest, e.g. in carcinogenesis, such as those involved in
apoptosis, cell-cycle control, carcinogen metabolism or DNA repair. It is also possible
to select the candidate-genes based on initial linkage or microsatellite marker
association studies or animal models. Ideally, single nucleotide polymorphisms of
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known functional significance are studied. The rationale for the candidate-gene
approach is that by maximising the biological plausibility, the chances of success are
increased. However, this approach is limited by its reliance on existing knowledge to
identify candidate-genes based on function. (Pharoah et al. 2004).
 In the ideal candidate-gene association study the common polymorphisms in the
studied population and the extent of LD are first identified in order to estimate the
minimum set of polymorphisms that need to be genotyped to be able to report on all
other polymorphisms (htSNPs). When an association study is completed there might be
residual uncertainty about the risks that are associated with the susceptibility allele.
Also, the observed associated marker might not be the true functional variant and it has
to be determined separately, possibly requiring functional assays. (Pharoah et al. 2004).
Difficulties in assessing the actual risk-associated variant are also due to the fact that in
most Western populations the linkage disequilibrium within genes is so uniform that
differentiating the associated variant is impossible. At this point using another ancestral
population, e.g. African or Asian, might provide further support due to weaker LD.
(Risch et al. 2001, Easton et al. 2007).
 Candidate-gene approach can be improved by sample selection. By choosing cases
with a family history of the studied disease, e.g. breast cancer, or bilateral cases,
improves the power and the sample size needed to detect an association is reduced,
relative to a standard case-control association study (Antoniou and Easton 2003). The
relative efficiency obtained by using familial cases is greater for rarer alleles (Antoniou
and Easton 2003). Enrichment for genetic factors may also be sought by selecting cases
with an early onset, although it may have a limited effect on the power to detect
association in breast cancer (Antoniou and Easton 2003). Using a founder population
has been extremely powerful for mapping Mendelian disorders because genetic
heterogeneity is reduced and the disease might be associated with a single founder
haplotype. In the search for genes for complex disorders the advantages are less clear
but in the study of rarer variants of more recent origin a founder population might be
useful. (Pharoah et al. 2004, Dunning et al. 2000). (Table 16).
 Current efforts to identify genetic variation have concentrated on common
polymorphisms. However, it is possible that much of the variation in cancer risk is due
80
to rarer alleles. In fact, virtually all susceptibility alleles identified so far have
frequencies less than 1 %. The rarity of these variants is likely to be due to the fact that
they are of recent origin and have not had time to spread through the population. It is
possible that rare alleles turn out to be the more important component in cancer
susceptibility. (Pharoah et al. 2004).
Table 16. Benefits of isolated versus outbred populations in genetic studies. (Adapted from
Peltonen et al. 2000).
Population isolate Outbred population
Higher prevalence for some diseases More affected people
More inbreeding and the opportunity to map
recessive genes
More opportunity for replication
Markers more polymorphic
More uniform genetic background Genes mapped pertinent to more humanity
Good genealogical records
Easier to standardise phenotypic definitions
Wider intervals of LD
Closer to HWE
Less migration and more intact families
More uniform environment
2.5.4 The Finnish population
Finland has been inhabited continuously at least since the last glacial period, for some
10 000 years (Norio 2003a). It is not known exactly who these original arctic people
were but most likely they were not the only immigrants who arrived in Finland, thus the
country was inhabited by small immigrant groups mainly from the South and East but
also from the West (Peltonen et al. 1999, Norio 2003a). Both paternally inherited Y-
chromosomal haplotypes and maternally inherited mitochondrial sequences show an
exceptional decrease in the genetic diversity of the Finns when compared with other
European populations (Sajantila et al. 1996). The establishment of agriculture in Finland
may have happened about 3 500 years ago, although it is not certain at which time and
by which people it was started (Norio 2003a). In the historical era, the expansion of
agriculture to "uninhabited" hunting grounds has had a decisive role in the generation of
the Finnish disease heritage (Norio 2003b).
 The size of the Finnish population has been estimated to have been about 2 500-10
000 until 3 300 years ago. In 1100 the population is estimated to have been less than 50
000 and in 1500-1700 around 300 000. (Norio 2003a). The first inhabited areas were the
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Southern, Southeast, Southwest and coastal regions, the so called early-settlement
region (Figure 7). The population expansion, populating the late-settlement region, i.e.
the Eastern and Northern parts of Finland, started only after 1500 from the region of
South Savo (Figure 7). Small groups of founders settled in uninhabited areas resulting
in formation of small, rural sub-isolates (multiple founder effects). The population of
the late-settlement region, including Northern Savo, has been expanding for 20-25
generations in isolation (mainly because of distance) and is still characterized by sub-
isolates with 50 000 or less inhabitants (Nevanlinna 1972, Norio et al. 1973, Norio
2003b).
Figure 7. The early and late-settlement regions in Finland. The region of South Savo is shaded
in grey. An example of a regional (internal) isolate of Kuusamo is also shown (shaded in black).
(Adapted from Varilo and Peltonen 2004).
 The main expansion of the Finnish population occurred in remarkable isolation due
to linguistic, religious, cultural and geographical barriers. There has been very little
immigration in Finland in the last 80-100 generations of expansion and population
bottlenecks have occurred. Epidemics and particularly famines in a Northern country
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sensitive to frost have probably been more important than wars in respect of the
bottlenecks. The famine with its accompanying epidemics in 1696-1697 killed a quarter
to a third of the population of fewer than 450 000. The latest bottleneck, due to
consecutive years of crop failure, occurred as late as in 1866-1868 killing 15 % of the
population. Official population statistics were founded as early as 1749. Thus, the
population was about 480 000 in 1750, 1.6 millions in 1850 and 4 millions in 1950.
Only during the most recent 10-12 generations, the number of people has grown rapidly
to the present day 5.2 millions. The influence of the bottleneck phenomenon is similar
to that of the founder effect. In both cases, genetic drift favours some genes and
removes others. (Nevanlinna 1972, Norio et al. 1973, Norio 2003a).
2.5.4.1 The Finnish Disease Heritage
Genetic drift worked in the population sub-isolates modifying the gene pool resulting in
enrichment of mainly recessive diseases, denoted as The Finnish Disease Heritage
(FDH). This concept was first introduced in 1973 and it refers to monogenic diseases
that are more prevalent in the Finnish population than in other populations (Norio et al.
1973). On the other hand, some diseases that are common elsewhere are extremely rare
in Finland. Currently 36 rare hereditary diseases belong to the FDH, 32 of which are
autosomal recessive, two are autosomal dominant and two are X-linked disorders
(Norio 2003c). The gene has been mapped in 33 and characterized in 27 of the disorders
belonging to the FDH (Norio 2003c). In the three non-mapped disorders, the number of
known families is still small. Diseases of the FDH are typically caused by one major
mutation originating from a common ancestor, i.e. a founder mutation, but for some
diseases also other minor mutations are known (Norio 2003c). Regional clusters of
some of the FDH diseases still exist, reflecting the regional sub-isolates characteristic
for a founder population (Peltonen et al. 1999). Founder mutations are characterized by
linkage disequilibrium (LD) and significant LD extends over large genomic regions
around the disease alleles of the FDH, varying between 2 and 13 cM (Peltonen et al.
1999).
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 Outside of the FDH, dominant founder mutations in cancer predisposition
syndromes, e.g. in hereditary nonpolyposis colorectal cancer, have spread and become
highly enriched and specific for certain geographical areas (Nyström-Lahti et al. 1994,
Moisio et al. 1996). Similar effect can be seen with BRCA1 and BRCA2 mutations,
although these mutations are more various (Sarantaus et al. 2000). Thus, low-penetrance
susceptibility genes and alleles can be expected to be enriched in a population like the
Finns. Genes for several diseases of the FDH have been discovered in analyses
exploiting the extent of LD (Järvelä et al. 1991, Hästbacka et al. 1992, Kere et al 1993,
Höglund et al. 1995, Varilo et al. 1996, Visapää et al. 1999). The Eastern Finnish
population being a regional subpopulation is an especially suitable material for LD
analysis (Soininen 1981, Pirinen 1982).
2.6 Methods for mutation detection
However promising a candidate-gene for a hereditary predisposition is it must be shown
to be mutated in affected people. Autosomal dominant disease-causing mutations are
distinguished from polymorphisms by their functional consequences, their
cosegregation with the disease in a family, and their absence in unaffected and unrelated
individuals. In some circumstances the identification and interpretation of the mutations
may, however, be more difficult. These are unsuspected locus heterogeneity, mutational
homogeneity, mutations may not be unambiguously pathogenic or mutations are
difficult to find, e.g. BRCA1 and BRCA2 genes are large and screening them for
mutations is laborious. Mutation testing methods can be divided into two groups: 1)
Mutation detection methods for testing samples for known mutations and 2) Mutation
screening methods for screening samples for (unknown) mutations in an entire
candidate-gene. (Strachan and Read 2003).
2.6.1 Heteroduplex analysis, HA
Heteroduplex analysis is suitable for general mutation screening. It is based on
heteroduplex formation when complementary single DNA strands of a wild-type allele
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and a mutant allele are allowed to hybridize. Heteroduplexes are formed when PCR
products are denatured and then renaturated by cooling down slowly. The detection of
heteroduplexes is based on their different mobility on nondenaturing polyacrylamide
electrophoresis gels compared to wild-type (or mutant-mutant) homoduplexes.
Heteroduplexes have lower electrophoretic mobility and they can be detected as extra
slow-moving bands. After electrophoresis the bands are made visible by e.g. ethidium
bromide staining.  Insertions, deletions and most single base substitutions are detectable
in fragments of ? 200 bp. HA method does not detect homozygous mutations and it
does not reveal the precise position of the mutation. (Keen et al. 1991, White et al.
1992).
2.6.2 Single-strand conformation polymorphism, SSCP/Conformation-sensitive gel
  electrophoresis, CSGE
SSCP/CSGE can be used to detect known mutations or to screen for unknown
mutations. Like HA, SSCP is based on different electrophoretic mobility between
mutant and wild-type alleles. In SSCP the gene-specific PCR products are denatured to
be single-stranded and run on a nondenaturing polyacrylamide gel. Single-strand
molecules adopt conformations that are dependent upon their sequence. In 80-100 % of
cases a single-base change is sufficient to cause altered electrophoretic mobility.
Radiolabelled primers or silver staining can be used for detecting the bands on gels.
Control samples must be run so that differences from the wild-type pattern can be
noticed. SSCP is simple and adequately sensitive, but is inefficient for fragments longer
than 200 bp, and does not reveal the nature or position of any mutation detected. The
precise pattern of bands seen is very dependent on details of the electrophoresis
conditions. (Orita et al. 1989, Spinardi et al. 1991, Sheffield et al. 1993).
2.6.3 Protein truncation test, PTT
PTT is a specific test for frameshift, splice-site or nonsense mutations that cause a
truncated protein product (Roest et al. 1993, van der Luijt et al. 1994). In certain genes,
e.g. BRCA1 and BRCA2, missense mutations are seldom found and are probably usually
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nonpathogenic. For such genes the PTT has several advantages. It conveniently ignores
the nonpathogenic (nontruncating) silent or missense base substitutions, and it reveals
the approximate location of any mutation. Also, in PTT analysis longer fragments can
be analysed compared to HA and SSCP.
 In the procedure coding sequence without introns (cDNA made by RT-PCR or large
exons in genomic DNA) is PCR amplified using a special forward primer that includes
(in addition to the gene specific sequence) a T7 promoter sequence and a eukaryotic
translation initiator with an ATG start codon, designed so that the sequence amplified
reads in-frame from the ATG. The PCR product is put into a coupled in vitro
transcription-translation system, which uses the T7 promoter to make mRNA and the
translation initiator to translate it. The protein product is run out on a SDS-
polyacrylamide gel (PAGE). The protein products can be visualised by using
autoradiography e.g. incorporating a radioactive labeled (S35) amino acid in the
translation reaction. Truncating mutations result in shorter products than the wild-type
protein and the size of the fragment reveals the position of the mutation. (Roest et al.
1993, van der Luijt et al. 1994).
2.6.4 Restriction fragment length polymorphism, RFLP
Restriction fragment length polymorphism analysis, RFLP, is based on the variation on
the length of DNA fragments cut by different restriction enzymes. A mutation may
create a cleavage site for a restriction enzyme which can be used in detecting the
mutation. By this technique mutated alleles may be differentiated from wild-type alleles
by analysis of patterns derived from cleavage of their DNA. If two alleles differ in the
distance between sites of cleavage of a particular restriction endonuclease, the length of
the fragments produced will differ when the DNA is digested with a restriction enzyme.
(Strachan and Read 2003).
2.6.5 Sequencing
Sequencing can be used to further characterize and verify a mutation found in analyses
done by other mutation screening methods. Sequencing can also be used to screen for
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mutations but it can be more laborious than usual mutation screening methods if the
mutations searched for are not known in advance. The two best-known DNA-
sequencing techniques are the enzymatic (dideoxy-mediated chain-termination) method
of Sanger et al. (1977) and the chemical degradation method of Maxam and Gilbert
(1977). Of these two Sanger's method is more widely used.
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3. AIMS OF THE STUDY
The general aim of this study was to investigate the genetic background of familial
breast/ovarian cancer and sporadic breast cancer in Eastern Finnish population. Since
the population in this area has been relatively stable and genetically isolated, founder
effect in the hereditary forms of breast/ovarian cancer could be expected. The frequency
and type of germ-line mutations in known high-risk breast/ovarian cancer susceptibility
genes, BRCA1 and BRCA2, were evaluated in Eastern Finnish breast/ovarian cancer
families. In addition, the autosomes were screened to identify new chromosomal regions
and genes on them as genetic risk factors for sporadic breast cancer in the Eastern
Finnish population. Due to the character of a founder population, linkage disequilibrium
could be utilized.
The specific aims of the study were:
I To screen 36 breast/ovarian cancer families for BRCA1 and BRCA2 germ-line
mutations for evaluation of the contribution of these genes in Eastern Finland.
II To analyse the novel BRCA2 exon 11 4088insA mutation in an Eastern Finnish
family with multiple breast/ovarian cancers and favourable clinical course.
III  To study the effect of BRCA1 4216-2nt A?G splice acceptor site mutation on
BRCA1 protein product.
IV  To find new low-penetrance genetic risk factors for Eastern Finnish sporadic
breast cancer by using autosome-wide microsatellite scan for linkage
disequilibrium-based association in a case-control material.
V To identify the putative breast cancer risk-associated gene on 22q12-q13 region
by single nucleotide polymorphism (SNP) association analysis.
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4. MATERIAL AND METHODS
4.1 Study subjects
4.1.1 Breast and ovarian cancer families (I-III)
The pedigrees in the study are from the Kuopio University Hospital district and of
Eastern Finnish origin. Of the below described 516 new breast cancer cases diagnosed
between April 1990 and December 1995, 102 patients were selected on the basis of
some positive family history of cancer, i.e. breast or ovarian cancer in one first degree
relative and in one other relative, according to the interview data collected by the
Kuopio Breast Cancer Project (Männistö et al. 1996). The criteria were not strict at this
point. The 102 selected patients were invited for an additional interview, gynaecologic
ultrasound examination and were offered preliminary genetic counseling. They were
also asked to fill in a questionnaire to further determine their family history of cancer. A
filled questionnaire was returned by 85/102 patients and 82/102 patients participated in
the ultrasound examination and agreed to the interview. On the basis of the data arising
from the pedigrees, 15/82 families were selected for the germ-line BRCA1 and BRCA2
gene mutation screening study. The selection criteria were a minimum of three first-
degree relatives with breast or ovarian cancer. However, 7/15 families with less than
three first-degree relatives with breast or ovarian cancer were included in the study, due
to history of cancer at early age, bilateral breast cancer or several cases of breast/ovarian
cancer in the second or third-degree relatives.
 The questionnaire was also sent to ovarian cancer patients treated in Kuopio
University Hospital between January 1993 and October 1997. Out of over 90 Eastern
Finnish pedigrees, 14 were selected to be included in the study following discussions
with the index patients. Criteria for the ovarian cancer families were at least two cases
of ovarian cancer in the family. Seven other families fulfilling the criteria were also
included in this study. Six of these seven families were identified through genetic
counseling at the local Cancer Society policlinic, and one was identified by the clinical
oncologist of the research group in routine clinical consultations. Thus, altogether 36
breast and ovarian cancer families were included in the germ-line mutation screening
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study (Tables 17 and 18). In addition to breast and ovarian cancers, other cancers were
also reported among first degree relatives in 2/3 of the families.
Table 17. Characteristics of the studied breast/ovarian cancer families.
No. of cancer in family
Family Breast Ovarian Other cancers in family
BR10 7 gastric, colon x3, lung x2
BR14/16 6 gastric, unknown cancer
BR17 6 (1 bilat.) skin melanoma
BR13 5 unknown cancer, lung
PS20 3 (1 bilat.) Wilms tumour, brain, colon
BR02 3
BJ01 3 (1 bilat.) leukaemia, unknown cancer x3
BR12 4 (1 bilat.) lung
BR08 3 (1 bilat.) lung
BR05 3
PS04 2 skin melanoma, liver, thyroid, oesophageal, lymph node,
endometrial
PS19 2 (1 bilat.) endometrial x2, unknown cancer x2
BR01 2 endometrial
BR04 2 melanoma
BR11 2 lung, colon
BR15 2 unknown cancer x2
OV03 5 2 brain
BR09 4 3 (1 bilat.) rectal, prostate
PS02 4 1 gastric x2
OV30 2 3 pancreas, gastric, lip
OV01 2 2
OV85 3 1 lymphoma, leukaemia, colon
BR06 4 1 chloledocal, gastric, lung, kidney
BR18 2 2 prostate
BR03 2 1 prostate, bladder, oesophageal or laryngeal, liver, unknown
cancer
BR07 1 1 gastric x2, endometrial x3
OV28 2 1 lung, colon
OV73 2 1 melanoma, gastric x2, cervix, thyroid, oesophageal
OV37 1 1 colon, lung
OV84 1 1
OV20 3 unknown cancer x3
OV22 3 lip, lung x3, gastric, lymphoma, laryngeal
OV36 2 pancreas, lung x3, endometrial, lip, cervix, gastric, colon
OV38 2 endometrial x2, bone, prostate, neck, leukaemia, lymphoma
OV77 1 neuroblastoma
OV33 1 bladder, gastric
EDTA blood samples were collected from the breast and ovarian cancer patients
participating in the study and from their relatives who were willing to participate and
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who gave their consent. Genomic DNA was extracted from peripheral blood
lymphocytes as described below.
4.1.2 Population-based breast cancer case-control material (IV-V)
The population-based sample material is carefully selected from the province of
Northern Savo in the late-settlement area of Eastern Finland. This study is an extension
of the Kuopio Breast Cancer Project, through which the cases for this study were
ascertained (Männistö 1999). The material was collected from 1 919 women who came
to Kuopio University Hospital (hospital district of 750 000 people) between April 1990
and December 1995 with any suspected breast disease for breast examination. Of these
women 516 were diagnosed and histologically confirmed to have breast cancer. These
women with breast cancer were asked to participate in the study and only twelve refused
to participate. Thus, the participation/cooperation rate was 98 % (504/516). The
recruitment protocol missed 88 women diagnosed with breast cancer in Kuopio
University Hospital catchment area during the collection period, 51 of which were
private patients, 11 were missed during the nurses' one-month strike in 1995 and 26
were treated elsewhere. Therefore the total contact rate was 85 % (516/604) and overall
response rate 83 % (504/604). Thus, the sample is a representative collection of
unselected typical breast cancer cases from Kuopio area. A proper DNA sample was
available from 497 breast cancer cases for the association study.
 In addition to breast cancer cases, the Kuopio Breast Cancer Project material
includes randomly selected and individually matched age (within ± 5 years) and area-of-
residence (urban/rural) controls from the National Population Register for each case of
breast cancer (Männistö 1999). Seventy-two percent (359/497) of the cases and 73 %
(334/458) of the population controls included in study V were born in the Province of
Northern Savo. (Table 18). Each participant gave informed written consent. EDTA
blood samples were collected from the breast cancer cases and controls participating in
the study. Genomic DNA was extracted from peripheral blood lymphocytes as
described below.
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4.1.2.1 Cases and controls in the autosome-wide scan for LD (IV)
For the autosome-wide scan for linkage disequilibrium with breast cancer 49 cases and
50 controls selected from the above described population-based material were used.
Forty-nine breast cancer cases who did not have a strong family history of cancer
according to the initial interview and who were born around Kuopio in four rural
communities whereto moving has been minimal were selected for the study IV (Table
18). The included 50 controls are matched for age and long-term area-of-residence with
the cases. Age of onset of breast cancer ranged between 30 and 82 years, median age of
onset being 54.0 years. Seventy-three percent of the cases had breast cancer at or after
the age of 50 years. The median age of the controls was 54.5 years (range 30-76 years).
4.1.2.2 Cases and controls in refining of the breast cancer-associated region on
    22q12-q13 (V)
For the further study of chromosome 22q12-q13 breast cancer association we had DNA
available from 497 breast cancer cases and 458 age and long-term area-of-residence
matched controls. The selected cases represent 96 % of the total of 516 breast cancers
diagnosed in Kuopio University Hospital between 04/90 and 12/95.
Table 18. Summary of study subjects used in each study.
Study I Study II Study III Study IV Study V
Study design Familial Familial Familial Case-control Case-control
Cancer Breast/ovarian Breast/ovarian Breast Breast Breast
No. of studied
individuals
89,
in 36 families
11,
in 1/36 family
20, in 2/36
families
49 + 50 497 + 458
(subsample
280 + 257)
4.2 Extraction of DNA from blood lymphocytes (I-V)
EDTA blood samples were collected from the familial breast and ovarian cancer
patients participating in the study and from their relatives who were willing to
participate and who gave their consent (I-III), and from the sporadic, population-based
breast cancer patients and controls participating in the study (IV, V). Genomic DNA
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was extracted from peripheral blood lymphocytes using standard chloroform-phenol
extraction method (Vandenplas et al. 1984).
4.3 BRCA gene mutation detection (I-III)
In study I the DNA samples were screened for germ-line mutations in the coding region
and exon-intron boundaries of the BRCA1 and BRCA2 genes by heteroduplex analysis
(Ganguly et al. 1993), protein truncation test (PTT) (Roest et al. 1993) and direct
sequencing. Variants found in PTT and HA were confirmed by sequencing. In study II
the BRCA2 4088insA mutation was detected in PTT analysis and confirmed by
sequencing. In study III the BRCA1 4216-2nt A?G mutation was confirmed, after
sequencing, with restriction fragment length polymorphism analysis (RFLP) using the
restriction enzyme MseI (New England BioLabs, Beverly, MA, USA). Additionally, in
study III the effect of the mutation on the intron splice-site was confirmed by cDNA
analysis.
4.3.1 PCR amplification and protein truncation test (PTT) of BRCA1 and BRCA2
  exon 11 (I, II)
The exon 11 of BRCA1 and BRCA2 gene were screened for germ-line mutations by
protein truncation test (PTT) (Roest et al. 1993, Hogervorst et al. 1995). First, exon 11
of both genes was PCR-amplified from genomic DNA in three overlapping segments
with a T7 promoter sequence attached to the 5’ end of the forward primers (Plummer et
al. 1995, Johannsson et al. 1996, Tavtigian et al. 1996) (Table 19, Figure 8). Annealing
temperature for each primer was 56-58°C and Taq DNA polymerase (Promega,
Madison, WI, USA) was used. The PCR products were used as a template for in vitro
transcription translation reaction. For PTT the TNT T7 Coupled Reticulocyte Lysate
System (Promega) was used according to manufacturer’s instructions. The protein
products were detected by autoradiography. First they were separated on a 12 % SDS-
PAGE minigel (BioRad, Hercules, CA, USA), then gels were fixed with 1 M sodium
acetate and dried.  X-ray films were exposed in -70°C for 1-5 days and developed.
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Table 19. Sequences of the primers used in PTT analysis of BRCA1 and BRCA2 gene exon 11.
Primer name Sequence 5' ? 3' Location (nt) in cDNA
BR1-AF T7-CTGCTTGTGAATTTTCTG 790 - 807
BR1-AR CATGAGATCTTTGGGGTC 2355 - 2372
BR1-BF T7-AGCAGAATGGTCAAGTG 1738 - 1754
BR1-BR GTCCAGTTTCGTTGCCTC 2995 - 3012
BR1-CF T7-TCAAGGTTTCAAAGCGCCAG 2701 - 2720
BR1-CR GACGTCCTAGCTGTGTGAAG 4215+185nt in intron 11
BR2-AF T7-GTTTATTGCATTCTTCTGTG 2138 - 2157
BR2-AR TGACTTCCTGATTCTTCTAA 3580 - 3599
BR2-BF T7-GTGTAAAGCAGCATATAAAAAT 3101 - 3122
BR2-BR TTCGGAGAGATGATTTTTGTC 5410 - 5430
BR2-CF T7-GCCTTAGCTTTTTACACAA 5230 - 5248
BR2-CR CCCCCAAACTGACTACACAA 7069+135nt in intron 11
T7 promoter sequence: 5'-GGATCCTAATACGACTCACTATAGGAACAGACCACCATGG-3'
Figure 8. Exon 11 of BRCA1 and BRCA2 genes were analysed in three overlapping fragments
using PTT. Size of each fragment (BR1-A - BR2-C) is shown in base pairs (bp). A) Schematic
presentation of BRCA1 exon 11. B) Schematic presentation of BRCA2 exon 11.
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4.3.2 Heteroduplex analysis of BRCA1 and BRCA2 genes (I, III)
In study I and III exons 2, 3, 5-10 and 12-24 of the BRCA1 gene were amplified from
genomic DNA using the primers described by Friedman et al. (1994), Dynazyme DNA
polymerase (Finnzymes, Espoo, Finland) and annealing temperatures 56-63°C (Table
20). In study I exons 2 and 12 of the BRCA2 gene were amplified using the primers
described by Couch et al. (1996) and exons 3-9 and 13-27B using primers described
by Friedman et al. (1997) (Table 21). Annealing temperatures were 47-59°C and
Dynazyme DNA polymerase was used. An aliquot of 3-8 µl of the PCR product was
used for the DNA pairing reaction of the heteroduplex (HA) analysis. The sample was
first denatured in 98°C for 5 minutes and then it was renaturated by cooling the
heatblock slowly to 37°C. The hetero- and homoduplexes are formed during the slow
renaturation. After cooling, 6 ?l of loading buffer (30 % glycerol, 0.25 % bromophenol
blue, 0.25 % xylencyanol) was added into sample tube and then briefly centrifuged. The
samples were analyzed on 10 % CSGE gel. Electrophoresis was carried out with 150V
voltage for 12-15 hours depending on the size of the exon analysed. After
electrophoresis the gels were either silver stained and dried or ethidiumbromide (EtBr)
stained and photographed.
4.3.3 Sequencing (I-III, V)
In study I the exon 10 of the BRCA2 gene was screened for mutations by direct
sequencing. The exon 10 was PCR amplified in two overlapping fragments using
Phusion High-Fidelity DNA Polymerase (Finnzymes, Espoo, Finland) according to
manufacturer's instructions. The forward and reverse primers were 5'- TGTTTCT
ATGAGAAAGGTTGTGAGA-3' and 5'- TTGCCTGCTTTACTGCAAGA-3' for the
first fragment, and 5'- TAAATGGAGCCCAGATGGAG-3' and 5'- AAAACACA
GAAGGAATCGTCATC-3' for the second fragment. A 1.0-1.5-µl aliquot of the PCR
product was included in the sequencing reactions using Big Dye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems) according to manufaturer's instructions.
Sequences were run on an ABIPRISM 3100 Genetic Analyzer (Applied Biosystems)
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and analysed using Sequencing Analysis and Sequence Scanner v1.0 softwares (Applied
Biosystems).
 When aberrant mobility on heteroduplex gels or PTT protein product differing from
the wild-type protein was detected in studies I-III, the variants were reamplified from
genomic DNA and sequenced and analysed using dRhodamine Terminator Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and AbiPrism 310
Genetic Analyzer (Applied Biosystems) according to manufacturer’s instructions. The
primers used for HA in study I and III were used also for sequencing the fragments. For
sequencing the variant in PTT in study I and II new primers were designed (BR2-05F
5'- ATGAAGTGGGGTTTAGGGGC-3' and BR2-05R 5'-ATTTTGCTCCGTTTTAGT
AG-3'). In study III primers SPL1F 5'-ACCGTTGCTACCGAGTGTCT-3' and SPL1R
5'- AGTTCAGCCATTTCCTGCTG-3' and the above technique and equipment were
used for sequencing of the purified cDNA.
 In study V the variants from DHPLC analysis were re-amplified and sequenced using
the primers used in DHPLC analysis and AbiPrism Big Dye Terminator Cycle
Sequencing Ready Reaction kit with Ampli Taq DNA Polymerase (Applied
Biosystems, Foster City, CA) according to manufacturer's instructions. Samples were
analysed on AbiPrism 377 DNA sequencer and Sequencing Analysis 3.3 software
(Applied Biosystems).
4.3.4 RFLP analysis, extraction of RNA, and cDNA analysis of the BRCA1 4216-
 2nt A to G mutation (III)
In addition to HA and sequencing, the 4216-2nt A?G splice-site mutation was
confirmed by restriction fragment length polymorphism (RFLP) analysis from genomic
DNA. A 265-bp-fragment was PCR amplified using the primers (12F and 12R) used in
HA and the fragment was digested using 5 units of the restriction enzyme MseI (New
England BioLabs, Beverly, MA, USA) in conditions recommended by the
manufacturer. The recognition sequence for MseI is T/TAA. Two cleaving sites for
MseI locate in the wild-type allele, but only one in the 4216-2nt A?G mutated allele.
Thus, digested fragments are 82, 83 and 100 bp in non-carriers and 100 and 165 bp in
98
4216-2nt A?G mutation carriers. After digestion the fragments were separated on a 2.5
% LE agarose gel (FMC Bio Products), visualised by EtBr staining and photographed.
  For study III also a fresh EDTA blood sample was drawn from BRCA1 exon 12
4216-2nt A?G splice-site mutation carrier in one of the families. Total RNA was
extracted from the blood lymphocytes using a Trizol LS Reagent (GibcoBRL Life
Technologies, Rockville, MD, USA) according to the manufacturer’s instructions.
Reverse transcriptase PCR (RT-PCR) was performed from approximately 0.5 mg of
total RNA using Titanä One Tube RT-PCR System (Boehringer Mannheim,
Mannheim, Germany) and primers SPL1F and SPL1R designed with the Primer3
program available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi.
SPL1F is located in BRCA1 exon 11 at the nucleotides from 3855 to 3874 and SPL1R in
exon 13 at the nucleotides from 4341 to 4360. The size of the normal cDNA fragment
amplified with SPL1F and SPL1R primers is 506 bp and mutated fragment 507 bp.
(Figure 9). The RT-PCR conditions were 50° for 30 min, 94° for 2 min, 46 cycles of 94°
for 30 sec, 55° for 30 sec and 68° for 2 min and the final step 68° for 5 min. After
amplification the size of the cDNA product was checked on a 2 % LE agarose (FMC
Bio Products, Rockland, ME, USA) gel and purified with QIAquick PCR Purification
kit (QIAGEN, Hilden, Germany). The purified cDNA product was used for sequencing
as described above in 4.3.3.
Figure 9. Schematic presentation of reverse transcriptase (RT) PCR amplification for BRCA1
4216-2nt A?G splice-site mutation analysis. Length of BRCA1 exons 11-13 and location of
primers is shown in nucleotides (nt). The size of amplified cDNA fragment is 506 bp and in
mutation carriers 507 bp.
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4.3.5 Analysis of mutation-associated haplotypes (I-III)
Microsatellite markers D13S260, D13S1701 and D13S267 were genotyped for the
identification of the BRCA2 gene mutation-associated haplotypes (Table 22). The
microsatellites were PCR amplified with fluorescent-labelled primers using standard
procedures (Sheffield et al. 1995) and analysed using an automated ABIPrism 310
Genetic Analyzer (Applied Biosystems), GeneScan 2.1 software and internal standard
(see below at 4.4). Haplotypes were constructed manually utilizing the pedigree data.
The location and distance between markers (kb and cM) was obtained from the human
Genome Browser Gateway at the University of California at Santa Cruz (UCSC)
(http://genome.ucsc.edu).
Table 22. Microsatellites used for BRCA2 mutation-associated haplotypes.
Marker Location on Chr.13 Distance in kb Genetic location (cM)
cen 0
D13S260 31334758 - 31335105 23.65
BRCA2 (gene) 31787617 - 31871805 452.512
D13S1701 32042530 - 32042819 170.725
D13S267 33162119 - 33162387 1119.300 26.87
tel 114142980
4.4 Genotyping of microsatellites in the autosome-wide scan for LD (IV)
In study IV, 366 microsatellite markers from the 6th version of the Weber lab marker
set (http://research.marshfieldclinic.org/genetics/GeneticResearch/sets/scrset6.txt) were
genotyped in the first-stage autosome-wide scan for LD with breast cancer. The distance
between markers span approximately 10 cM (range 1-20 cM) in the genome and the
average heterozygosity of the markers was 0.76. The microsatellite repeats were PCR
amplified from genomic DNA in single or multiplex reactions with fluorescent-labelled
primers using standard procedures (Sheffield et al. 1995). PCR products from several
microsatellites were pooled individually for each case and control and an internal
GeneScan-500 [TAMRA] size standard (Applied Biosystems) was added into each
sample. The size of the microsatellites was determined with an automated AbiPrism 310
Genetic Analyser (Applied Biosystems) and analysed using the GeneScan 2.1 software
(Applied Biosystems) according to the size standard.
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 The number of samples was designed so that it was possible to run all controls, 45 of
the cases and a blank control in one run on 96-well plate using AbiPrism 310. This was
done to minimize possible variations in the sample running conditions (e.g. by using the
same capillary for all samples). The remaining four of the cases were run first on
another run to re-check that the reaction conditions for the marker are fine.
 When linkage disequilibrium with breast cancer was observed, additional markers
close to those with significant (or near significant) P-values were selected from the
Genome Database (http://www.gdb.org/) for the second-stage scan (Table 23).
Altogether 69 additional markers were genotyped. Intermarker distances and order were
obtained from the databases at the Sanger Institute (http://www.sanger.ac.uk), the
Human Genome Browser Gateway at the UCSC (http://genome.ucsc.edu), Cedar
Genetics at the University of Southampton (http://cedar.genetics.soton.ac.uk) and
Marshfield Center for Medical Genetics (http://research.marshfieldclinic.org/genetics).
In the second-stage scan an AbiPrism 377 DNA Sequencer (Applied Biosystems) and
GeneScan 2.1 (Applied Biosystems) software were used for size determination.
Table 23. Additional markers used in the second-stage of the genome-wide scan.
Chromosome 1 Chromosome 7 Chromosome 13 Chromosome 20
D1S2800 D7S519 D13S280 D20S445=D20S79
Chromosome 2 D7S2422 D13S1265 D20S887
D2S363 D7S2423 Chromosome 14 D20S196
D2S1277 Chromosome 8 D14S1016 Chromosome 21
D2S2289 D8S1008 D14S1054 D21S1255
D2S2358 D8S1694 Chromosome 16 Chromosome 22
D2S2248 Chromosome 9 D16S3091 D22S277
D2S163 D9S157 D16S488 D22S1142
D2S2202 D9S1684 Chromosome 17 D22S924
D2S2253 Chromosome 10 D17S1810 D22S283
Chromosome 3 D10S580 D17S1289 D22S426
D3S3630 D10S607 D17S799 D22S1177
D3S1229=D3S1246 D10S201 D17S1785 IL2RB
D3S3725 D10S523 D17S1820 D22S1156
D3S3520 Chromosome 11 D17S941 D22S272
Chromosome 4 D11S1302 D17S1302 D22S284
D4S2975 D11S1893 Chromosome 19 D22S279
D4S1615 D11S1347 D19S198 D22S270
D4S1575 D11S897 D19S420
Chromosome 6 Chromosome 12 D19S559
D6S1660 D12S1659 D19S219
D6S980 D19S545
D6S1599
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4.5 Validating and selecting of SNPs for the refining of the breast cancer-
  associated region on 22q12-q13 (V)
SNPs in genes in the 550-kb region between microsatellites D22S426 and D22S445 on
chromosome 22q12-q13 were searched from databases (http://www.sanger.ac.uk,
http://www.ncbi.nlm.nih.gov/SNP and http://snp.cshl.org/db/snp) and assays were
designed for confirming the frequencies of 26 suggested SNPs and a small deletion on
denaturing high-pressure liquid chromatography (DHPLC). Also the coding, 5'UTR and
3'UTR sequences of one of the genes in the associated region (RABL4) were screened
for sequence variations using DHPLC. (Table 24). For these validations genomic DNA
from 48 anonymous British samples and 48 of the 49 Eastern Finnish breast cancer
cases used in the genome-wide LD scan were used. PCR amplifications for DHPLC
analysis were carried out using: 1x GeneAmp PCR Gold buffer (Applied Biosystems),
0.16mM dNTP, 1.5-1.6 mM MgCl, 0.3-0.4 mM primers, 1.25-2.5 U AmpliTaq Gold
DNA polymerase (Applied Biosystems) and 20 ng genomic DNA in a 60-ml reaction
and standard protocols. After amplification the samples were denatured and slowly
renatured using 3 min denaturation at 95°C followed by cooling down to 25°C one
degree per min. PCR amplified samples were analysed on WAVE DHPLC equipment
(Transgenomics, Crewe, UK) according to manufacturer’s instructions and using
specific conditions for each fragment. The variants from DHPLC analysis were re-
amplified and sequenced as described above in section 4.3.3.
 Ten of the validated SNPs were selected for genotyping in 497 sporadic breast cancer
cases and 458 matched controls (material described in 4.1.2.2). The SNP selection was
based on the allele frequency (rare allele frequency > 0.1), location and distance
between the SNPs (region covered as evenly as possible) and the suitability of the SNP
to be detected by the 5' nuclease (Taqman®) assays. Also coding SNPs were preferred
over intronic SNPs. The selected SNPs cover a 541-kb region on chromosome 22q12-
q13 and adjacent SNPs are 0.9-132 kb apart. The selected SNPs are shown in Table 24
and Figure 10.
 Artificial templates were prepared for both alleles in each assay for using as controls
for the homozygous genotypes in the analysis. Long oligonucleotides were designed for
using as primers in the artificial template synthesis (Table 25). For each SNP three
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oligonucleotides were designed, two of them allele specific and one common for both
alleles. Depending on the position of the SNP in the amplicon allele specific primers
were either forward or reverse and common primer correspondingly reverse or forward.
In the 100-?l synthesis reaction 10 pmol of each primer (forward and reverse), 1X
Klenow E.Coli Buffer, 0.4 mM dNTP, Klenow enzyme and 2 ?l of 0.5 M EDTA was
used. After synthesis 900 ?l of dH2O was added and cooled to 4°C. For using in
Taqman reactions the artificial templates were diluted to 1/100 - 1/1 000 000, depending
on the assay.
Figure 10. The selected SNPs cover a 541-kb region on chromosome 22q12-q13.
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4.6 Genotyping of SNPs for the refining of the breast cancer-associated region on
  22q12-q13 (V)
For the ten selected SNPs forward and reverse primers and two fluorescent labelled
probes were designed for 5' nuclease (Taqman) assays. Genotyping was carried out in
497 sporadic breast cancer cases and 458 matched controls according to assay
manufacturer's instructions. The primer and probe sequences of the genotyped SNPs are
shown in Table 26. In the 15-ml Taqman reactions we used 1x Taqman universal PCR
master mix (Applied Biosystems), 900 nM forward and reverse primers (Applied
Biosystems), 100, 200 or 400 nM each probe (Applied Biosystems) and 20 ng of
genomic DNA. All assays were carried out in 96-well plates. Each plate contained 72
test samples, 8 negative controls with no DNA and 8 positive controls for each SNP
allele. The following PCR conditions were used on an MJ Tetrad thermal cycler (MJ
Research, Waltham, MA, USA) for Taqman® reactions: first 2 min at 50°C, then 10
min at 95°C followed by 39 cycles of 15 s at 95°C and 1 min at 60, 62 or 64°C.
Samples were post-read on an AbiPrism 7700 Sequence Detector (Applied Biosystems)
and were analysed using the Allelic Discrimination Sequence Detection Analysis 1.7
software (Applied Biosystems). Genotypes were manually assigned under dye
components.
4.7 Allelic imbalance (AI) analysis (V)
4.7.1 Paraffin-embedded samples and extraction of DNA for AI analysis
Paraffin-embedded samples of breast cancer tissue from 45 of the 49 cases in study IV
were used for the AI analysis in study V. An experienced pathologist microdissected the
samples using a 24 G needle under a light microscope in carefully matched tumour
areas containing at least 70 % tumour cells (Tuhkanen et al. 2004). For each specimen
DNA was extracted from five 10 mm thick consecutive sections by the proteinase K-
phenol-chloroform method according to standard protocols (Karjalainen et al. 2000).
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4.7.2 Genotyping of microsatellites for AI analysis
For the AI studies 13 microsatellite markers from study IV were used (Figure 11.).
These markers span an approximate 6.8 Mb on chromosome 22. Microsatellite repeats
were PCR amplified from genomic (blood sample) DNA (in study IV) and from tumour
DNA with fluorescent-labelled (FAM, HEX or TET) forward primers and an ordinary
reverse primer using standard procedures (Sheffield et al. 1995). Fragment sizes were
analysed using internal size standard, AbiPrism 310 Genetic Analyser (Applied
Biosystems) and GeneScan 2.1 software (Applied Biosystems). Some of the markers
were run multiplex. Intermarker distances and order were obtained from Human
Genome Browser Gateway at the University of California at Santa Cruz
(http://genome.ucsc.edu) and at http://www.sanger.ac.uk.
Figure 11. Microsatellite markers used in the AI study. Location of each marker is shown in
megabases (Mb) from the centromere.
Marker Location
D22S277 34.596
D22S1142 34.598
D22S924 34.956
D22S283 35.075
D22S426 35.348
D22S1177 35.588
IL2RB 35.871
D22S445 35.890
D22S1156 36.706
D22S272 37.410
D22S284 38.641
D22S279 39.347
D22S270 41.378
Chr. 22
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4.7.3 Calculation of AI values
AI was calculated from the informative cases which were heterozygous in the normal
tissue (blood) sample, using the peak heights from GeneScan analysis in formula AI =
(T2 x N1) / (T1 x N2), where T is the tumour allele and N is the normal allele (1 and 2
representing the two alleles). An AI value greater than 1.67 or less than 0.60 was
considered AI (Canzian et al. 1996). Samples with values from 0.6 to 0.7 and from 1.55
to 1.67 were re-amplified and reanalysed at this particular locus. Only when this second
result was positive tumour was assessed to have AI. A locus with AI in more than 30 %
of the cases was considered significant.
4.8 Statistical analyses (IV, V)
4.8.1 Microsatellite and SNP allele and genotype frequencies (IV, V)
Significance levels for comparisons of the microsatellite and SNP allele and genotype
frequencies between cases and controls were computed using Fisher’s exact test and
Monte Carlo approximation implemented in SPSS. c2 and Fisher’s exact tests were also
performed to compare the frequency of the possible associated allele versus the
frequency of all other alleles pooled together between cases and controls. P-values less
than or equal to 0.05 were considered significant and P-values were unadjusted for
multiple comparisons.
4.8.2 Hardy-Weinberg equilibrium (IV, V)
Deviation of the SNP and microsatellite genotype distributions from the Hardy-
Weinberg equilibrium (HWE) was assessed using the standard ?2 -test in Associate
v2.33 or HWE softwares of the LINKUTIL software package
(http://www.genemapping.cn/util.htm, Terwilliger and Ott 1994), analysing cases and
controls combined as well as cases and controls separately. P-values less than 0.05 were
considered as significant deviation from the HW equilibrium. P-values in HW
equilibrium tests were not adjusted for multiple correction.
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4.8.3 Breast cancer risk estimations (Odds ratios, OR) (IV, V)
Breast cancer-associated risks for the SNP genotypes and rare/common allele carriers
and the associated alleles of the significant microsatellites were estimated as odds ratios
(OR) with 95 % confidence intervals (CI) using crosstabulation in SPSS. Odds ratio
estimation was considered reliable when the 95 % confidence interval did not intersect
unity.
4.8.4 Haplotype estimation (IV, V)
In study IV the haplotype frequencies were computed using the ‘haplo.score’ software
(Schaid et al. 2002). Haplo.score uses unphased genotype data and via the EM
(Expectation Maximization) algorithm (Slatkin and Excoffier 1996) it estimates the
haplotype frequencies. This software implements a global score test for haplotype
frequency differences between the cases and controls, and provides haplotype-specific
tests, which allow evaluation of all individual haplotypes when the global score test is
significant. To improve the c2 approximation of the score test we used a threshold level
of 0.005 and omitted haplotypes with frequency less than 0.5 %. Marker combinations
where the global score test for differences in haplotype frequencies between cases and
controls reached significance (at P=0.05 level), were investigated further by simulations
(10 000). This involved simulating the case/control status of the individuals in the study
and performing the test each time. The simulations were carried out using haplo.score.
 In study V the haplotype frequencies for multiple SNP loci were estimated using the
EM algorithm implemented in SNPAlyze v4.0 software (Dynacom, Chiba, Japan).
SNPAlyze was also used for testing the association of the estimated haplotypes and
breast cancer. SNPAlyze implements a global test for haplotype frequency differences
between cases and controls and provides haplotype-specific tests which allow
evaluation of all individual haplotypes. It also provides permutated (empirical) P-values
for the global test and individual haplotypes. Permutation tests were done using
FASTEHPLUS (Zhao and Sham 2002) and SNPAlyze. All permutated P-values were
reached using 10 000 replicates. P-values ?0.05 were considered significant.
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4.8.5 Pairwise linkage disequilibrium (V)
Linkage disequilibrium (LD) between two SNPs was estimated by calculating the D'-
values for all 45 possible pairs of the ten SNPs using the combined set of cases and
controls (altogether 891-931 samples for each SNP) (Devlin and Risch 1995).
4.8.6 Power estimations (V)
Power estimations for the SNP association studies were calculated using the Genetic
Power Calculator at http://pngu.mgh.harvard.edu/~purcell/gpc/, case-control for discrete
traits (Purcell et al. 2003). In these estimations we used a=0.05 and breast cancer
prevalence of 0.8 % (http://www.cancerregistry.fi/). D' was set at 1 (assuming complete
linkage disequilibrium between marker allele and disease-associated allele) and the
allele frequencies were assumed equal for the risk SNP and the marker SNP. Also the
risks were assumed equal (1.5 or 2) for the homozygous and heterozygous high-risk
allele carrying genotypes.
4.9 Ethical aspects
All study participants gave their informed written consent. The mutation screening
study was approved by the joint ethics committee of Kuopio University and Kuopio
University Hospital and appropriate permission from the Ministry of Social Affairs and
Health in Finland was obtained. The Kuopio Breast Cancer Project was approved by the
joint ethics committee of Kuopio University and Kuopio University Hospital.
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5. RESULTS
5.1 BRCA1 and BRCA2 mutations in breast/ovarian cancer families (I-III)
Altogether 89 individuals in 36 breast and ovarian cancer families were studied and five
different BRCA1/BRCA2 gene mutations were found; two in BRCA1 gene and three in
BRCA2 (Table 27). In addition to the truncating mutations three polymorphisms were
detected in the BRCA1 gene and seven in BRCA2 gene (Table 28).
Table 27. BRCA1 and BRCA2 gene mutations found.
Mutation Family Index case* No. of brca in family†   No. of ovca in
family§
Other cancers in
family‡
BRCA1:
ex 12
4216-2ntA?G
BR01 brca (36) 1 (50) - endometrial (50)
ex 12
4216-2ntA?G
OV01 ovca (46) 2 (51, 43) 1 (38) na
ex 20
5730 C?T
PS04 - 2 (32, 52) - melanoma (77),
liver (43),
thyroid (60-70),
oesophageal (65),
lymph node (29)
endometrial (73)
BRCA2:
ex 9
999del5
BR17 brca (34, 45) 4 (25, 40 bilat., 43, 58) - melanoma (35)
ex 9
999del5
OV30 ovca (62) 2 (27, na) 2 (na, na) gastric (na),
lip (na),
lymphoma (4),
pancreas (na)
ex 11
4088insA
BR09 brca (74, 77)  2 (86, 46) 3 (61, 58, 58 bilat.) rectal (57),
prostate (80)
ex 11
6503delTT
OV03 ovca (51) 5 (37, na, na, na, na) 1 (na) brain (na)
*Carcinoma and age at diagnosis of the index patient
†Number of breast cancer cases in the family, index case not included, age at diagnosis in parenthesis.
§Number of ovarian cancer cases in the family, index case not included, age at diagnosis in parenthesis.
‡Other cancers in family, age at diagnosis in parenthesis.
na=not available
5.1.1 BRCA1 mutations found (I, III)
The detected BRCA1 gene mutations were 4216-2nt A?G in exon 12, and 5370 C?T
in exon 20. The 5370 C?T mutation in exon 20 was found in sequencing analysis and
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exon 12 4216-2nt A?G mutation was detected in heteroduplex analysis and confirmed
by RFLP and sequencing from genomic DNA and cDNA.
Table 28. Polymorphisms found in the BRCA1 and BRCA2 genes.
Gene/ Observed in
Exon/Intron Alteration* Effect rs Number † Cases Controls
BRCA1:
Intron 7 -34ntT®C IVS7 -34T?C -   1/24 na
Exon 13 T4427C Ser1436Ser (S1436S) rs1060915 12/24 na
Exon 16 A4956G Ser1613Gly (S1613G) rs1799966 11/24
BRCA2:
5'UTR 203G?A 5'UTR -26nt G?A rs1799943 14/33 6/31 ‡
Intron 8 +56ntC®T IVS8 +56C?T rs2126042   7/33 9/31 ‡
Exon 10 A1093C Asn289His rs766173   1/29 na
Exon 10 A1342C Asn372His rs144848 17/30 na
Exon 10 A1593G Ser455Ser rs1801439   1/34 na
Intron 14B +53ntC®T IVS14 +53C?T rs11147489   1/33 0/31 ‡
Intron 24 -16ntT®C IVS24 -16T?C rs11571818   1/33 1/31 ‡
* nt corresponding to mRNA sequence GenBank U43746; †  RefSNP number, obtained from the NCBI dbSNP at
http://www.ncbi.nih.gov/SNP/. ‡Anonymous population controls were used.  na= not analysed
5.1.1.1 BRCA1 exon 12 4216-2nt A?G (III)
The BRCA1 exon 12 4216-2nt A?G mutation was found in 3/8 and 3/12 individuals
tested in two families. This mutation substitutes the adenine (A) nucleotide at position
4216-2nt to guanine (G) and disrupts the splice acceptor AG dinucleotide. The
substituted guanine creates a new splice acceptor AG with an adenine at position 4216-
3nt causing splicing error which leads to the inclusion of an extra nucleotide G in the
mRNA. Aberrant splicing causes a frame-shift and changes the codon GGU for Glysine
at position 1366 to GGG and codon GAA for Glutamine at 1367 to translation
termination codon UGA (Figure 12). This leads to a truncated BRCA1 protein of 1366
amino acid instead of the 1863-amino-acid wild-type protein.
 In family A (BR01) the 4216-2nt A?G mutation was found in one breast cancer
patient (female) and in two healthy individuals (male and female). Other five tested
family members (male and female) were non-carriers. In family OV01 one breast cancer
patient, one ovarian cancer patient and one healthy male were 4216-2nt A?G mutation
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carriers. Nine other tested family members were non-carriers, one of them being
affected with breast cancer at the age of 51 years.
Figure 12. The 4612-2nt A to G splice-site mutation in BRCA1 gene leads to aberrant splicing
and truncated protein. Wild-type sequence is shown in the upper part and mutated sequence in
the lower part. The splice acceptor ag dinucleotide is shown in italics.
5.1.1.2 BRCA1 exon 20 5370 C?T (I)
The 5370 C?T mutation in exon 20 was found in one family (PS04). This mutation
changes the codon for Arginine (AGA) at position 1751 to a translation termination
codon UGA. This leads to a truncated BRCA1 protein of 1751 amino acid. The
mutation was found in the only individual (female melanoma patient) tested in the
family.
5.1.2 BRCA2 mutations found (I, II)
Three mutations were detected in the BRCA2 gene; 999del5 in exon 9, 4088insA in
exon 11 and 6503delTT in exon 11. The 4088insA and 6503delTT mutations were
detected in PTT analysis and confirmed by sequencing. Exon 9 999del5 was detected in
heteroduplex analysis and confirmed by sequencing.
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5.1.2.1 BRCA2 exon 9 999del5 (I)
The exon 9 999del5 mutation was found in two families. This mutation is a five base-
pair deletion TCAAA, starting at nucleotide 999 in codon 257. The deletion causes a
frameshift leading to early translation termination in codon 273 and a truncated protein
of 273 amino acids instead of the 3418-amino-acid wild-type protein.
 In family BR30 the mutation was found in a breast cancer patient who was the only
individual whom a sample was available for testing.
 In family OV30 the 999del5 mutation was found in three of eleven tested family
members. One of the mutation carriers had ovarian cancer and the other two were
healthy females.
5.1.2.2 BRCA2 exon 11 4088insA (II)
The 4088insA mutation was found in one family (BR09). The insertion of an adenine in
a chain of 7 adenines at nucleotides 4081-4087 causes a frameshift leading to the
change of Asparagine (AAT) at codon 1287 to Lysine (AAA), and the Asparagine
(AAT) at 1288 to a stop codon UAA. This leads to premature translation termination at
1288 and a truncated protein of 1288 amino acids (Figure 13). In the family BR09 the
mutation was found in 6/11 tested family members. One male carrying the mutation is
healthy. One male carrier is affected with prostate cancer and four female carriers are
affected with bilateral breast cancer, bilateral ovarian cancer, breast, ovarian and rectal
cancer, and one with breast and ovarian cancer. Other five tested family members were
non-carriers.
5.1.2.3 BRCA2 exon 11 6503delTT (I)
The third BRCA2 gene mutation detected was 6503delTT in exon 11. This mutation was
found in one family (OV03). The deletion of nucleotides 6503 and 6504 causes a
frameshift starting at codon 2092 and creates a stop codon at 2098 leading to a truncated
protein of 2098 amino acids. In the family OV03 four 6504delTT mutation carriers
were detected, three of them healthy (one male and two females) and one affected with
ovarian cancer. The three other tested family members were non-carriers.
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Figure 13. Sequencing of the BRCA2 4088insA mutation. (a) Wild-type sequence in the region
of the mutation. The arrow indicates the position of the adenine insertion. (b) Sequence of the
4088insA mutated allele. The arrow indicates the inserted adenine. The frame-shift resulting
from the adenine insertion is visible as tangled sequence.
5.1.3 Haplotype analysis (I, II)
Three-marker haplotypes consisting of alleles at markers D13S260, D13S1701 and
D13S267, spanning 1.83 Mb (3.2 cM), were manually constructed for the three BRCA2
exon 9 999del5 mutation carriers and 8 non-carriers in family OV30. The mutation
carriers shared haplotype 166 - 304 - 258. This haplotype was not detected in any of the
non-carriers. In family BR17 a DNA sample was available only from the mutation
carrier and her haplotype was 168/174 - 292/304 - 252/256. It is likely that the allele
304 of the closest marker to the 999del5 mutation, D13S1701, is shared by all mutation
carriers in families OV30 and BR17.
 In family OV03 with BRCA2 exon 11 6503delTT mutation the haplotype using
markers D13S260, D13S1701 and D13S267 was constructed for two mutation carriers
and two non-carriers. The 6503delTT mutation associated haplotype was 170 - 292 -
244/256 and it was not detected among the non-carriers.
 Two-marker haplotype was constructed for six mutation carriers and five non-
carriers in family BR09 with the BRCA2 4088insA mutation using markers D13S260
and D13S267. All mutation carriers shared the haplotype 166 - 250 and it was not
detected in the non-carriers.
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 Haplotypes in families BR01, OV01 and PS04 carrying BRCA1 4216-2ntA?G and
5370 C?T mutations, have been assessed as part of the collaborative analysis of
haplotypes and founder effects of BRCA1 and BRCA2 families in Finland (Sarantaus et
al. 2000).
5.2 Autosome-wide scan for linkage disequilibrium-based association with breast
  cancer (IV)
5.2.1 Allelic association
In the first-stage scan 366 microsatellite markers were genotyped on 22 chromosomes
in 49 breast cancer cases and 50 controls from Eastern Finnish population. In 16
chromosomes altogether 21 markers showed significant difference in allele frequencies
when compared between breast cancer cases and controls, with P-values 0.003-0.049 in
Fisher's exact test, indicating that these markers are in LD with breast cancer (Study IV,
Table 1). In addition, two markers associated with breast cancer with borderline
significance, with P-values 0.054 and 0.057 (Study IV, Table 1). More than one marker
on same chromosome was detected to be in LD with breast cancer on 5 chromosomes,
but none of these markers were adjacent. On six chromosomes no markers were
detected to be in LD with breast cancer. For the second-stage scan 23 loci (21 with the
most significant P-values and 2 near significant) on 16 chromosomes were selected and
altogether 69 additional flanking markers were analysed. Four of the 69 analysed
markers showed significant LD with breast cancer with P-values 0.013-0.046 (Study
IV, Table 1). The breast cancer association was further analysed by single-allele tests
for 25 of the 27 significant markers where the difference between cases and controls in
the count of the tested allele was ? 10. Thirty-nine alleles of 25 markers were tested and
28 alleles showed significant association, two showed borderline significance and 8
were not significant (Study IV, Table 1). The odds ratios indicated 9 alleles possibly
being protective (OR 0.013-0.47) and 21 alleles associating with increased breast cancer
risk (OR 1.84-12.86) (Study IV, Table 1).
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5.2.2 Genotype association and Hardy-Weinberg equilibrium (HWE)
Among all analysed markers (366+69) only six markers showed significant difference
in genotype frequencies between cases and controls. These were D3S3053, D7S1818,
D19S178, D19S254, D22S1177 and D22S445, with P-values 0.041, 0.014, 0.048, 0,007,
0.040 and 0.010, respectively. In the HWE analysis the genotypes of controls deviated
significantly from equilibrium at one marker, D1S179, and slightly at D22S426 (Study
IV, Table 1). The cases deviated also at D1S179 and at D17S809 with P-values ~0 and
0.011, respectively. In the combined analysis of cases and controls together deviation
from HWE was detected with markers D1S179, D17S809 and D22S426 with P-values
~0, 0.013 and 0.006, respectively. The substantial deviation at marker D1S179 in all
three tests is probably due to the large number of observed alleles, 15, at this marker.
5.2.3 Haplotypes
In the haplotype analysis 76 different marker combinations were tested for two-, three
and four-marker haplotypes. Four marker combinations showed significant difference in
haplotype frequencies between cases and controls with global test score ?0.05 and
simulated P-values of 0.003-0.021 (Study IV, Table 2). In addition, three other showed
borderline significance with global scores 0.077, 0.095 and 0.068 (Study IV, Table
Table 2). With the four significant marker combinations the number of observed
haplotypes with frequency of ?0.5 % varied from 22 to 45. Among these individual
haplotypes four were found more frequently in cases and seven were more frequent in
controls (P-values 0.007-0.038, simulated P-values 0.004-0.030; Study IV, Table 2).
The simulations and haplotype frequency estimations for cases and controls separately
were not done for the three marker combinations with borderline significance.
 The results from allelic association and haplotype analysis suggest that in the Eastern
Finnish population breast cancer associated regions locate on chromosomes 3p26,
11q23 and 22q12-q13.
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5.3  Further refinement of chromosome 22q12-q13 breast cancer-associated
   region (V)
5.3.1 SNP allelic and genotype association
Ten SNPs were genotyped in the 550-kb breast cancer-associated region on
chromosome 22q12-13, detected in the autosome-wide scan in study IV. Breast cancer
association of the SNPs were tested by comparing the allele and genotype frequencies
between 497 breast cancer cases and 458 controls using the entire sample and a
subsample that included the cases born in the province of Northern Savo (n=280) and
their age and long-term area-of-residence matched controls (n=257). In the entire
sample no significant difference were detected in allele frequencies between cases and
controls with any of the ten SNPs but a borderline significance was detected for the rare
allele carriers (genotypes TC and CC) of rs733655 with an OR of 1.28 (95% CI=0.99-
1.65, Table 29). In the subsample two SNPs associated with breast cancer, rs728506
with P-value 0.033, and rs733655 with P of 0.009 (Table 29). In the subsample also the
rs733655 rare allele carriers (genotypes TC and CC) had a significant risk of breast
cancer compared to the homozygous common allele carriers (TT) with an OR of 1.90
(95% CI=1.34-2.69). The genotype frequencies differed significantly with rs733655 in
the entire sample (P=0.044) and the heterozygous genotype TC was the risk-associated
genotype with OR 1.39 (95% CI=1.06-1.83, Study V, Table 2). Breast cancer
association with rs733655 was detected also in the subsample where the genotype
frequencies differed between cases and controls significantly with P of 0.0003 and the
TC genotype associated with breast cancer risk with an OR of 2.11 (95% CI=1.46-3.05,
Study V, Table 3). In the subsample a protective effect associated with rs7285064
heterozygous genotype CT with OR 0.62 (95% CI=0.41-0.96, Study V, Table 3).
5.3.2 Hardy-Weinberg equilibrium
The deviation of the genotype frequencies from the Hardy-Weinberg equilibrium was
tested separately for cases and controls in each sample (entire and subsample). In the
controls the rs733655 genotypes were slightly off from HWE in the entire sample and
more significantly in the subsample. A borderline deviation was detected among cases
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in the subsample in rs738977 and rs733655 genotypes with P-values 0.052 and 0.082,
respectively. (Study V, Tables 2 and 3).
5.3.3 Pairwise linkage disequilibrium
Linkage disequilibrium between SNPs was estimated in the entire sample by calculating
pairwise D' values for all 45 possible SNP pairs. In six of the 45 pairs a D'?0.5 were
observed (Table 30). D' was detected to decline as distance between SNPs increased, as
was expected. The highest D', 0.99, was detected between rs228941 and rs228942
which are in the same gene (IL2RB) and only 898 kb apart. Moderate LD with D' 0.49-
0.61 was observed between SNPs that are up to 236 kb apart.
Table 30. D' values for pairwise linkage disequilibrium in the entire sample (cases and and
controls combined). The distance between a SNP pair is shown in kilobases (kb) in the upper
half and D' value in the lower half.
5.3.4 Haplotypes
Two-marker haplotypes were estimated for the adjacent SNPs that were in LD with D' ?
0.5. Altogether five pairs were tested separately in the entire sample and subsample. The
global chi-squared P value and empirical P were significant for only one marker pair in
the subsample, rs25095-rs733655. An individual haplotype AC of this SNP pair is
significantly more frequent in cases with empirical P of 0.003 (Study V, Table 5). In the
entire sample this haplotype has a borderline significance with empirical P 0.073, but
non-significant global P. Other haplotypes were not significant.
rs738977 rs3827351 rs3484 rs760517 rs738148 rs7285064 rs25095 rs733655 rs228941 rs228942
rs738977 148.3 187.9 250.1 261.6 321.1 425.1 486.1 514.8 515.7
rs3827351 0.56 39.6 101.7 113.3 172.8 276.8 337.8 366.5 367.4
rs3484 0.05 0.59 62.1 73.6 133.1 237.2 298.2 326.9 327.7
rs760517 0.08 0.26 0.17 11.5 71.0 175.0 236.1 264.7 265.6
rs738148 0.12 0.04 0.10 0.57 59.5 163.5 224.5 253.2 254.1
rs7285064 0.14 0.06 0.08 0.16 0.18 104.0 165.1 193.7 194.6
rs25095 0.04 0.08 0.12 0.15 0.06 0.25 61.0 89.7 90.6
rs733655 0.13 0.28 0.26 0.04 0.28 0.09 0.49 28.7 29.6
rs228941 0.02 0.03 0.13 0.10 0.24 0.19 0.24 0.05 0.9
rs228942 0.23 0.08 0.02 0.07 0.24 0.61 0.01 0.02  0.99
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5.3.5 Allelic imbalance analysis
In 37/45 (82%) of the studied breast tumours AI was detected at one or more of the 13
microsatellite marker loci analysed on chromosome 22q12-q13. Five microsatellite loci,
D22S1142, D22S924, D22S1177, D22S445 and D22S279, showed significant AI (Table
31).
Table 31. Allelic imbalance detected on chromosome 22q12-q13.
AI
Marker Location (Mb) n* %†
D22S277 34.596 5/35 14
D22S1142 34.598 12/36 33
D22S924 34.956 15/33 45
D22S283 35.075 11/40 28
D22S426 35.348 2/12 17
D22S1177 35.588 12/22 55
IL2RB 35.871 10/40 25
D22S445 35.890 9/26 35
D22S1156 36.706 2/25 13
D22S272 37.410 8/32 25
D22S284 38.641 9/35 26
D22S279 39.347 7/18 39
D22S270 41.378 1/30 3
* Number of tumours showing AI/Total number of informative tumours.
†AI percentage.
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6. DISCUSSION
6.1 High-risk susceptibility genes in Eastern Finnish breast and ovarian cancer
  families (I-III)
6.1.1  Eastern Finnish BRCA1 and BRCA2 mutation frequency is not different
  from  other parts of Finland (I)
Five different BRCA1 and BRCA2 gene mutations were found in the Eastern Finnish
population; 4216-2nt A?G in exon 12, and 5370 C?T in exon 20 of BRCA1 gene, and
999del5 in exon 9, 4088insA in exon 11 and 6503delTT in exon 11 of BRCA2. These
mutations account for 19.4 % of the 36 families studied. BRCA1 mutations were
detected in 8.3 % (3/36) and BRCA2 mutations in 11.1 % (4/36) of the families. In the
previous studies conducted in Northern or Southern Finnish families the corresponding
figures were 7 % and 10 % for BRCA1, and 6 % and 11% for BRCA2 (Huusko et al.
1998, Vehmanen et al. 1997a). Thus, the frequencies that we observed do not differ
significantly from those previously reported in Finland.
 Some mutations in the present study may have remained undetected since the
sensitivity of mutation detection methods is not complete. It is also possible to miss
some mutations due to phenocopies as in some families DNA from only one breast or
ovarian cancer case was available for mutation screening. However, missing many
mutations is unlikely because 17 previously detected Finnish BRCA1 and BRCA2
mutations were tested, and the mutation frequencies are similar to those previously
reported in Finnish breast/ovarian cancer families. Also, large genomic rearrangements
involving BRCA genes have not been found in the Finnish population (Lahti-Domenici
et al. 2001, Laurila et al. 2005, Karhu et al. 2006).
In addition to truncating mutations three polymorphisms were detected in the BRCA1
gene and seven in BRCA2 gene. All ten polymorphisms are known and have been found
in other populations. BRCA2 Asn372His has been associated with an increased risk of
breast cancer although in a very large collaborative sample set the association was not
confirmed (Healey et al. 2000a, Breast Cancer Association Consortium 2006). In
Kuopio Breast Cancer Project sample material the association was not significant
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(Healey et al. 2000a). Some evidence was however reported of the 372His homozygotes
in the youngest age group having an increased risk of breast cancer (Breast Cancer
Association Consortium 2006). Increased risk of ovarian cancer has also been detected
among Asn372His carriers (Auranen et al. 2003). None of the other nine
polymorphisms has been reported to associate with breast/ovarian cancer risk. Thus, it
is unlikely that these polymorphisms contribute significantly to risk of familial breast
cancer in our sample material.
 In general, the mutations in the present study were found in families with several
cancer cases. However, in many families with breast and ovarian cancer a mutation was
not found, and two mutations were found in families with only two cases of breast
cancer. The BRCA1 5370 C?T mutation was found in a family in which only two cases
of breast cancer (second-degree relatives) were known, but additionally many cases of
other cancers. The mutation in this family was found from a patient with melanoma, and
DNA from the breast cancer cases was not available for testing. The BRCA1 4216-2nt
??G mutation was also detected in a family where the index case had breast cancer at
the age of 36 and her mother had endometrial and breast cancers but no other cancer
cases were known in the family. This demonstrates that very strict criteria, i.e. three
first-degree relatives with breast/ovarian cancer, for BRCA1/2 mutation testing are not
applicable in all cases.
 In the present study BRCA mutations were not detected in any of the six families
with ovarian cancer only, which is consistent with the previous findings. In a study of
233 unselected Finnish ovarian cancer patients BRCA1/2 mutations were detected in 5.6
% of the patients (Sarantaus et al. 2001b). Mutations were present in 13 families and
only two of them did not have a history of breast cancer in the family, in addition to
ovarian cancer (Sarantaus et al. 2001b). Even though the number of families with
ovarian cancer only is low in the present study, it supports the previous conclusion that
ovarian cancer patients who have also been diagnosed with breast cancer or have family
history of breast or breast/ovarian cancer could benefit from referral to genetic
counselling and BRCA mutation testing (Sarantaus et al. 2001b).
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6.1.2 Limited BRCA1 and BRCA2 mutation spectrum in Eastern Finland (I)
Although the BRCA1 and BRCA2 mutation frequencies observed in the present study
correspond to those previously found in Finland, the mutation spectrum, however, is
different. We detected only two of the 15 previously reported BRCA1 and two of the 11
reported BRCA2 mutations (Vehmanen et al. 1997a, Vehmanen et al. 1997b, Roth et al.
1998, Huusko et al.1998, Sarantaus et al. 2000, Syrjäkoski et al. 2000, Sarantaus et al.
2001a, Sarantaus et al. 2001b, Pääkkönen et al. 2001, Eerola et al. 2001, Vahteristo et
al. 2001a, Syrjäkoski et al. 2004a). The Eastern Finnish (Northern Savo) mutation
spectrum resembles that of the Northern part of the country where only a few BRCA1/2
mutations have been found (Huusko et al. 1998). Two of the four recurrent mutations
that we detected represent the most frequently observed BRCA1/2 gene founder
mutations in Finland, 4216-2nt A?G in BRCA1 and 999del5 in BRCA2. The other two,
BRCA1 5370 C?T and BRCA2 6503delTT, have been less frequently detected in
Finland and have been observed in other countries too. In addition to BRCA1 4216-2nt
??G and BRCA2 999del5, the three other most frequent Finnish mutations in each
gene were not detected in the Eastern Finnish families (BRCA1 3604delA, 3744delT/
3745delT and 4446C?T, and BRCA2 7708C?T, 8555T?G and 9346-2ntA?T).
Additionally, we observed the 4088insA mutation in BRCA2 exon 11. In Finland
BRCA2 4088insA mutation is unique to the family described in study II. It has been
reported in the BIC database to have been found in one Italian ovarian cancer patient
but not anywhere else.
 However, it should be kept in mind that the 36 families in the present study cover
only a portion of the families with hereditary breast and ovarian cancer in the Northern
Savo region, and are a portion diagnosed in the 1990's. It is possible that if the study
material was larger some of the most prevalent founder mutations would be found,
especially BRCA2 7708C?T and 9346-2ntA?T, which have been described in Finnish
families originating from Northern Savo (Sarantaus et al. 2000).
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6.1.3 Geography and haplotypes in the BRCA mutation-carrier families (I, II)
The BRCA1 gene 4216-2nt A?G mutation was detected in two families, which are
from the Northern part of Central Finland and in Northern Savo region (Figure 14). In
the collaborative analysis the origins of the Finnish families with 4216-2nt A?G
mutation were observed to cluster in Central Ostrobothnia and further in Central
Finland (Sarantaus et al. 2000).
Figure 14. Birth places of the oldest generation available in five BRCA1/2 mutation families.
Black circles represent the birth places of BRCA2 999del5 mutation family (grandparents of
index case in family OV30), black square BRCA2 6503delTT (father of index case in family
OV03), star BRCA1 4216-2nt A?G mutation families (index cases of families BR01 and
OV01), diamond BRCA2 4088insA (index case of family BR09). Location of Kuopio is shown
with a triangle.
The origin of the BRCA1 5370 C?T mutation families in Finland seems to be in the
most Eastern parts, or in Russia (Sarantaus et al. 2000). The birthplace of the oldest
generation known (father of the index case) in the family with BRCA2 6503delTT
Late settlement
Early settlement
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mutation is also from Eastern Finland, close to Kuopio (Figure 14). The single family
carrying BRCA2 4088insA mutation originates from Karelia (Figure 14).
 The BRCA2 999del5 mutation was also detected in two families. In one of the
families all four grandparents of the index case could be traced to have been born in a
small region in Eastern Finland, communities in Northern Savo and Northern Karelia
(Figure 14). In the other family with 999del5 mutation the birth places were not
available. A haplotype analysis in Finnish and Icelandic breast cancer families with
BRCA2 999del5 mutation revealed two distinct haplotypes; a rare one that shared a
core-haplotype with the Icelandic haplotype, and another one more frequent in Finland
(Barkardottir et al. 2001). Families with this more frequent haplotype originated from
two regions in Finland, the other of them in Eastern Finland near Kuopio where the
family in the present study also originates.
Our results support the idea of the birth of population islets in Finland during
resettlement of the Eastern parts of Finland in the 16th century. Only two of the eight
most common Finnish founder mutations were detected in our material. In addition, the
novel mutation BRCA2 4088insA has not been found in Southern or Northern Finland.
Our study agrees with the suggestion that there are only a limited number of
BRCA1/BRCA2 mutations in the Finnish population and the majority of them have been
found. The relatively low total number of known BRCA1/BRCA2 mutations in Finland,
including the ones reported in this study, suggests that other possibly moderate risk
inducing gene mutations may exist in the Finnish population. Indeed, recently a
founder mutation in PALB2 gene has been found in Finnish breast cancer families,
including a family from Kuopio region (Erkko et al. 2007). The knowledge of founder
mutations representative of certain geographical regions facilitates the laborious
mutation screening of large BRCA1 and BRCA2 genes.
6.1.4 A novel Eastern Finnish BRCA2 mutation and favourable prognosis (II)
In the present study we have identified a rare 4088insA mutation in the BRCA2 gene. In
addition to the Eastern Finnish family in the present study it has not been detected in
other families in Finland. The mutation is associated with high penetrance: all four
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female mutation carriers have presented with breast/ovarian cancer and all of them were
either bilateral breast cancer or ovarian cancer, or breast and ovarian cancer in the same
patient. One of the two male mutation carriers has prostate cancer. The 4088insA
mutation seems to be of an auspicious nature as despite of even an advanced stage and
poor prognosis assessed by classical factors all affected family members had an
excellent response to treatment and a better than expected clinical course. Still, the
mutation is persistent as breast cancer occurred in a patient even 25 years after the first
(ovarian) cancer. On the other hand, the patient diagnosed with bilateral ovarian cancer
of the size of two grape fruits and metastatic spreads, was also cured and is still disease
free and alive after nearly 26 years.
 An interesting question is whether the mutation itself is associated with good
prognosis/outcome or is there another gene that modifies the outcome of the mutation-
associated cancers in the family. Also, as BRCA2 gene functions in double-stranded
DNA break (DSDB) repair, cells deficient in functional BRCA2 are more sensitive to
agents that cause DSDB (Patel et al. 1998, Sharan et al. 1997, Abbott et al. 1998).
Therefore certain chemotherapeutic drugs and radiation may be especially efficient in
BRCA2-deficient cancer patients but on the other hand the radiation therapy in mutation
carriers may initiate tumorigenesis by causing DSDB that are not subsequently repaired.
Indeed, some evidence for BRCA2-deficient cancer cells being more sensitive to
ionizing radiation, mitoxantrone, amsacrine and etoposide have been presented (Sharan
et al. 1997). Also BRCA1/2-related breast cancer cases had a better clinical response
rate to neoadjuvant chemotherapy than non-carriers (Chappuis et al. 2002). In the family
described here the patient with bilateral breast cancer did not receive radiation therapy
for the first breast cancer and patient who received radiation therapy for breast cancer
had subsequent rectal and ovarian cancers which are unlikely due to scatter dose of
radiation to breast. The third breast cancer patient in the family has also received
radiation therapy, but only recently, and has not developed bilateral breast cancer.
Better response to platinum chemotherapy has been shown among BRCA1 or BRCA1/2
mutation heterozygotes but not among BRCA2 mutation carriers only, compared to non-
carriers, and it may have contribution to the improved prognosis (Husain et al. 1998,
Cass et al. 2003). Patients in the present study received cisplatinum-based
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chemotherapy for ovarian cancer, and one patient received also chemotherapy including
mitoxantrone (CMF/CNF) for breast cancer prior to the ovarian cancer. Thus, it can be
speculated that the mutation enhances the response to such chemotherapy, improving
prognosis.
 There is clearly need for collection of data on the effect of individual mutations, as
well as of response to treatment among mutation carriers. The 4088insA mutation
provides an example of how the knowledge of the effect of an individual mutation may
be important in estimating prognosis for mutation carriers. The mutation in a
breast/ovarian cancer family may be of auspicious nature and the knowledge of this may
provide some relief in the distress for the family members carrying the mutation. In the
near future the genetic information of the germ-line of the cancer patient may be
important in assessing prognosis of the disease on a wider scale.
6.2 Sporadic breast cancer and new low-penetrance susceptibility genes in
  Eastern Finland (IV, V)
6.2.1 Autosome-wide scan for LD-based breast cancer association (IV)
Our scan was conducted in order to gain knowledge of possible genetic breast cancer
risk factors on population level. We selected the cases that did not have a strong family
history of breast cancer from a small geographical region for optimal homogeneous
gene pool and as small effective number of unrelated founders as possible (Kruglyak
1999). Also when the cases are a homogeneous group from small geographical region
the subset of genetic risk factors they carry could be also homogeneous and the number
of them reduced. We aimed at identifying low-penetrance risk factors for breast cancer
which does not show up clearly in families. The genetic diversity of this population is
believed to be lower than that of the Finnish population in general and this feature has
been the basis for mapping several genes and even genes for complex diseases (Ekelund
et al. 2000). Due to the nature of our population this study falls in between traditional
LD study and family linkage study. Being a young isolated population this group of
Eastern Finns could be seen as a sample set in between a family set and a group of non-
relatives. When this work was initiated (1996) it was not recognised as it is according to
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the current knowledge that it could be useful to have family material even in association
studies (Antoniou and Easton 2003). Also, at the time of the sample selection the
contribution of high-penetrance genes, e.g. BRCA1 and BRCA2, was not known and we
threfore chose non-familial breast cancer cases in order to identify low-penetrance
susceptibility genes. Very recently though, it has been shown that the same low-
penetrance risk factors could be identified in a sample set of sporadic breast cancer and
among cases with a strong family history of breast cancer (Hunter et al. 2007, Easton et
al. 2007).
 Of the 366 markers in the first-stage scan 59 % were spaced by £10 cM, 30 % by 11-
15 cM and 11 % were spaced by 16-20 cM. Less than half of the screened chromosomes
harboured one or two gaps of 18-20 cM. However, in this approximately 20 generations
old founder population relatively few meioses have occurred and linkage disequilibrium
should extend beyond the distances between adjacent markers in the first and second-
stage scans in general (Ophoff et al. 2002). In a sub-isolate of Kuusamo in the late-
settlement region up to 50 % of microsatellites showed LD at distances 3.5-7.5 cM and
30 % at distances >7.5 cM (Varilo et al. 2003). Our study population was selected from
a small rural area in the late-settlement region and could possess the genetic
characteristics more similar to the Kuusamo population than the late-settlement
population in general. It is also worth noting that with a 10-cM map LD between marker
and risk allele needs to extend 5 cM, as our scan is not for LD between markers but
between marker and risk allele that lies somewhere between two markers spaced by 10
cM in average. LD between SNP markers extends a much shorter distance. A study
comparing the extent of LD between SNP markers with minor allele frequency >0.1 in
four populations of European ancestry but different demographic histories, Ashkenazim,
Africaners, East Anglian British and Eastern Finns, found that the average LD was
similar in all populations (Dunning et al. 2000). However, there are regions in the
genome where the LD varies between populations, e.g. the Eastern Finnish population
showed somewhat higher LD in regions on chromosome 22 (Dunning et al. 2000). Also,
in the Eastern Finnish poulation LD was detected at marker pairs 200-500 kb apart
while the other three studied populations did not show LD different from the baseline at
these distances (Dunning et al. 2000).
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6.2.1.1 Candidate-genes for further studies on breast cancer association (IV)
In the present study altogether 27 markers in 16 chromosomes showed association with
breast cancer in the two-staged autosome-wide scan using 435 microsatellite markers. In
the haplotype analysis three chromosomal regions, 3p26, 11q23 and 22q12-q13 were
further suggested as candidate locations for breast cancer-associated genes.
 Testing 366 markers at the 0.05 significance level is predicted to give 18 positive
associations by chance alone (366x0.05). Since we found 21 positives in the first stage,
it is reasonable to propose that some of these represent true associations. Haplotype
analysis using global-score method and markers in and around associated chromosomal
sites revealed four positive regions, which fits well with this assumption. Estimating the
number of possible false positive results in the second-stage scan is more complicated
because the markers were selected next to the markers that are in LD with breast cancer
and therefore are not independent. The Bonferroni correction was not used here as it is
very conservative and we view these results as a guide for further investigation and not
statistically definite significant associations. Thus we wanted to follow up all possible
associations in the second-stage scan. Also, it is unclear how the adjusting for multiple
comparisons should be best done in genome-wide screenings (Ophoff et al. 2002) and a
method that identifies false positives has not been introduced. When studying complex
diseases it is expected that there will be multiple loci affecting the trait and a very strict
control of the number of false positives (such as the Bonferroni method) will result in a
considerable loss of power to identify secondary signals (Ophoff et al. 2002).
 We are aware that all possible breast cancer-associated loci may not have been
recognised in our screen due to the longer distance between markers in some
chromosomal regions and a limited sample set. Also, at the time when this scan was
initiated the exact physical locations of some markers were not available. As a
consequence some markers used in the second-stage scan are not as close to markers
that were in LD in the first-stage scan as initially expected. This, in turn, could lead to
false negative results. Therefore, a denser marker map and a bigger sample set could
probably have led to an improved result of the scan. Considering all that, it may not be
best to limit the search in the three chromosomal regions, 3p26, 11q23 and 22q12-q13,
identified in the haplotype analysis but to investigate possible candidate-genes near all
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individual markers that showed breast cancer association. Some of the genes are
proposed to be cancer-related and some of them could be candidates for breast cancer-
associated genes based on the proposed function of the gene product. In the 560-kb
haplotype region on 3p26 there are three genes, two of which are not very well
characterised or properly named. Evidence from loss of heterozygosity (LOH) studies
suggests a few candidate tumour suppressor genes lie on chromosome 3p (Yang et al.
2002c) but none of them locates in the 560-kb region of the significant haplotype found
in our scan. Interestingly though, a linkage analysis conducted on Finnish prostate
cancer families identified 3p26 as a locus for hereditary prostate cancer gene
(Schleutker et al. 2003, Rökman et al. 2005). On 11q23 the 900-kb haplotype region
includes 13 named genes and four hypothetical genes. Chromosome 11q21-24 region is
also known for LOH in several different cancers including breast cancer. In the 550-kb
region of the two significant haplotypes on 22q13.1 locates seven named genes, two
non-characterised and two hypothetical genes. Another 16 interesting genes locate near
the markers with breast cancer association in other chromosomes.
 Recently three genome-wide association studies for breast cancer risk alleles have
been conducted (Easton et al. 2007, Stacey et al. 2007, Hunter at el. 2007). Two of them
used sporadic case-control material (Hunter et al. 2007, Stacey et al. 2007), whereas in
the third GWS case material selected for a strong family history of breast cancer was
used in the initial scan (Easton et al. 2007). Regardless, these GWSs identified the
strongest associations to FGFR2 (Easton et al. 2007, Hunter et al. 2007) and TNRC9
(Easton et al. 2007, Stacey et al. 2007) genes, although each of them identified also
additional associations that were not detected in other studies. This indicates that low-
penetrance risk factors for breast cancer can be detected using GWS. On the other hand
even the new-generation GWSs using SNPs do not find all risk factors and the
identification of the causal variant can be troublesome. In our microsatellite scan we
detected 27 positive associations. One of these (D2S434) locates near to (670 kb) the
chromosome 2q35 association found in the GWS conducted by Stacey and coworkers
(2007). A borderline significant (P=0.95) marker (D10S1213) and an associated allele
with it was detected 2 Mb from the described FGFR2 association, and only 400 kb from
the other associated SNP on 10q (rs10510126). Clearly though, it can not be argued to
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be the same association without further studies. Other associations detected in our scan
were not in the vicinity of the associations described in the more recent GWSs.
However, more associations were detected than expected by chance alone and some of
these can represent true risk factors. Thus, our scan is also a feasible method for initial
screen for identification of potential candidate regions for follow-up studies.
6.2.2  Breast cancer association on chromosome 22q12-q13 (V)
6.2.2.1 TMPRSS6 as a candidate-gene (V)
In the present study, the most promising breast cancer association was detected with a
SNP rs733655 in TMPRSS6 gene. We observed an increased risk associating with the
heterozygous genotype TC of rs733655 and with the rare allele C carriers but not at the
homozygous genotype CC carriers. This may be partly explained by too small number
of observed rare homozygotes alone to show significant increase in risk and a larger
sample set might solve this problem.
 In the controls the rs733655 genotypes deviated slightly from HWE whereas the
cases were in equilibrium. However, in the RefSNP European test population sample
the HWE probability is 0.05 indicating that in the normal situation the genotype
frequencies deviate from those expected under HWE
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=733655). The rs733655 allele
frequencies that we observed among controls are also similar to those expected in the
NCBI RefSNP database. The allele frequencies among our cases differ from those
expected (RefSNP) as genotypes that we observed do not deviate from HWE. If the
number of controls by genotype is replaced by the numbers expected under HWE, the
difference in genotype frequencies between cases and controls still remains significant
in the subsample (which includes only cases born in the province of Northern Savo and
their age and long-term area-of-residence matched controls) (P=0.013). Also, the risk
for the heterozygous genotype TC remains significant in the subsample, although
reducing from 2.11 to 1.67 (CI 1.17-2.39). When validating the SNPs for this study we
sequenced 20 samples for rs733655 and no sequence variation other than rs733655 was
observed in the region of the designed TaqMan primer and probe sequences.
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Genotyping assays were optimized and allele calling was unambiguous as allele
controls were used. Also 141 samples from altogether six plates were re-genotyped,
confirming the original genotype and thus, a genotyping error is also excluded.
Therefore, we consider that the detected difference between the case and control
populations is real. Although it is common to exclude markers which deviate from
HWE from association studies it is possible to miss true risk factors by doing so. When
genotyping artefacts are excluded it leaves open the possibility that common variants
that show departure from HWE are subject to selection, acting either directly or
indirectly via selective sweep accross other variants in LD with them (Baynes et al.
2007).
TMPRSS6 gene encodes a membrane-bound serine proteinase 6 called matriptase-2.
Matriptase-2 is a member of a family of type II transmembrane serine proteinases which
have possible role in cancer development. Matriptase-2 has the ability to degrade
extracellular matrix components, suggesting that it may participate in some of the
matrix-degrading processes occurring in both normal and pathological conditions,
including cancer progression (Velasco et al. 2002, Netzel-Arnett et al. 2003). As
matriptase-2 is only recently discovered, little is known about the physiological
function. Matriptase-2 is expressed in normal breast tissue and the expression is
elevated in breast cancer (invasive ductal carcinoma) (Overall et al. 2004). TMPRSS6
has also been detected to be mutated in breast carcinomas (Sjöblom et al. 2006). Thus,
the possibility of matriptase-2 involvement in cancer progression is supported and
TMPRSS6 is a potential novel candidate for breast cancer risk affecting gene. More
specific investigation for the association between matriptase-2 and breast cancer, as well
as the identification of the causal genetic variant is needed. To resolve the global
importance of TMPRSS6 in genetic risk of breast cancer the association has to be tested
in other populations also.
 According to the power calculations our sample set of 497 cases and 458 controls
had >95 % power to detect a risk allele that is in perfect LD with the marker allele
(D'=1) and has a relative risk of 2. The power to detect a risk allele that is not in perfect
LD with the marker allele (D'=0.5) and has a relative risk of 2 varies between 44-74 %
with the ten SNPs. In the stratified sample the power for the detected risk (2.11 for the
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TC and 1.16 for TT genotype) with SNP rs733655 is 83 %. Within a short distance (1
kb) we detected highly significant LD (D'=1) and even at distances longer than 200 kb
D' is ? 0.5 at some instances. It is presumable that LD does not remain at the constant
level across the whole 516-kb region and some associations may therefore have been
missed.
 Our negative results do not rule out association involving other nearby SNPs and
positive results do not necessarily indicate the discovery of the causal SNP but a marker
in LD with a true causal SNP located some distance away.
6.2.2.2 Other genes on chromosome region 22q12-q13 (V)
Another SNP, rs7285064 in CSF2RB gene, showed moderate association with breast
cancer. In the subsample the heterozygous genotype associated with a reduced risk of
breast cancer indicating a protective effect. Further evidence concerning the importance
of this gene in breast cancer is necessary. Other genes in the studied region have not
been reported to associate with (breast) cancer.
6.2.2.3 Allelic imbalance on chromosome region 22q12-q13 (V)
Matriptase-2 is expressed in normal breast tissue and the expression is elevated in breast
cancer (invasive ductal carcinoma) (Overall et al. 2004), which points out that
matriptase-2 is expected not to be a tumor suppressor. Our AI analysis provided further
support to this since AI was not detected in the vicinity of TMPRSS6 gene. This also
indicates that the detected AI seems to be a separate event from the original breast
cancer association, i.e. hereditary risk factor, while AI may indicate the involvement of
a nonhereditary factor. However, in line with other studies (Allione et al. 1998, Iida et
al. 1998, Bryan et al. 2000, Castells et al. 2000, Hirano et al. 2001) the observed AI on
the 22q12-q13 region does not exclude existence of a tumor suppressor, other than
TMPRSS6.
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7. SUMMARY AND CONCLUSIONS
Breast cancer is the most common cancer in women and ovarian cancer is also among
the most common cancers. The objective of this study was to study the contribution of
known high-risk breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2, in
Eastern Finnish families. The second objective was to find chromosomal regions and
genes in them that associate with the risk of (sporadic) breast cancer.
This study demonstrated that:
1. Germ-line mutations in BRCA1 and BRCA2 genes account for 19.4 % of the studied
Eastern Finnish breast/ovarian cancer families. The observed Eastern Finnish
mutation spectrum differs from those observed in the Northern and Southern parts
of the country. Only two of the eight most common Finnish founder mutations were
detected in the Eastern Finnish families. In addition, one of the mutations has not
been found elsewhere in Finland (BRCA2 4088insA). The results add to the
evidence of the geographical differences in distribution of Finnish BRCA1 and
BRCA2 mutations. This screen also provides further evidence for the presumption
that the majority of Finnish BRCA1/BRCA2 founder mutations have been found and
that the proportion of BRCA1/BRCA2 mutations in Finnish breast/ovarian cancer
families is around 20 %.
2. A BRCA2 mutation 4088insA, novel to Finland, was found in one family of Eastern
Finnish origin. The mutation is highly penetrant; four of the six carriers are affected
with breast and ovarian, bilateral breast or bilateral ovarian cancer and one with
prostate cancer. Despite of the high penetrance this mutation seems to be associated
with better than expected outcome. The mutation positive breast/ovarian cancer
patients in this family had an excellent response to treatment even when prognosis
assessed by classical factors was poor.
3. The BRCA1 exon 12 4216-2nt A?G substitution mutation was confirmed to disrupt
the splice acceptor dinucleotide AG and to form another splice acceptor
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dinucleotide. Wrong splicing site leads to inclusion of an extra nucleotide and a
frameshift in translation that causes a premature translation termination and a
truncated protein product.
4. In the first stage of the autosome-wide linkage disequilibrium-based screen 21 STR
markers on 16 chromosomes showed initial association with breast cancer. A further
analysis with additional markers and haplotypes restricted breast cancer associations
to three chromosomal regions, 3p26, 11q23 and 22q13.
5. A 516-kb region on chromosome 22q12-q13 was further refined using 10 SNP
markers. Significant association was detected with one SNP located in the intronic
sequence of TMPRSS6 gene encoding matriptase-2. The heterozygous genotype and
the minor allele were associated with increased risk of breast cancer. In the AI
analysis of 22q12-q13 abundant AI was detected more centromeric than previously
reported, further supporting the existence of a tumour suppressor gene or genes in
this region.
In conclusion, mutations detected in the known high-risk and high-penetrance breast
and ovarian cancer susceptibility genes, BRCA1 and BRCA2, account for approximately
20 % of the familial breast/ovarian cancer in Eastern Finland. This corresponds to the
observed contribution of these genes in families in other parts of our country. In our
search for additional breast cancer risk associated genes we have found an interesting
new candidate, TMPRSS6, which warrants additional association and functional studies.
In addition, chromosomal regions 3p26 and 11q23 may harbour breast cancer-
associated genes.
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